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ejemplo agradecer a Itziar y Ioana por transmitir su alegría y estar siempre dispuestas a 
ayudar. Podría dar las gracias a Javier o a Maialen. Podría decir que ha sido un placer 
compartir charla y bromas con Tamara, aún a sabiendas de que quizás Baltasar al año 
siguiente le trajera carbón. Podría mencionar que las visitas de Álvaro y su famoso 
“Zasca” han amenizado el día a día del Biodonosti.  
 
Tampoco estaría de más si dijera que ha sido un verdadero placer aprender y disfrutar 
del que considero mi hermano argentino, Matías, con el cual tuve la suerte de poder 
montarme en ese tren. O que la atención, cariño y consejos de Haritz han sido una 
autentica maravilla y un placer. No quedaría mal si mencionara las amenas charlas con 
	
Ainhoa, en las cuales nos sincerábamos el uno con el otro, y en un alarde de 
imaginación soñábamos con un mundo perfecto. Se podría mencionar que ha sido un 
placer compartir este tiempo con Amaia y agradecer su cariño y aunque corta, buena 
charla. O agradecer a Laura por ayudarme y acompañarme en esta recta final de la tesis 
con sus consejos y ánimos. Las historias algo exageradas pero sobre todo la sonrisa y 
cariño de Lucía podría ser algo a remarcar, al igual que el cariño y los comentarios de 
Leire, que desde el primer día se guardaba siempre bajo la manga para soltarlos en el 
momento oportuno. No sobraría si agradecería a todas las personas que han pasado por 
el labo como Mikel, Maier, Esti o Telmo entre otros, con los que siempre he aprendido 
mucho. 
 
También podría agradecer a mis directores y amigos, Maider y David. Agradecerles su 
confianza en mi. De Maider podría decir que ha sido un placer aprender de ella, al fin y 
al cabo la primera PCR la hice bajo su supervisión. Y a David podría darle las gracias 
por preocuparse tanto por mi formación profesional como personal. Sin embargo, no 
todo podía ser alabanzas hacia ellos, puesto que no han sido capaces de cumplir con una 
de las, si bien estúpidas, ampliamente mencionada verdad del doctorando: “el tiempo 
restante hasta la defensa de la tesis es inversamente proporcional al odio hacia tus 
directores”. Lo siento chicos, no podíais hacer todo bien.  
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hecho de compartir un rato con ellos. A todos vosotros, gracias. Sois un grupo con el 
que realmente apetece trabajar. Durante este tiempo he sentido todo vuestro cariño y me 
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RESUMEN 	
La mielina es una estructura lipídica formada por los oligodendrocitos en el sistema 
nervioso central y que cumple dos funciones principales: por un lado permite la correcta 
transmisión del impulso nervioso y por el otro mantiene la homeostasis de los axones. 
En la esclerosis múltiple, enfermedad que afecta al sistema nervioso central, esta 
mielina se ve dañada por un ataque autoinmune. A modo muy resumido, linfocitos T 
activados cruzan la barrera hematoencefálica y atacan a la mielina provocando la 
muerte de los oligodendrocitos. Esto conlleva un fallo en la transmisión del impulso 
nervioso y un desequilibrio de la homeostasis axonal, lo que puede dar lugar a la 
degeneración del mismo. Sin embargo, en los primeros estadios de la enfermedad el 
organismo es capaz de regenerar la mielina; tras el daño desmielinizante se liberan una 
serie de señales que hacen que las células precursoras de oligodendrocitos proliferen, 
migren y se diferencien a oligodendrocitos, los cuales generarán nueva mielina 
alrededor de los axones. Mediante este proceso conocido como remielinización, se 
restablece el impulso nervioso saltatorio y se mantiene la homeostasis de los axones.  
 
Desafortunadamente, con la evolución de la enfermedad este proceso termina por 
decaer. Aunque todavía no se conocen las causas exactas de la perdida del potencial 
remielinizante, estas parecen estar relacionadas con una población de células 
precursoras de oligodendrocitos escasa o con una pobre proliferación, migración o 
diferenciación celular. Actualmente, todos los fármacos disponibles para el tratamiento 
de la esclerosis múltiple se centran en prevenir el daño en la mielina. Estos son 
inmunomoduladores o inmunosupresores que evitan que el sistema inmune dañe la 
mielina, evitando de esta manera la desmielinización. Sin embargo, a pesar de que estos 
tratamientos son altamente efectivos, persiste una desmielinización subclínica. Además, 
con la evolución de la enfermedad, los pacientes terminan por entrar en una fase crónica 
en la que las lesiones desmielinizantes son abundantes. Por todo ello, se hace necesario 
el desarrollo de nuevos fármacos neuroprotectores o neurorreparradores, que 
combinados con los tratamientos inmunomoduladores o inmunosupresores disponibles, 
sean eficientes estrategias terapéuticas para los pacientes.  
 
Actualmente existen dos líneas principales de investigación en relación con la 
promoción de la remielinización: el reemplazo de las células precursoras de 
oligodendrocitos o su estimulación para aumentar la proliferación, migración o 
diferenciación. La primera vía ha sido ampliamente investigada con resultados 
RESUMEN 	
prometedores. Sin embargo, el efecto positivo parece deberse más a una regulación 
inmune que a la propia regeneración de la mielina. Esto, unido a los riesgos de una 
terapia con células madre y al hecho de que la diferenciación celular parece ser un 
factor clave en el fallo de la remielinización ha hecho que la segunda vía sea postulada 
como un método más eficiente para estimular la regeneración de la mielina. Se han 
realizado distintos abordajes en este sentido, desde aproximaciones farmacológicas 
hasta el uso de vesículas extracelulares o de microRNAs. 
 
Las vesículas extracelulares son partículas de entre 50 y 1000 nanometros liberadas por 
las células y que en función de su génesis pueden subdividirse en exosomas o 
micropartículas. Su principal función es la comunicación celular a distancia y para ello 
transmiten entre otros proteínas y material genético que producen cambios en la célula 
receptora. En cuanto a los microRNAs, son RNA pequeños de aproximadamente 22 
pares de bases que tienen funciones reguladoras. Tanto las vesículas extracelulares 
como los microRNAs han sido relacionados con procesos de remielinización. 
 
En el año 2014 el grupo liderado por Richard Kraig en la universidad de Chicago 
propuso que los exosomas derivados de sangre de ratas jóvenes eran capaces de 
fomentar la mielinización en modelos ex vivo y la remielinización en ratas adultas. Sin 
embargo, no demostraban si este tratamiento podría ser eficaz en la regeneración de la 
mielina en un modelo patológico. Por ello, nosotros quisimos testar el efecto de estos 
exosomas en el modelo animal de la esclerosis múltiple (el modelo de encefalitis 
autoinmune experimental). Con la misma aproximación metodológica, administramos 
por vía intranasal al modelo EAE dos concentraciones diferentes de exosomas aislados 
de sangre de animales jóvenes. Sin embargo no fuimos capaces de ver ninguna mejoría 
clínica en los animales tratados. Por ello decidimos analizar el potencial remielinizante 
de los exosomas en modelos más sencillos, como lo son los modelos ex vivo (Cultivo 
organotípico de cerebelo) o in vitro (Cultivos de células precursoras de oligodendrocitos 
(OPC; de sus siglas en inglés)). Nuevamente, los resultados indicaron que los exosomas 
no eran eficientes estimulando la remielinización en el cultivo organotípico (medida 
mediante microscopia confocal, western blot y resonancia magnética nuclear), ni en la 
diferenciación de las OPC (medida mediante reacción en cadena de la polimerasa 
cuantitativa (qPCR, de sus siglas en inglés) e inmunofluorescencia) . El efecto positivo 
de los exosomas derivados de sangre de animales jóvenes había sido relacionado con su 
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cargo, y más concretamente con la presencia de una serie de microRNAs, entre los que 
se encontraba el miR-219a-5p, que habían sido descritos previamente como inductores 
de la diferenciación de células precursoras de oligodendrocitos. Por ello, nos 
planteamos analizar el cargo de los exosomas mediante qPCR y micro arrays de 
expresión para ver si éstos contenían los microRNAs previamente descritos. 
Sorprendentemente, estos exosomas no solo no contenían el miR-219a-5p, sino que no 
contenían ningún otro microRNA relacionado con procesos de remielinización.  
 
Este resultado nos permitió concluir que el ambiente podría estar relacionado con la 
carga de los exosomas, como estudios previos acreditaban y que su uso como posible 
terapia o vehículo necesita de una gran estandarización. 
 
En este punto, decidimos confirmar si el miR-219a-5p por si solo era capaz de estimular 
la diferenciación de células precursoras de oligodendrocitos y por tanto la 
remielinización. Utilizando los mismos modelos in vitro y ex vivo que habíamos 
utilizado previamente, fuimos capaces de determinar que el microRNA por sí solo era 
capaz de estimular la diferenciación de los OPCs y por tanto promover la 
remielinización. Esto nos llevo a proponer que el factor clave en la capacidad 
remielinizante de los exosomas jóvenes podía deberse a la presencia en su cargo de 
miR-219a-5p.  
 
En paralelo a la realización de este proyecto, pensamos que la monitorización de los 
animales del modelo animal podía ser mejorada por lo que diseñamos una nueva escala 
con la que evaluar a los animales. Además, generamos una aplicación móvil que 
permitiera la recopilación de datos de manera sencilla, evitando errores y facilitando su 
posterior análisis.  
 
Retomando la línea anterior y tras los resultados obtenidos, decidimos determinar el 
papel que podía estar desempeñando miR-219a-5p en los pacientes de esclerosis 
múltiple. Para ello obtuvimos muestras de plasma de pacientes en dos estadíos de la 
enfermedad (brote y remisión) y analizamos los valores de miR-219a-5p mediante la 
técnica de la reacción en cadena de la polimerasa digital en gotas (ddPCR). La idea 
subyacente a este análisis consistía en que si el microRNA estaba involucrado en la 
regeneración de la mielina, este presentaría valores mayores en los estadíos de brote 
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puesto que el organismo se encuentra en un momento de remielinización para reparar 
las lesiones producidas durante el brote. A pesar de que no obtuvimos diferencias 
significativas entre los grupos estudiados, sí pudimos observar una tendencia a presentar 
valores mayores de miR-219a-5p en brote frente a remisión.  
 
Dada la interesante información previa y con el fin de ir un paso más allá en el estudio 
de la capacidad remielinizante de miR-219a-5p decidimos generar el modelo animal de 
la enfermedad previamente utilizado en este trabajo y administrar el microRNA al 
animal. La administración directa del miR-219a-5p ya había sido testada en modelos de 
desmielinización toxica mediante vía intratecal, demostrando ser un eficiente factor pro-
remielinizante. Sin embargo, nosotros quisimos administrar el microRNA de manera no 
invasiva, con el fin de que esta terapia fuera trasladable más fácilmente a la clínica, y 
por ello se realizó de la misma manera que se hizo con los exosomas derivados de 
sangre de animales jóvenes, por vía intranasal.  
 
Consideramos que, dado que el microRNA tenía que llegar intacto hasta el sistema 
nervioso central, su encapsulación en sistemas de envío debía de ser primordial para 
protegerlo. Por ello, tras establecer una colaboración con dos centros tecnológicos 
locales (CICbiomaGUNE y TECNALIA) y una universidad extranjera (University of 
Oxford; donde realice mi estancia predoctoral), produjimos liposomas y nanopartículas 
cargadas con el miR-219a-5p como vehículos sintéticos y exosomas enriquecidos en 
miR-219a-5p como vehículo biológico. Tanto en los liposomas como en las 
nanopartículas el microRNA fue añadido a las formulaciones de la síntesis con el fin de 
que éste se encontrase embebido o en el interior de las vesículas. Por otro lado, los 
exosomas enriquecidos en miR-219a-5p fueron aislados de células HEK 293T 
transfectadas con el plásmido PlkO1 para que expresaran de manera constitutiva el 
microRNA. Cabe señalar que los exosomas contenían además del microRNA de interés, 
otras proteínas y material genético procedente de las células de origen. 
 
Tras proceder a caracterizar morfológicamente los tres vehículos mediante técnicas de 
análisis de trazado de nanopartículas (nanoparticle tracking analysis) y de microscopia 
electrónica, analizamos mediante la técnica de la ddPCR la cantidad de microRNA-
219a-5p que contenía cada vehículo, determinando que los liposomas tenían el mayor 
número de copias por partícula, seguidos de las nanopartículas y por último los 
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exosomas. En este punto, quisimos estudiar la capacidad de los vehículos de ser 
absorbidos por las células precursoras de oligodendrocitos. Para ello, tras generar el 
mismo cultivo primario de estas células que el mencionado en párrafos anteriores y tras 
marcar las partículas de manera fluorescente, fuimos capaces de determinar mediante 
inmunosfluorescencia que los liposomas eran captados más eficientemente que las 
nanopartículas y éstas a su vez que los exosomas. Sin embargo, los exosomas eran los 
más eficientes induciendo la diferenciación de las células precursoras de 
oligodendrocitos. Este dato fue muy llamativo puesto que los exosomas presentaban el 
menor numero de copias de microRNA por partícula y el menor porcentaje de 
captación. Sin embargo, como hemos dicho anteriormente y en comparación con los 
liposomas y las nanopartículas, los exosomas son vesículas biológicas cuya función es 
la de transmitir información de una célula a otra, por lo que se puede suponer que estos 
son mucho más eficientes que los vehículos sintéticos. Además, contienen otra serie de 
compuestos, como procesadores de microRNAs u otras moléculas que pueden aumentar 
la eficiencia del miR219a-5p.  
 
Una vez seleccionados los exosomas como el vehículo más eficiente induciendo la 
diferenciación de las células precursoras de oligodendrocitos, decidimos administrarlos 
a los animales del modelo de esclerosis múltiple. Siguiendo el mismo procedimiento 
utilizado previamente, estos fueron administrados por vía intranasal. El estudio de la 
evolución clínica de los animales mostró diferencias significativas entre los animales 
tratados con los exosomas enriquecidos en miR-219a-5p y los tratados con los 
exosomas sin enriquecer. Además, tras analizar el patrón de inflamación de los animales 
pudimos determinar que la mejoría en la escala clínica no se debía a una regulación del 
sistema inmunitario de los animales, lo que hacia indicar que la mejoría se debía a un 
aumento en el nivel de remielinización, como así lo demostró posteriormente los 
estudios de resonancia magnética nuclear. 
 
Estos resultados demostraban que el microRNA-219a-5p encapsulado en exosomas era 
capaz de inducir la diferenciación de las células precursoras de oligodendrocitos y que 
además estimulaba la remielinización en un modelo patológico de desmielinización. De 
esta manera pudimos concretar que los exosomas enriquecidos en miR-219a-5p podían 
ser una factible y posible estrategia terapéutica para pacientes de esclerosis múltiple. 
Asimismo, tras este trabajo, los exosomas se postulan como una vía efectiva de 
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administración de microRNAs al sistema nervioso central para otro tipo de patologías 
neurodegenerativas. 
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7 
219-Ex miR-219a-5p enriched exosomes 
219-Lp miR-219a-5p enriched liposomes 
219-Np miR-219a-5p enriched nanoparticles 
AD  Axial diffusivity 
BBB  Blood brain barrier 
CNP  2´,3´cyclic nucleotide 3´ phosphodiesterase 
CNS  Central nervous system 
ddPCR Droplet digital polymerase chain reaction 
DiOC18 Dioctadecyloxacarbocyanine perchorate 
DMEM Dulbecco´s modified eagle´s medium 
DNA  Deoxyribonucleic acid 
DPBS  Dulbecco´s phosphate buffered saline 
EAE  Experimental autoimmune encephalomyelitis 
EB  Ethidium bromide 
ESC  Embryonic stem cell 
EV  Extracellular vesicle 
Ex  Exosome 
FA  Fractial anisotropy 
HC  Healthy control 
HEK293T Human embryonic kidney cells 293T 
HSC  Hematopoietic stem cell  
iPSC  Induced pluripotent stem cell 
lncRNA Long non-coding RNA 
Lp  Liposome 
LPC  Lysophosphatidylcholine 
MAG  Myelin-associated glycoprotein 
MBP  Myelin basic protein 
MD  Mean diffusivity 
miRNA microRNA 
MOG  Myelin oligodendrocyte glycoprotein 
MP  Microparticle 
MRI  Magnetic resonance imaging 
mRNA Messenger RNA 
MS  Multiple sclerosis 
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MSC  Mesenchymal stem cell 
MV  Microvesicle 
ncRNA Non-coding RNA 
Ne-Ex  Non-enriched exosomes 
Ne-Lp  Non-enriched liposome 
Ne-Np  Non-enriched nanoparticle 
NFL  Neurofilament 
NG2  Neuron-glia antigen 2 
NP  Nanoparticle 
NSPC  Neural stem precursor cell 
NTA  Nanoparticle tracking analysis 
Ol  Oligodendrocyte 
OLIG2 Oligodendrocyte transcription factor 2 
OPC  Oligodendrocyte precursor cell 
PD  Parkinson disease 
PDGFRα Platelet derived growth factor alpha 
PEG  Polyethylene Glycol 
PGK1  Phosphoglycerate Kinase 1 
PLGA  Poly(lactic-co-glycolic acid)  
PLP  Proteolipid protein 
PPP  Platelet poor plasma 
PVA  Poly vinyl alcohol 
qPCR  Quantitative polymerase chain reaction 
RA  Radial diffusivity 
RNA  Ribonucleic acid 
RPL13α Ribosomal protein L13 α 
RRMS Relapsing-Remitting multiple sclerosis 
RVG  Rabies virus glycoprotein 
siRNA  Small interfering RNA 
snoRNA Small nuclear RNA 
soRNA Small nucleolar RNA 
WB  Western blot 
WT  Wild type 
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NOTE: During this work microRNA 219 is mentioned several times. However, we want 
to point out that depending on the reference source, the nomenclature changes and miR-
219 or miR-219a-5p are used as synonyms. Nevertheless and according to miRBase, 
miR-219 was previously used to refer to miR-219a-5p. We did not want to change the 
nomenclature used in the original paper and both can be found during the text referring 
to miR-219a-5p. 
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Humans are complex organisms formed by more than 30 trillion cells each. These cells 
form structures named tissues, which reorganization is responsible of the appearance of 
organs. These organs form systems such as the immune system, the cardiovascular 
system or the excretory system, among others. This complex machinery allows us to be 
born, grow, reproduce and die, but also to interact to each other in the most complex 
society ever discovered in the animal world.  
 
The nervous system is responsible for the correct running of all these parts, interacting 
with all of them and making unconscious decisions for that. In addition, our brain can 
not only receive and interpret inner information, but also external information taking 
conscious decisions. As an example, when we are having a conversation with a 
colleague, we are breathing, our heart is pumping blood and our stomach is digesting 
the delicious food we had one hour before our meeting. Moreover, the brain is 
processing the information that our colleague is presenting us about the last experiment 
and we are trying to analyse these results. Our hand is also moving extremely fast to 
write down the most important conclusion of the work. In addition, we are able to watch 
the slides that are shown on the screen. In summary our brain is working hard.  
 
But, how can the brain make so many complex things at the same time? A network of 
neurons is sending information from one to another activating and inhibiting concrete 
cells of this network in order to be able to conduct all the required actions. The 
transmission of the information by the neuron is called nerve impulse. 
 
1. The nerve impulse transmission  
 
Neurons are cells formed by a soma, in which the information is received and 
processed, and an axon that transmits the information by an electric potential change 
that activates the following neuron. This is called excitatory potential and consists of the 
modification of the ionic concentration that produces an imbalance in the charge of both 
intra and extracellular spaces. Basically, sodium and potassium pumps, which are 
located in the membrane of the axons, are responsible for it. On the one hand, potassium 
concentration is higher in the intracellular space. Interestingly, axons´ membranes are 
selectively permeable to potassium ions, allowing potassium to scape from the cell to 
compensate its excess. This creates a positive charge outside the cell and a negative 
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charge inside the axon (Figure 1; 0). The difference on the charge is called action 
potential. On the other hand, sodium concentration is higher in the extracellular space. 
A concrete stimulation of the cell allows sodium membrane pumps to pump sodium into 
the cell, as a mechanism to compensate the negative charge (Figure 1; 1). This inverts 
the charge generating a positive charge inside the cell and a negative one outside. This 
is called depolarization of the membrane and lasts around 1 millisecond (Figure 1; 2).  
This process activates adjacent sodium pumps spreading the nerve impulse along the 
axon and stimulating the following cell.  Again, potassium pumps try to compensate the 
charge by pumping potassium to the extracellular space and restoring the action 
potential in a process called repolarization (Figure 1; 3). However, there is an 
intermediate step which creates a hyperpolarization of the axons due to an excess of 
potassium that flow outside the cell (Figure 1; 4). Then sodium-potassium pumps 
restore the initial ionic distribution in the intra- and extracellular space (Figure 1; 0). 
The whole process takes place in around 4 milliseconds 1. 
 
 
Figure 1: Schematic representation of the action potential and the changes in the axon 
polarization that take place during it. 
 
However, when the action potential travels along the axon, ions leave the axon and its 
magnitude decreases proportionally to the travelled distance 2. To prevent this, most 
axons in the central nervous system (CNS) are covered by myelin, which is an 
oligodendrocyte (Ols) membrane extension that wraps axons. Myelin is a potent 
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insulatior which decreases capacitance and increases electrical resistance along the 
axon, preventing on the one hand the electric potential from leaving the cell 3, and 
allowing on the other hand the action potential to travel without decreasing the speed of 
transmission. Additionally, myelin is disrupted every millimetre in a structure called 
node of Ranvier in which axons are naked and where action potentials are generated. 
Interestingly, nodes of Ranvier are enriched in sodium and potassium channels, 
facilitating this task 4. In this way, action potentials “jump” from one node to another, in 
a process called saltatory nerve impulse transmission, allowing a transmission speed of 
120 meter per second (much faster than the 10 meters per second of non-myelinated 
fibres) 2 (Figure 2). In addition to this, myelin protects and gives trophic support to 
neurons. More concretely, oligodendrocytes have been proposed to support axons with 
energetic metabolites such as glucose or lactate 5,6. As an example, glycolytic 
oligodendrocytes have shown to maintain long-term axonal integrity 7. 
 
Figure 2: In this image, the soma and the myelinated axon of a neuron are shown. Red 
arrows represent the saltatory nerve impulse transmission. Adapted from Antrik.org 8 
In summary, myelin provides metabolic support to the axon and allows the transmission 
of the nerve impulses fast and with low energetic requirements. To understand these 
functions and as it can be appreciated in Figure 3, myelinating oligodendrocytes 
generate a growth zone that attaches and encircles an axon segment generating a 
multilayered and spiral structure 9. One oligodendrocyte can myelinate more than one 
axon, and one axon can be myelinated by more than one oligodendrocyte. Myelin is 
mainly formed by cholesterol, lipids and proteins including myelin basic protein (MBP), 
myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP) that play a 
role in myelin compaction 10. 
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Figure 3: In the centre of the image and axon and the myelin can be appreciated. 
Adapted from MacKay, 2016 11. 
2. Myelin and Multiple Sclerosis 
 
Multiple sclerosis (MS) is a central nervous system disease in which myelin is damaged 
by an autoimmune attack. It is not clear which factors are implicated in the development 
of MS, but a combination of genetic predisposition 12 and environmental factors (such 
as vitamin D, time of birth or smoking 13–15) which lead to an immune dysregulation, 
have been described to be behind MS 16. It seems to be clear that activated T cells cross 
the blood brain barrier (BBB), and react against the myelin. The BBB is an anatomical 
barrier that separates the blood from the glial cells and that carries out several important 
functions such as the regulation and protection of CNS cells. However, as it is 
mentioned in 17, the BBB is more a concept rather than a proper barrier, with dynamic 
properties that allows for instance immunological surveillance. Lymphocytes have been 
described to be able to cross the BBB under normal conditions by several routes 18. 
However, an increased migration of autoreactive lymphocytes across the BBB together 
with an aberrant immune response are thought to be the causes of multiple sclerosis 
outbreak and therefore myelin damage 19. This damage causes demyelinating lesions, 
also known as plaques. While they are distributed heterogeneously along the CNS; they 
appear mainly in the white matter, which are the areas with more myelin content.  
 
Demyelinating lesions are responsible, at the very beginning, for producing an 
inadequate nerve impulse transmission that can concur with the first clinical symptoms. 
Although clinical manifestations might vary from one patient to another, we could say 
that these are related with sensitive and motor alterations, such as paresthesia, 
hypoesthesia or optic neuritis 20. In addition to this, naked axons are exposed to 
INTRODUCTION 
	 17 
potential harmful factors and are deprived from trophic support, which can lead to 
axonal death.  
 
Fortunately, at the first stages of the disease, the body is able to regenerate the myelin in 
a complex process called remyelination. It is of extreme importance because myelin 
regeneration will restore both metabolic support to the axon, avoiding its degeneration, 
and nodes of Ranvier that are required for a proper nerve conduction and function 21. 
This is, remyelination restores nerve impulses conduction 22. 
 
Demyelination induces the secretion of signalling molecules and cytokines that activate 
astrocytes which in turn secrete a range of factors that activate progenitor cells and 
induce their proliferation 21,23. This activation is related to an increase in transcription 
factors that finally induces the regenerative process 24,25.  These progenitor cells are 
adult oligodendrocyte precursor cells (OPC) which are abundant throughout the CNS 
(being a 6% of the total number of the cells in this region of the body 26) and that have 
been described as the major source of new oligodendrocytes 27. In addition, OPC have 
been described as self-renewing multipotent cells, being proposed as adult CNS stem 
cells 28, highlighting the role that they can play after a demyelinating insult.  
 
Activated OPC migrate and colonize areas of demyelination in order to differentiate and 
generate the number of required oligodendrocytes to regenerate myelin 21 (Figure 4). 
Microglia, monocyte-derived macrophages, astrocytes and OPC themselves release 
regulators of migration and mitogens that induce the process 21. In addition, the 
clearance of myelin debris after demyelination made by macrophages is of extreme 
importance for OPC differentiation as myelin debris inhibits this process 29–31. Finally, 
differentiation phase begins when OPC exit the cell cycle 32 and oligodendrocytes 
generate new compact myelin that wraps axons.  
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Figure 4: Schematic meyliantion process: Proliferation of OPC is follow by their 
migration into the lesions, their differentiation and finally the generation of new myelin. 
Modified from Stangel M. et al 2017 33.  
 
However, as it has been described, myelin generated in remyelination is thinner and 
with shorter internodal distances than myelin generated during development, reducing 
its effectiveness 34,35 (Figure 5). This can be expressed by the g-ratio, a number that 
relates the axon diameter to the myelin thickness. These differences between both 
processes have been associated with dynamic growth, having in mind that during 
development axons and myelin are growing at the same time sending information from 
one to another. On the contrary, in remyelination axons are perfectly formed and no 
variation in their size can be produced 36. 
 
Figure 5 Differences shown in myelin during development (A), in an adult axon (B), 
after demyelination (in which no myelin is present)(C) and after remyelination (D), 
when myelin is thinner and with shorter internodal distances. From Franklin and Hinks 
1999 36. 
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Remyelination has not been described to be uniform along the CNS as subcortical 
lesions tend to remyelinate better than perivascular ones 37. In addition, it can vary from 
one patient to another 38. Moreover, remyelination has been found to loss efficiency 
with disease evolution as 80.7% of early lesions are remyelinated compared to a 60% of 
chronic ones 39.  
 
Related with this last point, after several cycles of demyelination-remyelination, and 
together with disease progression and aging, remyelination process terms to fail 40. It is 
not exactly clear why remyelination fails but researchers have postulated that it is 
related with a decrease in the numbers of OPCs, with an inefficient migration, with an 
inexistent or poor differentiation or with a combination of all these factors 41. However, 
other evidences indicate that there is no an aging-related decline in OPC but a lower 
recruitment and differentiation levels of these cells 42. Remarkably, more evidences 
point out that differentiation might be the key factor, as the promotion of OPC 
recruitment in experimental demyelination mice do not improve remyelination 43. In 
addition, chronic no remyelinated lesions have been described to contain OPC but not 
oligodendrocytes 44–47, highlighting the role that OPC differentiation stimulation can 
play in remyelination therapies.  
 
As it has been previously introduced, remyelination failure makes naked axons to be 
unprotected, which at final term cause neuronal death and therefore neurodegeneration. 
This is an irreversible process that when occurs, neuronal circuits get interrupted 
(Figure 6). 
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Figure 6: Following demyelination, axon remains intact enabling the regenerative 
response of remyelination. However, in the absence of remyelination, saltatory 
conduction can not be restored leading to axonal degeneration. From Franklin 2017 21. 
 
MS is an heterogeneous disease and the evolution that has been explained above with 
cycles of demyelination-remyelination with progressive disability of the patient is called 
relapsing-remitting MS (RRMS) and 85% of the patients develop this form of disease.  
It is usually followed by a secondary progressive form in which neurodegeneration is 
the main characteristic. Interestingly, therapies for RRMS are focused in protecting 
myelin to be damaged by developing immunomodulatory or immunosuppressive 
treatments that kill, attenuate or disable overactive and autoreactive lymphocytes 48. 
Although they are very effective in this task, a subclinical neurodegeneration progresses 
and age-associated decline in remyelination efficiency finally increases patients´ 
disability. Unfortunately, progressive MS is nowadays untreatable, and a big effort is 
being done trying to discover new and promising treatments to improve remyelination 
and prevent neurodegeneration.  
 
 
3. Models for studying myelination demyelination and remyelination 
 
Adapted from Osorio-Querejeta et al 2017 49 . 
 
Experimental models are needed in order to understand in deep myelin formation, 
demyelination and remyelination processes, with the final goal of developing therapies 
that can promote remyelination and prevent axonal degeneration. We should bear in 
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mind that no model, no matter how sophisticated, can mimic all physiopathological 
processes that occur in humans. Nevertheless, there are models that simulate several 
aspects of myelin-related diseases and enable us to study myelination, demyelination 
and remyelination as well as the potential of remyelinating therapies. Different models 
can be used depending on the final goal of the research.  
 
In this section, several models will be presented, in order of complexity, emphasizing 
the main characteristics and potentials of the most commonly used models for studying 
the different pieces of the myelin puzzle. 
 
3.1. In vitro models 
 
3.1.1. OPC culture 
The isolation and culture of OPCs can be a helpful tool for understanding the 
mechanisms involved in the development of myelin and studying the effect of new 
therapies on these types of cells in relation with migration, differentiation, survival and 
proliferation 50,51. 
 
A wide variety of protocols have been elaborated for obtaining these cells from human 
tissue, namely, cryopreserved umbilical cord 52, foetal brain 53 brain biopsies and 
embryonic stem cells (ESC) 54. These sources enable to work with human OPCs but 
they have the drawback that samples are difficult to obtain and their use raises ethical 
concerns. Due to this inconvenience, induced Pluripotent Stem Cells (iPSC) has 
emerged as an alternative for obtaining human OPCs 55 (and also rodent OPCs 56). 
Working with iPSC allows working with human derived OPCs and with a large number 
of cells. Moreover, iPSC have their goal in therapeutics since they can be obtained from 
the own patient allowing autologous transplantation. Another possibility is to obtain 
OPCs from the optic nerve 57 or brain cortex of young and adult rodents.  
 
There are a variety of methods for isolating OPCs: Oligodendrocyte Selection Kit 58, 
Magnetic-activated cell sorting 51, Manual method 59, Immunopanning 60, Fluorescence 
activated cell sorting 50 and Immortalized cell line 61. All these methods can achieve a 
good quality of OPC and high content cultures. Therefore, the choice of the method 
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should be accomplished based on the equipment and resources of each lab. Once the 
OPC are isolated, differentiation, proliferation, survival or migration assays can be 
performed. To characterise the ability of a drug to promote the migration of the cells, 
after culturing them in transwells, the number of cells that did cross the membrane can 
be measured.  
 
In order to characterise each stage of OL differentiation after the administration of a 
treatment, various types of markers can be used for specific proteins, including platelet 
derived growth factor (PDGFR) α, neuron-glial antigen 2 (NG2) and A2B5 for OPCs, 
2',3'-cyclic nucleotide 3' phosphodiesterase (CNP), O1 and O4 for pre-OLs; myelin 
basic protein (MBP), Proteolipid Protein (PLP), Myelin Oligodendrocyte glycoprotein 
(MOG) and Myelin-associated glycoprotein (MAG) for OLs; and oligodendrocyte 
lineage transcription factor 2 (OLIG2) for all OL-lineage cells, among others (Figure 8). 
For survival or proliferation a specific markers of cell death (caspase-3) or cell 
proliferation (5-bromodeoxyuridine) can be used respectively. Then, results can be 
analysed by fluorescence microscopy. Alternatively, flow cytometry can be used, 
facilitating multiparametric analysis, however, it does not enable the visualization of the 
cell morphology. Gene expression analysis can also be used to characterize the culture 
(Figure 7) 62,63. 
 
 
Figure 7: OPC differentiation stages at gene expression level. Modified from Osorio-
Querejeta et al. Submitted. 
 
This in vitro model based on OPC culture is simple, low cost and high-throughput. They 
represent a first step towards ascertaining whether treatments have positive effects on 
the cells responsible for myelination and remyelination and understanding the 
mechanisms involved. Moreover, since the cells are not influenced by other types of cell 
or the environment, exposure of these cells to a drug simplifies the interpretation of 
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results 61. With this approach, we can lay the foundations for further work with more 
complex models.  
  
3.1.2. “Axon-based models”- Co-cultures  
These models of myelination involve obtaining axons, either natural or artificial, in 
which to test the myelination ability of cells under study, as a potential therapy for 
demyelinating diseases. It is possible to administer a drug together with the cells as a 
treatment, and then study their influence in terms of myelin production by these cells. 
Below, we describe two methods for obtaining axons: from spinal cord explants and by 
producing synthetic axons.  
3.1.2.1. Spinal cord explants 
In this model spinal cord explants (mainly from rat or mouse embryos) or dorsal root 
ganglion explants 64 are cultured allowing neurons to extend their axons outwards, 
serving this as a substrate for myelination by exogenous cells added to the culture 65,66.  
Using these models, it is possible to assess the capacity of myelinating cells to form 
myelin around axons 67, as well as the effect of drugs on these cells under neuro-glia 
interaction.  
 
Once the explants are cultured 68, myelinating cells are added. The effect of these cells 
can be analysed by measuring the amount of myelin by using immunofluorescence 
microscopy. In parallel the myelin g-ratio can be determined by electron microscopy 
6769. 
 
This is a myelination model that allows researchers to study interactions between 
neurons and myelinating cells during the myelination process. However, we need to 
bear in mind that in these explants, besides neurons, there are other types of cells that 
can also influence the myelination process 70. For this reason, some authors classify 
these as ex vivo models. 
 
3.1.2.2. Synthetic axons 
In order to avoid interactions between myelinating cells and other cells from explants a 
variant of the previous model type was developed involving inert or synthetic axons71. 
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Synthetic axons can be obtained by fixing axons with paraformaraldehyde72 or by 
producing artificial nanofibers that mimic axons. Artificial nanofibers have been 
developed with a range of techniques, going from glass microfibers coated with a glial 
cell matrix 73 continuing with vicryl microfibers 74, finishing with polystyrene 71,75 or 
polycaprolactone 76 nanofibers designed using electrospinning. A variant of this model 
uses micropillar arrays, formed in a 96-well plate, which contain 50-µm-diameter 
conical structures that cells are able to myelinate 77. 
 
These artificial fibres can be coated with a selected substance (from proteins to 
microRNAs) 78, in order to study in depth their effect in myelination 75, facilitating the 
subsequent design of remyelinating therapies based on these factors. 
 
3.2. Ex vivo models 
 
3.2.1. Organotypic cultures    
These types of cultures involve the growing of tissue in three dimensions mimicking the 
structure and cell types of living organs, making them an intermediate step between cell 
cultures and animal models. These cultures enable the development of models for 
certain neurological diseases such as ischaemia, Parkinson´s disease and Huntington’s 
disease, as well as MS 79. 
 
Several CNS structures including brain, cerebellum and spinal cord can serve as the 
source for developing myelination, demyelination and remyelination cultures, each with 
their own characteristics 80. The cerebellum provides homogeneity in the type of axons 
(mostly Purkinje cell axons), while the brain and the spinal cord have more axonal 
variety in terms of type and diameter. In particular, the spinal cord may be a choice for 
OPC migration studies 81.  
 
With the help of a vibratome or a tissue chopper (McIlwain), approximately 300-µm 
slices of tissue are obtained and then cultured on membranes ( specifically designed for 
this type of culture) for subsequent demyelination. The first report of induced 
demyelination dates from 1959, in which Bornstein et al. describe that they succeeded 
in demyelinating a cerebellar organotypic culture by adding serum derived from animals 
with Experimental Autoimmune Encephalomyelitis 82 an animal model of MS. 
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Nowadays lysophosphatidylcholine, a detergent that mainly destroys myelin, is used as 
a demyelinating agent 83. After removing the detergent, the OPCs present in the culture 
are capable of regenerating myelin enabling remyelination studies  81. 
 
This type of model allows assessing the regenerative capacity and speed of endogenous 
cells to regenerate myelin under the influence of different drugs. It is also possible to 
analyse remyelination by cell therapy. For this, cytosine arabinose should be added to 
the culture to supress the proliferation of endogenous cells 84 and avoiding therefore the 
remyelinating potential of endogenous OPCs.  
 
Culture growth can be followed with time-lapse imaging 81,85. At the end of the culture 
period, the tissue is fixed and immunofluorescence staining is performed to label axons 
and myelin. By confocal microscopy the area occupied by myelin-coated axons 
compared to the total area of axons is analysed obtaining semi-quantitative data 70 
(Figure 8). Internodal length and g-ratios analysed by electron microscopy can be 
indicators of the remyelination quality. 
 
To achieve a favourable culture growth, young animals should be used. Nevertheless, it 
should be also taken into account that demyelinating diseases do not tend to occur in 
early stages of development. Finally, although the structure of the original tissue is 
maintained, these models do not replace in vivo models. However, they are useful tools 
for screening treatments in advance of in vivo testing, thereby reducing the number of 
animals to be used 79. 
 
Figure 8: Left: Oligodendrocyte precursor cell image labelled for NG-2 (Green) and 
Hoechts (blue). Right: Cerebellar organotypic culture confocal image stained for MBP 
(red), Neurofilament (green) and Hoechts (blue). Yellow represents the colocaliation of 
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myelin and axons. Notice that both images have been modified to obtain more intense 
colours.  
3.3. In vivo models 
 
3.3.1. Zebrafish  
Zebrafish is a vertebrate animal that has been widely used in developmental studies. 
Given the fact that it gets to the adult stage quickly and that is transparent, it makes 
possible to visualise internal structures noninvasively. In addition, myelination in this 
fish species is similar to the one that takes place in mammals 86. In fact, it has 
homologous genes involved in the myelination process 87. Due to these reasons, this 
animal has been used in myelination studies and in drug screening 88. 
 
Further, transgenic zebrafish have been developed in which OLs express membrane-
targeted green fluorescent protein 89, and in which both OLs and Schwann cells express 
a fluorescent protein making them visible90. These models are useful for studying 
myelination in vivo 90, but do not allow analysis of remyelination due to the lack of 
physiological demyelination. To perform remyelination studies in this model, 
demyelination has been achieved by destroying myelin with laser microsurgery 89, or by 
producing transgenic individuals such as the system reported in 2013 by Park’s research 
group, in which OLs die after exposure to metronidazole 91. After the microsurgery or 
when metronidazole is taken off, remyelination process starts. 
 
These processes can be monitored in vivo by time-lapse confocal microscopy without 
the need of sacrificing the animal, provided that OLs express a fluorescent protein 89. In 
addition, post-mortem immunofluorescence can be performed to search for the proteins 
of interest. 
 
This model provides a rapid method for assessing candidate agents for the treatment of 
demyelinating diseases, given that it is possible to monitor OLs in vivo 87,92. Related 
with this, Franklin’s research group developed a screening platform based on this type 
of model. They identified the most promising compounds to be tested later in 
mammalian models 92. However, these models are not suitable for testing cell therapy, 
given the technical difficulties involved. 
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3.3.2. Mammalian animal models  
A great variety of models allow us to study remyelination in mammals. The main 
advantage of using mammals is their closeness to humans. Here, we will focus on 
murine models, which are the most widely used ones. These have been carried out for 
studying pathological processes associated with demyelinating diseases and 
remyelination, and can be classified into three types: models of toxicity, models of viral 
infection and immune response based models.  
 
The ways of obtaining data are similar for all the murine models listed below, with 
some exceptions that will be specified later. During the development of the model, 
magnetic resonance imaging can be used for monitoring animals. After sacrificing 
animals, histopathological studies can be performed to detect myelin by using Luxol 
Fast Blue, immunohistochemical or immunofluorescence analyses. The remyelination 
quality can be studied determining the g-ratio of axons by electron microscopy. Another 
possibility is to extract the CNS, do an emulsion with the tissue and analyse the cell 
content by flow cytometry or gene expression 62  
   
3.3.2.1. Models of toxicity  
Toxin-induced local lesions: These are models of localised acute cytotoxicity, in which 
OLs are depleted93 following an stereotaxic injection of lysophosphatidylcholine (LPC) 
or ethidium bromide (EB), among other agents. EB is an intercalant dye that produces 
the loss of OLs and astrocytes, but does not affect axons 94. LPC alters the membrane 
composition, specifically of OLs, due to its membrane fusogenic properties, destroying 
the myelin 95,96. As a consequence, microglia and macrophages move towards the 
generated lesions, a reactive astrogliosis in generated, axonal homeostasis is disturbed 
and OPCs proliferate and migrate to the damaged tissue 97. There is no consensus 
regarding the presence of concomitant demyelination and excessive inflammation 94,98. 
Further, lesions can be directed to different regions of the CNS and peripheral nervous 
system, including the dentate gyrus 99, sciatic nerve 100, spinal cord 97 and centrum 
semiovale 101.  
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These toxin-induced models are highly reproducible 98 and useful for studying the effect 
of different drugs on remyelination alone, in the absence of inflammation. However, it 
needs to be taken into account that there is necrotic damage around the injection site 
98,101.  
  
Models of general toxicity: These models are based on the production of demyelinating 
lesions by neurotoxic, chemical, or biological agents administered through the diet. The 
most widely used toxin is cuprizone, a copper-chelating agent that induces OLs 
apoptosis, and as a consequence, demyelination. Though the mechanism involved 
remains unclear, it has been proposed that it produces errors in the mitochondrial 
respiratory chain 102. In contrast to Experimental Autoimmune Encephalomyelitis, that 
will be explained further, T cells do not play a role in the generation of this model, and 
not all the regions of the brain are affected in the same way 103. Depending on the 
duration of cuprizone treatment, 6 or 12 weeks of treatment, it is possible to produce an 
acute or a chronic model, respectively. In both of them, after stopping the cuprizone 
treatment, there is a spontaneous remyelination of the lesion, this being slower and more 
limited in the chronic model 102,104. A variation of these models has been developed, 
using curpizone in combination with rapamycin, achieving a complete demyelination 
and slower remyelination when compared to cuprizone alone 105.  
  
The model is simple and reproducible, but age, sex and the species of animals used, can 
modify the results 102. For instance, remyelination is slower and more limited in old 
animals103.  
 
The model enables to study demyelination and remyelination processes that occur in the 
CNS and the effect of drugs and cell therapies 104. However, it should take into account 
that to study cell therapies it is necessary to administer cells after withdrawing 
cuprizone from the diet in order to avoid these cells to be damaged. Further, we should 
emphasize that precursor cells are not affected by cuprizone and hence they will 
compete with the administered cells to repair the lesions 102. 
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3.3.2.2. Models based on viral infection  
These models are based on the hypothesis that some viral infections may cause 
demyelinating diseases such as MS. The most commonly used viruses are the Semliki 
Forest virus 106 and Theiler's murine encephalomyelitis virus 107. Semliki Forest virus 
was first isolated in mosquitoes and rarely affects humans. This virus can infect OLs 
and due to the highly virulent feature of the M9 mutant, the avirulent A7 strain is more 
frequently used. After the virus has infected oligodendrocytes, the immune system 
responds by attacking OLs, generating in this way demyelination. Theiler's murine 
encephalomyelitis virus leads to neurological pathological features (such as paralysis 
and encephalomyelitis) in a wide range of animal species. The most commonly used 
strains include the virulent GDVII and the less virulent ones, Daniels and BeAn strains. 
 
Models of viral infection allow us to explore the potential effect of immunomodulatory 
and remyelination therapies on CNS cells infected by a neurotrophic virus 108. This 
feature is interesting since some authors described that MS may be cause by a viral 
infection109. However, these models are not extensively used, due to the long incubation 
periods between infection and the onset of the symptoms, the high mortality rates 
among infected animals, and the technical difficulties related with the manipulation of 
viruses. Lastly, these models are not appropriate for testing cell therapies, as the virus 
would have tropism for injected cells, being affected in the same way as endogenous 
cells.  
3.3.2.3. Models based on immune response: Experimental Autoimmune 
Encephalomyelitis (EAE) 
The first reference to this experimental model dates from 1933, when Berry’s research 
group succeeded in causing inflammation and demyelinating lesions in the CNS of 
monkeys after several consecutive intramuscular injections of brain emulsion 110. The 
mechanism involved in the generation of the models were not clearly elucidated, but 
now it is known that this condition is mediated by specific T cells against myelin 
antigens, and that it has clinical and histopathological similarities to MS 111. In fact, this 
is the experimental model that exhibits most similarities to the human disease and the 
most commonly used for studying remyelinating drugs.  
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The features it shares with MS include the destruction of myelin, the development of 
lesions over time and across the CNS, though mainly perivascular in scattered foci, and 
the presence of immunoglobulins in both the cerebrospinal fluid and the CNS. 
Although, demyelination and remyelination in these models are less extensive and more 
acute than in humans 112, this model is considered the gold standard for the study of MS. 
It is used for preclinical proof of concept of new pathways and mechanisms of action in 
the pathogenesis of autoimmune diseases. Finally, many of the findings with this model 
have been applied to treatments in patients.  
 
There are two subtypes of this model. The active one, in which animals are immunised 
against a myelin peptide, together with Freund´s adjuvant and pertussis toxin. 
Depending on the peptide and the animal host and strain, there are a range of different 
models, and these are widely reviewed in the literature 80,108,113. The passive or the 
adoptive cell transfer model one is produced by injecting specific active lymphocytes 
against myelin, which are obtained from the lymph nodes of animals that have 
undergone active immunisation. 
 
We have to be cautious when analysing the results obtained with this model, since there 
are many cases of therapies that have been proven to be effective in the animal model 
but did not shown the same positive effects in humans 114. Moreover, this type of model 
fails to predict adverse effects of treatments, especially long term effects, due to the 
short periods of time of the model 79,115. On top of that, it is an expensive animal model 
in terms of numbers of animals that need to be used, time and money 81. Its limitations 
are mainly related with the lack of understanding of all the mechanisms involved in the 
pathogenesis of the model, and the short time frame of the model for studying chronic 
conditions. Finally, this is the most complex model of all those mentioned in this 
section and this sometimes makes the interpretation of findings difficult 116. 
 
Remyelination failure is more characteristic of the chronic forms of MS. For this reason, 
chronic EAE models are more suitable for studying remyelination due to the more 
similarities with the secondary progressive MS114. These models are the ones produced 
by MOG peptide in Dark Agouti rat and C57BL/6 mouse 117,118. 
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The principal information obtained from this model is the animal clinical score. This 
information is subjected to the observer’s bias; therefore it is essential to carry out 
double-blinded experiments as well as appropriate statistical analyses 119.  
3.3.2.4. Other models 
In 2015, Gocke’s research group published a study that combined the EAE model with a 
toxin-induced demyelination model. In this new model, demyelination occurs in the 
absence of neurodegeneration which, according to the authors, makes possible to assess 
remyelinating therapies that have previously been difficult to study given the 
neurodegeneration in EAE 120. 
 
Lastly, there are other models that are based on the use of genetically modified animals, 
in which T cells express specific receptors of myelinating cells, in order to produce 
demyelinating lesions. However, these models are not yet commercially available, 
rarely used, and require long periods of development. 
  
3.4. Choosing the appropriate model 
 
Models to study myelination, demyelination and/or remyelination have been 
recapitulated. In order to obtain valuable results and proper conclusions, it is of high 
relevance to choose an appropriate model.  For that, the following points whould be 
taken into account.   
• Myelination, demyelination and remyelination: Although the final goal is to 
induce the production of new myelin after damage, not all the models allow us 
to analyse this directly. Nevertheless, all the models do provide information 
needed to improve our understanding of the mechanisms related to 
remyelination processes. 
• What question do we want to answer? Not all the models can provide answers to 
all questions. For this reason, it is important to clearly define which data we 
would like to obtain and chose the most appropriate model for this aim (Table 
1).  
• Models are complementary: It is advisable to use more than one model, since 
different models can provide complementary information that increases the 
quality of the results. Each model has strengths and weaknesses, and provides 
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different types of data, which well used allows the researchers to obtain more 
robust conclusions. 
• The most complex is not always the best: The greater the complexity of the 
model, the more appropriate for studying remyelination. However, 
understanding the mechanisms prior to remyelination with simpler models may 
help identifying and improving our comprehension of processes that lead to the 
development of remyelinating therapies.    
• From simple to complex models: The simplest models allow testing higher 
numbers of molecules/therapies, since it is easier to obtain larger sample sizes 
and there are few ethical constraints. Moreover, those models are easier to 
manage and less expensive. Then, the agents that have yield positive results can 
be analysed in more complex models, which mimic better the mechanisms 
occurring in humans. In this way, as we move to more complex models we 
reduce the number of candidate agents that eventually are going to be tested in 
clinical trials (Figure 9). 
• We cure mice; what about humans? Treatments studied in experimental models 
with positive results not always show the same effects in patients, being not 
effective or producing serious side effects.  It is necessary to remember that we 
are working with in vitro, ex vivo and/or in vivo experimental models and that it 
is indispensable to be careful extrapolating the results to humans.  
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4. Remyelination therapies 
 
Neurodegeneration is the most incapacitating factor in MS and enhancing remyelination 
has been postulated as the main strategy to avoid axons to be damaged. Remyelination 
therapies can be divided in two main strategies, which consist in the transplantation of 
exogenous pro-remyelinating cells (cell therapies) and the stimulation of endogenous 
cells to generate new myelin (pharmacological approach). 
Table 1: Summary of the main characteristics of models for studying myelination, demyelination 
and remyelination 
Figure 9: Summary of the models in complexity order and the number of candidate 
treatments that can be tested in each model. Form left to right: in vitro models (image of 
OPCs culture), ex vivo models (image of cerebellar organotypic culture), in vivo models 
(image of Zebrafish and mouse) and at the end of the process, humans. 
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The idea behind cell therapies is to repopulate the pool of OPC and several efforts have 
been made in this sense. Oligodendroglial cells demonstrated to remyelinate and restore 
neurological function in models of CNS demyelination 121,122. Schwann cells 123, 
olfactory ensheathing cells or embryonic stem cells  have also been postulated as 
feasible candidates 124. To continue, transplanted neural stem precursor cells (NSPC) 
were able to reach demyelinated lesions and produce positive effects 125. In addition, 
intravenously administered mesenchymal stem cells (MSC) reduced demyelination, 
increase neuroprotection and modulate inflammation in the animal model of the disease 
(reviewed in 126).  However, beneficial effects of NSPC and MSC have been related 
with the modulation of the microenvironment and with the release of soluble factors 
respectively, rather than with direct cellular regeneration 127,128. 
 
Although these are interesting results, there are some arguments against the use of cell 
therapy in MS. First, undifferentiated OPC have been found in MS patients´ lesions 
being unable to differentiate to oligodendrocytes and to generate new myelin and there 
is no reason to think that transplanted cells would not be inhibited in the same way. 
Secondly, it seems logical to think that these therapies could be useful when no OPC are 
present in the lesions, which seems not to be the case of MS. To continue, intravenous 
administration has not been effective and direct administration into the lesions is not 
feasible due to the multifocality of the disease. Finally, we should add the possible ethic 
limitations regarding the use of some cell types such as embryonic stem cells.  
 
Having these considerations in mind and remembering that OPC differentiation appears 
to be the most vulnerable step in remyelination failure, an increasing interest in 
targeting the pathways involved in this process is appearing (pharmacological 
approach)127. The strategies to promote OPC differentiation can be divided in two main 
approaches; the blocking of remyelination inhibitors or the use of remyelination 
accelerators 127. 
 
Regarding to the first approximation, for example, extracellular matrix has been shown 
to inhibit remyelination and the pharmacological manipulation of extracellular matrix 
can improve remyelination 129. Interestingly, Leucine-rich repeat and immunoglobulin-
like domain-containing nogo receptor-interacting protein 1 (LINGO1) has been 
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postulated as the most promising remyelination target. LINGO1 has shown to inhibit 
OPC differentiation 130 and  the inhibition of LINGO1 has demonstrated to accelerate 
CNS remyelination in a model of lysolecithin induced demyelination 131–133.  However, 
humanized monoclonal antibodies against LINGO1 failed in a phase 2 trial in MS due to 
poor results134.  
 
In order to accelerate remyelination, several strategies have been studied. For example, 
electrically stimulated demyelinated axons form new glutamatergic synapses with OPCs 
causing OPCs to exit the cell cycle and undergoing differentiation 135. In addition to 
this, the activation of RXRγ is able to induce OPC differentiation by binding to thyroid 
hormone receptor or peroxisome proliferator-activated receptor-γ 136. Vitamin D has 
also been identified to regulate OPC differentiation in the RXRγ pathway137.  
 
Moreover, in the last decade other strategies have also been postulated as feasible 
remyelination inducers. In the context of this work, the ability of Extracellular 
Vesicles (EVs) and non-coding RNAs (ncRNA) to induce remyelination is going to be 
studied. To understand in deep the role that both factors can play in promoting 
myelination regeneration, specific sections will address all the related information 
(sections 5 and 6 of the introduction respectively) 
 
5. Extracellular vesicles and remyelination  
Adapted from Sáenz-Cuesta et al (2014) 138 and Osorio-Querejeta et al (2018) 139. 
  
Extracellular vesicles (EVs) are membrane-bound particles coming from inside a cell or 
formed directly from its membrane, and excreted to the extracellular medium. They 
carry information whose function is cell-to-cell communication without direct contact. 
They play a role in physiological and pathological conditions, being released during cell 
activation, stress and apoptosis. Specifically, these vesicles carry proteins, lipids and 
genetic material such as DNA, mRNA, and ncRNA, producing genotypic 140 and 
phenotypic  141 modifications in the recipient cell. These interactions are facilitated by 
the receptors placed on the surface of the EVs membrane, which allow the recognition 
of the target cell and the vesicles 142.  
INTRODUCTION 
 
	 36 
5.1. EVs classification 
 
5.1.1. Biogenesis 
Though there are several ways of classifying EVs, the main division in nomenclature is 
based on biogenesis. Those formed inside multivesicular bodies and released 
extracellularly upon fusion of these bodies with the plasma membrane are called 
exosomes 143. Their main characteristic is to have a uniform size of between 30 and 150 
nm, making them the smallest EVs. On the other hand, those known as microparticles 
(MP), microvesicles (MV) or ectosomes come from the modification of the cell 
membrane after external or internal stimuli. This leads to a softening of the membrane-
adjacent structure and allows evagination and vesicle formation, which followed by 
fission on the connecting membrane stalks until their full detachment. These MV/MP 
vary greatly in size, ranging from 0.3 to 1 µm in diameter 144,145. However, the size 
distribution of vesicles is overlapped between groups and sometimes difficult to 
differentiate, therefore, the International Society of Extracellular Vesicles proposed to 
call the entire set “extracellular vesicles” 146 (Figure 10). 
 
Figure 10:  Classification and size of different EVs subtypes. From György, 
B. et al 2011 147. 
5.1.2. Cell origin 
EVs have been also classified in relation with the parental cell from which they arose, 
being so far those obtained from circulating cells in peripheral blood the most studied 
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ones. Each cell has characteristic markers on its membrane enabling subsequent 
identification of the EV, e.g., as erythrocyte-, leukocyte-, platelet-, endothelial- or 
monocyte-derived. Further, studies focusing on central nervous system (CNS)-derived 
EVs have described neural stem cell-, neuron-, astrocyte-, microglia-, and 
oligodendrocyte-derived vesicles 144.  Interestingly, these vesicles can be detected 
remote from the site of release after cell activation, and have been postulated as markers 
of the CNS status.  
5.2. Techniques for studying EVs 
 
The study of EVs is not straightforward, particularly with respect to isolation and 
characterization due to their small size and the low concentrations found in human 
fluids. Although efforts have been made to unify criteria in EV research 146,148–152, they 
are yet not clearly established, making it difficult to compare studies. Differences 
derived from centrifugation protocols, fluorochrome labelling and analysis represent 
unsolved barriers to standardization. Nevertheless, the most widely used techniques can 
be summarized as follows: 
5.2.1. Isolation 
One of the main approaches that has been used for isolating EVs from human fluids or 
culture media supernatants is a series of sequential centrifugation steps. Different 
purities are obtained depending on the number of steps completed. Briefly, a first 
centrifugation step at a low velocity (200 to 300 g) separates cells from EVs-containing 
fluid, which can be further purified or directly pelleted. For a further purification, a 
second centrifugation must be carried out (at 2,000 to 10,000 g, depending on the fluid 
or EVs fraction required). Otherwise, EVs can be directly pelleted from the first 
supernatant (centrifuging at forces of 10,000 up to 100,000 g; ultracentrifugation). 
Though there are many variations among authors, the first approach to EVs analysis is 
usually based on the aforementioned steps. As an alternative protocol to obtain EVs, a 
sucrose gradient can be combined with one of the centrifugation steps.  
Another isolation technique is polymeric precipitation (e.g., Exoquick, System 
Biosciences, CA). The main advantage of this approach is rapid sample processing. 
However, the low purity obtained and mixing of different EVs subsets makes results 
difficult to interpret. The extraction of EVs by passing a sample through filters is a 
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cheap and easy method that can be applied alone or combined with centrifugation. 
Finally, size-exclusion chromatography and immunoaffinity methods are also 
commonly used analysis methods.  
5.2.2. Characterization 
Flow cytometry is a widely employed technique for studying EVs, especially for 
characterizing EVs origin thanks to the possibility of characterizing the membrane 
markers of their cell of origin. It is a powerful characterization tool, the process is rapid 
and the results can be quantified. Its main limitation is poor discrimination under 0.5 
µm. However, new high-resolution cytometers can detect particles as small as 0.2-0.3 
µm.  
Other tools are available to characterize nanoparticles in size and concentration with 
high resolution. They measure particles based on tunable resistive pulse sensing 
(qNANO, IZON Science, New Zealand) and Brownian motion of the particle with 
nanoparticle tracking analysis software (NTA, Nanosight, UK). The simple and user-
friendly operation and powerful measurements provided by these instruments have 
made them reference in the analysis of EVs. 
Electron microscopy is usually performed in combination with previous techniques to 
provide direct evidence of the presence of EVs and morphological information. On the 
other hand, the expensive and complex processing of samples limits its use. 
Fluorescence microscopy is normally used to analyse EV function in vitro, as well as to 
localise EV in tissues and budding process. In particular, confocal microscopy is widely 
used in EV research. However the lower size of EVs makes the acquisition of the 
images a tricky question.  
Interestingly, in the last year the study of the cargo of EVs is increasing our knowledge 
about the functions of these vesicles. Enzyme-linked immunosorbent and Western blot 
assays are being employed for the analysis of EVs; nevertheless they are less 
extensively used due to the poor characterization and quantification they provide. 
Notably, expression arrays and next-generation sequencing techniques are currently 
expanding to the field of EVs, specifically in an attempt to characterize their genetic 
cargo together with other –omics techniques such as proteomics or lipidomics . 
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5.3. Why extracellular vesicles?  
 
As it has been previously mentioned, EVs are involved in many biological processes, 
being their capacity to regulate immune response and cell differentiation the two most 
important processes in the context of this work 153. Vesicle secretion and the transfer of 
material carried within them in the CNS under physiological conditions were described 
many decades ago 154. The classic example was the presence of vesicles in the neuronal 
synapses 155, which was also confirmed recently 156. It has been observed that EVs are 
released by neural cells, oligodendrocytes, neurons, microglia, astrocytes in the brain 
and Schwann cells in the peripheral nervous system (reviewed in 144,157) transmitting 
information across de CNS 158. Finally, they play a role in myelin sheath biogenesis 
159,160, as well as in the repair of damaged neurons 161. All these imply that EVs perform 
functions necessary for growth and normal functioning of the nervous system.  
In addition, EVs are involved in processes of CNS diseases carrying specific 
pathological cargo or performing functions that produce potential damage 144. 
Interestingly, several diseases have been linked to EVs, including neurodegenerative 
diseases 162,163. Many studies have found variations in the number and function of 
circulating EVs in diseases such as Alzheimer’s disease, dementia, epilepsy, stroke, 
traumatic brain injury, malaria, and tumours (mainly glioblastoma), among others 
(reviewed in 164). On the other hand, few studies have explored whether variations in 
EVs in CSF directly reflect the pathophysiology of the CNS 165–171 and only a couple of 
them have examined EVs derived from the CSF as a surrogate marker for what occurs 
in the CNS 165,166. Of particular interest to this work, alterations in the concentrations 
and cell origin of EVs have been related with MS 138,165,172,173. 
The implication of EVs in CNS physiological and pathological conditions and their 
ability to carry messages from one cell to another suggests that the use of EVs as a drug 
delivery system or as a treatment, might be an interesting way of targeting and 
modulating the course of a disease. Moreover, the fact that EVs are able to cross the 
BBB makes them strong candidates for CNS disease therapy 174. 
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5.4. Therapeutic potential of EVs for demyelinating diseases 
 
Several works have been published demonstrating the therapeutic potential of EVs. 
These works will be discussed in the following paragraphs and have been summarized 
in Table 2. 
 
In some demyelinating pathologies, such as MS, the immune system is responsible for 
the damage caused to myelin. In this way, the ability of exosomes isolated from 
pregnant mice serum or human periodontal ligament stem cells to reduce the clinical 
score of the EAE animal model, has been addressed by inhibiting the immune 
response175,176. In addition, the intranasal administration of curcumin-loaded 
glioblastoma-derived exosomes to EAE animals ameliorated the clinical symptoms of 
the model, demonstrating that exosomes could work as anti-inflammatory drug delivery 
vehicles 177. 
 
As it was mentioned in the introduction, Ols are responsible for generating myelin that 
enwraps axons. The communication between Ols and axons is essential for the survival 
and functional maintenance of both. Interestingly, this communication between Ols and 
axons has been shown to be mediated by exosomes and, in addition, the interactions 
between Ols and axons might affect the cargo of exosomes 178. Moreover, when the 
cargo of exosomes released by Ols was analysed, researchers found that those vesicles 
contained high levels of myelin related proteins; more concretely PLP, MBP, MOG and 
CNP 179. This data was the first evidence of the possible role that exosomes could be 
playing in myelination. In a more recent work, it was suggested that Ol-derived 
exosomes were able to inhibit the differentiation of OPCs 160. Even though the authors 
did not demonstrate the mechanism by which Ols regulate OPCs in an inhibitory way, 
these results reinforce the implication of exosomes in OPC differentiation, an essential 
step for myelination and remyelination. In a different work, the ability of pregnant mice 
serum-derived exosomes to promote the trafficking of OPCs into lesions after 
intravenous administration in the EAE was shown 175 emphasizing the implication of 
exosomes in myelination related processes. 
 
To analyse the role that EVs play in pathological systems, several models have been 
used. In a model of white matter infarction in rats, researchers demonstrated that EVs 
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derived from microvascular endothelial cells (MVECs) were taken up by OPCs, 
inhibiting the apoptosis of OPCs and promoting survival, proliferation and motility of 
the cells. The authors demonstrated that those EVs contained microRNAs and adhesion 
molecules which were responsible for the shown effects 180. Moreover, Mesenchymal 
Stem Cell-derived exosomes (MSC-Exs) have been shown to promote oligodendrocyte 
formation and remyelination in a model of subcortical ischemic stroke. After 
intravenous administration of MSC-Exs, authors were able to detect higher levels of 
MOG protein and more myelinated axons 181. 
 
Furthermore, a work published in 2014 demonstrated that exosomes from blood of 
young and environmentally enriched rats significantly increased the myelin content, 
oligodendrocyte precursor and neuronal stem cell levels and reduced oxidative stress 
and astrogliosis in demyelinated hippocampal slice cultures 182,183. They also tested the 
effect of these blood-derived exosomes in vivo by intranasal administration in aged rats, 
showing positive results in myelin generation. The authors related the exosomes-derived 
pro-remyelination effect to their cargo, suggesting that the presence of microRNAs 
could be responsible for promoting remyelination 182.  
 
Another aspect of demyelinating diseases is that the lack of myelin wrapping axons 
might, if remyelination does not take place, induce the disruption of the axons and, 
therefore, neurodegeneration. Neuroprotection is a key factor that might improve 
patients’ outcome and increase their life quality. Regarding to this, mesenchymal stem 
cells derived EVs were shown to be effective in models of traumatic brain injury after 
both intravenous or intraperitoneal administration, decreasing inflammation and 
increasing neuroprotection, angiogenesis and neurological function, opening therapeutic 
possibilities in which neuroprotection can be reinforced 184,185.  
 
5.5. Delivery into the Central Nervous System  
 
To be able to use EVs as therapeutic biopharmaceuticals for MS, it is imperative to 
ensure that EVs will reach the CNS. That can be achieved, for example, by delivering 
EVs directly to the brain, by using systemic injections, or by administering vesicles via 
intranasal route. The intranasal route can be efficient for different cell type derived EVs, 
including T-cell, fibroblast and tumour derived exosomes 177. This delivery route not 
INTRODUCTION 
 
	 42 
only leads to increased brain accumulation of exosomes, but more importantly, it has 
also shown to reduce inflammation in EAE animals when exosomes are loaded with 
therapeutic anti-inflammatory molecules, as was previously mentioned 177 . The latter 
clearly underlines the potential of EVs for treating MS via the intranasal route, which is 
further supported by successful experiments conducted in the context of other CNS 
diseases such as Parkinson’s disease (PD). In a mouse model of PD, catalase-loaded 
macrophage exosomes reached the brain and provided antioxidant-mediated 
neuroprotection 186. Neuroprotection was also induced by curcumin loaded embryonic 
stem cell exosomes in an ischemia-reperfusion injury model 187. Repeated treatments 
with curcumin-loaded exosomes led to a reduction of inflammation and improved 
neurological score and restored the expression of several BBB proteins.   
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However, it appears that EV loading with exogenous cargoes prior to intranasal 
administration is not always essential for therapeutic effects in the CNS, as recently 
demonstrated in a status epilepticus mouse model. Unmodified human bone marrow 
derived MSC-Exs reduced neuron loss and inflammation in the hippocampus of treated 
mice, which more importantly led to preservation of memory function 188. These 
properties of unmodified MSC-Exs for treating CNS disease are particularly interesting 
and promising for MS. Given the trend towards replacing certain MSC cell therapies 
with EV based therapies, and the fact that a number of MSC cell therapies have been 
tested in Phase I/II clinical trials for treating MS as well 189, it is likely that MSC EVs 
will gain further focus in the short term for targeting MS pathology as well. 
 
In addition to the intranasal administration route, as described above, other local 
delivery options have shown efficacy for EV based CNS therapies as well. Unilateral 
direct brain infusion of glioblastoma derived exosomes, pre-loaded with hydrophobic 
small interfering RNA (siRNA), led to exosome-dependent bilateral Huntington 
messenger RNA (mRNA) silencing in the brain of treated mice 190. Other therapeutic 
strategies not directly relying on drug delivery can be efficient as well. Intracerebral 
neuroblastoma exosome administration to an Alzheimer disease mouse model reduced 
amyloid-β levels in the brain and lowered the associated synaptotoxicity, tapping thus 
into natural EV-mediated Aβ clearance pathways 191. Similar effects were observed also 
when using primary neuron exosomes, the effect being cell type specific as glial 
exosomes were less efficient in the capture of amyloid-β 192. This is not surprising as the 
transport of exosomes to brain parenchyma can be specifically related to the presence of 
specific surface molecules such as folate receptor α 193 as well as other EV related 
signatures that can, for example, mediate periphery-brain signalling in inflammation 194. 
 
In many cases, however, systemic rather than local therapeutic EV administration would 
be preferred for various reasons, including the safety of the treatment administration. 
Despite the fact that BBB has been proposed as virtually impermeable to most 
molecules there is some evidence that unmodified exosomes can enter the brain to some 
extent 195, but brain exposure is significantly increased when using certain brain 
targeting ligands such as the rabies virus glycoprotein derived RVG peptide 196. The 
brain targeting RVG peptide, even though the precise targeting mechanism has not been 
fully elucidated, led to increased brain delivery of siRNA when decorated on dendritic 
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cell exosomes 197. Using that strategy, it was possible to lower the levels of a target gene 
on both mRNA and protein levels in the brains of wild type mice 197,198.  
 
6. Non-coding RNAs as remyelination mediator in MS  
 
Adapted from Osorio-Querejeta et al. (Book chapter in “Design and development of 
novel therapeutics agents for multiple sclerosis”. RSC drug discovery series. To be 
published in 2019) 
 
Non-coding RNAs (ncRNA) have been related with MS in many characterization 
studies in which different expression levels of small ncRNA has been described 
between MS patients and healthy controls and also between different classes of MS. In 
this context, the main established relation between sncRNA and MS has been through 
the potential interest of these molecules as biomarkers in MS 199. However, a functional 
role for this sncRNA in the etiopathology of MS has been also postulated. 
 
MicroRNAs (miRNAs), a type of sncRNA, are short sequences of RNA (21-24 nt) that 
regulate gene expression by binding to target messenger RNAs (mRNA) and preventing 
their translation to protein. Canonical microRNAs are transcribed by RNA polymerase 
II as part of a longer transcript called pri-miRNA. This primary transcript acquires a 
hairpin secondary structure that is processed by Microprocessor, a protein complex 
formed by one molecule of the Drosha endonuclease and two molecules of DGCR8. 
Drosha cuts at the base of the hairpin of the pri-microRNA to generate a shorter RNA of 
about 60 nucleotides-long. This stem-loop structure called pre-miRNA is transported to 
the cytoplasm by Exportin-5 200, where will further be processed by Dicer. This 
endonuclease will generate a miRNA duplex after cutting both strands near to the loop. 
Finally, this miRNA duplex is loaded into an Argonaute protein and only one of the two 
strands is kept in the complex, which will be the functional while the other strand is 
usually degraded. Once the microRNA is loaded into the silencing complex, it binds to 
the target mRNA by base-pairing and either produces its degradation or inhibits its 
translation to protein 201. 
 
In animals, microRNA-mediated repression requires the binding of the protein TNRC6, 
that recruits other proteins which depending on the context, cause mRNA decay or 
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translation repression202. The predominant way of microRNA-mediated regulation of 
transcription is through targeting mRNA 203,204, which means that the effects of 
microRNA regulation can be measured at mRNA level. 
 
It has been described that miRNA take part in virtually all biological functions such as 
development, cell differentiation, proliferation, cell death and cell signalling. Taking 
into account that they are part of the gene expression regulation network, it is not 
surprising that the alteration of these small molecules has an impact on human health. In 
fact, an increasing number of articles are being published describing the relationship of 
microRNA deregulation with several human diseases such as cancer, cardiovascular 
diseases, neurological disorders and immune mediated diseases205–209.  
 
The first evidence of the implication of microRNA in multiple sclerosis was reported in 
2009 by three groups 210–212. Otaegui and colleagues reported that miR-18b and miR-
599 were overexpressed in leucocytes from MS patients during relapse episodes. 
Moreover, they proposed that miR-96 was relevant for remitting phase of the disease, 
which was identified by co-expression networks210. Short after having described the 
deregulation of some microRNA in leucocytes from MS patients, another group 
reported the dysregulation of 165 microRNA in MS patients compared to healthy 
controls and they found that miR-145 was able to correctly classify 89.7% of the 
samples tested (a total of 39) 211. Interestingly, in an attempt to improve these results, 
Keller and colleagues apply machine-learning techniques to select a subset of 
microRNA, which was able to distinguish both groups. This analysis yielded a group of 
48 microRNA able to discriminate patients from healthy controls with an accuracy of 
96.3%, a specificity of 95%, and a sensitivity of 97.6%.  
 
After these first profiling studies, several studies have been published trying to elucidate 
the specific role of miRNA in multiple sclerosis. Those works, have analysed 
microRNA expression in different sample types in humans (leucocytes, serum, plasma, 
specific lymphocyte subsets, CSF and brain) and also in different tissues of the EAE 
model. These works have provided a list of miRNA that can have a role in multiple 
sclerosis by regulating different processes in the immune cell development and 
differentiation as well as in neurodegeneration and remyelination. 
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MicroRNA have been the most widely studied family of sncRNA, but other types, such 
as small nucleolar RNA (snoRNA) have also been related to MS. snoRNA are grouped 
into two main families: C/D box and H/ACA box snoRNA, according to the 
evolutionarily conserved sequence elements213 (Figure 11).  
 
Figure 11: Simplified scheme of RNA classificaition.  
 
The risk of developing multiple sclerosis has been, in part, associated with epigenetic 
modifications in which ncRNAs are implicated 214. In this sense Drosha, Dicer and 
DGCR8 have been found to be overexpressed in RR MS patients, underlining the 
possible involvement that the dysregulation of microRNAs might play in the 
pathogenesis of MS 215. In addition to this, long non-coding RNAs, which also regulate 
gene expression, have been associated with the regulation of OPC differentiation and 
the development of MS animal models 216. Although long non-coding RNAs (lncRNAs) 
as therapeutic targets in epigenetic diseases has been proposed 217, their functions and 
potential as therapeutic mediators remain largely undefined 218 and no papers have been 
published elucidating the role that this kind of ncRNAs may play in MS therapy. On the 
other hand, microRNAs have been postulated as feasible and promising molecules to 
induce both immunomodulation and remyelination (the two main goals in MS therapy).  
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6.1. NcRNA as Immunomodulators in MS therapy 
 
Several strategies have been used to identify potential targets and mediators for 
immunomodulatory ncRNA mediated therapy. One of these consists in the use of 
expression networks analysis, which has been used to identify dysregulated ncRNAs in 
patients, both in relapse and remission, and in controls. This kind of approaches can led 
to a list of therapeutic ncRNAs candidates 219. It has been shown that this dysregulation 
favoured proinflammatory and T cell mediated autoimmunity, highlighting the role that 
microRNA play in the development of the disease and opening therapeutic approaches 
in microRNA mediated immunotherapy for MS 220.  
 
Evaluation of microRNAs expression has been used as biomarkers of treatment 
efficiency and disease evolution given that different drugs affect miRNA expression. 
However, these studies have also been used to determine microRNAs that can be targets 
of immunomodulatory therapies.  
 
The dysregulation of microRNAs founded in MS (and in different stages of the disease) 
opened the opportunity to the discovery of new therapeutic targets 221.  For example, 
miR-141, miR-200a and miR-448 have been found to be up-regulated in MS patients. 
These microRNAs regulate Th17 cell differentiation while inhibiting Treg 
differentiation 222,223. Polarization of T cells to Th1, Th2 or Th17 is a critical process in 
cell mediated immunity and these microRNAs could be the targets for an 
immunomodulatory therapy in MS patients. Related with this, treatment of patients 
derived T-cell with microRNA inhibitors for miR-27, miR-128 and miR-340, which are 
overexpressed in MS patients, were able to restore Th2 cytokine production in vitro 220.  
Moreover the role of microRNAs as immunoregulators has also been addressed in vivo.  
MiR-155 is a positive regulator of CNS autoimmune inflammation and miR-155 knock 
out mice generated a less severe EAE by decreasing Th1 and Th17 response in the 
CNS. In addition, when EAE WT animals were treated with locked nucleic acied-
modified anti-miR-155 mice clinical severity was reduced 224. Moreover, the lentiviral 
infection of miR-326 in EAE mice, a microRNA which is up-regulated in MS patients, 
leads to an increase in disease severity by targeting ETS-1, a known negative regulator 
of Th17 cells 212. These results indicate that miR-155 and miR-326 may be  potential 
targets for MS patients. Finally the down-regulation of miR-106a-363 cluster and the 
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up-regulation of miR-132 have shown to lead to more severe EAE evolution and 
therefore they have been proposed as a therapeutic target for anti-inflammatory 
treatments in MS 225,226  
 
Taking all this information together, we can summarize that microRNAs are active 
players in immune alteration that take place in MS and therefore their utilization as 
mediators or targets in future MS therapies is a promising field that is giving its first 
steps.  
 
6.2. NcRNAs as remyelination promoters 
 
It has been widely proposed, as explained previously, that the stimulation of OPC 
differentiation could increase myelin regeneration being a promising therapeutic 
approach to induce remyelination in MS. As it will be discussed below, microRNAs 
play an important role in the precise and complex program that take place in OPC 
differentiation and remyelination (Table 3). 
 
Dicer knock out mice showed impaired myelination, which was related with a poor 
OPCs differentiation, as the observations of proliferating OPCs but the lack of 
oligodendrocytes suggested 227,228. Dicer 1 and Olig 1 knock out mice were used to 
search for the microRNAs responsible for oligodendrocyte maturation. miR-219 and 
miR-338 expression were significantly reduced in both animals indicating the role that 
these microRNA may be playing in OPCs differentiation. In addition to this, inducible 
oligodendrocyte Dicer knockout mice generate demyelination and inflammatory gliosis. 
Interestingly, these oligodendrocytes reduce the production of miR-219, highlighting 
the importance of this microRNA 229. In this sense, differentiating OPCs and human 
white matter have been shown to be enriched in miR-219 and conditional miR-219 
mutant mice showed reduce numbers of OL in the corpus callosum and optic nerve but 
not lower OPCs levels 230,231, suggesting that miR-219 is necessary for OPC 
differentiation. To reinforce this idea, OPCs were obtained from a Dicer 1 knock out 
mouse being unable to differentiate to Ol. However, when miR-219 was transfected to 
these cells, they increased the expression of MBP proteins and the overall expression of 
CNP, MBP and MOG genes, which are associated with oligodendrogenesis 228.  In 
addition, human endometrial-derived stromal cells have been shown to differentiate to 
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pre-oligodendrocytes after lentiviruses mediated miR-219 overexpression 232. Similar to 
this, mouse embryonic stem cells transfected with miR-219 were able to differentiate to 
OPCs, and induced remyelination more efficiently than wild type OPCs after their 
transplantation into a mice model of toxin demyelination 233. In the same model of 
cuprizone induced demyelination, lentivirus overexpressing miR-219 were intrathecally 
administered, increasing MBP and CNP levels and decreasing demyelination in the 
model 234. In addition, miR-219 inducible knockout mice were demyelinated by 
injection of lysolecithin and fewer remyelinating sings were detected indicating that 
miR-219 is critical for remyelination after a demyelinating insult. In order to confirm 
these results, miR-219 overexpressing mutant mice were generated and lysolecithin 
induced demyelination generated in the spinal cord. These animals were able to 
generate more OPCs and to increase the percentage of remyelinated axons 230.  Finally, 
when mimic-219 was administered intrathecally to the EAE animal model, a decreased 
in the clinical score was shown thanks to the generation of new myelin forming 
oligodendrocytes 230. These results suggest that the elevation of miR-219 induces OPCs 
differentiation and therefore remyelination, opening a promising therapeutic approach.   
 
Mir-219 has been predicted and experimentally demonstrated to target PDGFRα, Sox6, 
FoxJ3 and ZFP238, all of which are related with OPCs differentiation 228.  The 
expression of PDGFRα induces OPC proliferation and Sox6 prevents their 
differentiation. Another proposed route of action for miR-219 is related with the 
repression of Lingo1 expression, a protein that has demonstrated to inhibit OPC 
differentiation. 
 
Although miR-219-5p is the most promising candidate to show remyelinating potential, 
is not the only microRNA described to be involved in these processes. Both, miR-219 
and miR-338 are overexpressed in perinatal stages coinciding with oligodendrocyte 
maturation 227 and miR-338-5p appears also to be upregulated during mouse brain 
maturation and to regulate OPC differentiation in humans 231. Moreover, the 
overexpression of miR-338 in human endometrial stromal cells by lentivirus induce 
their differentiation to OPCs 235. Interestingly, miR-338 and miR-219 knock out mice 
did show lower myelin levels when compared to miR-219 knock out mice, indicating 
that miR-338 cooperate with miR-219 in the regulation of oligodendrocyte maturation 
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230. As a consequence, the combination of both microRNAs has seen to be more 
effective inducing OPC differentiation in vitro 76,78.  
 
MiR-146a has also been proposed to regulate this process. Primary OPCs culture 
transfected with miR-146a differentiate to oligodendrocytes whereas the inhibition of 
this microRNA with hairpin inhibitors block their differentiation 236. This microRNA 
has shown to be up-regulated during the first stages of cuprizone induce demyelination 
model 237. In addition, the infusion of miR-146a in the model stimulates the generation 
of oligodendrocytes and augments myelination 237, which has been related with the role 
that the microRNA might play in myelin restoration. This effect has shown to be 
mediated by Interleukin-1 receptor-associated Kinase 1 (IRAK1) 236. Nevertheless, 
these results are somehow in contrasts with latter ones that showed higher numbers of 
oligodendrocytes and reduced demyelination in a miR-146a knock out mice238. Mir-
146a has also been described to reduce the inflammatory response, and this might 
explain these contradictory results 239. 
 
To finish with the use of microRNAs as remyelination inductors, the overexpression of 
miR-23a in OPCs leads to an increase in CNP positive cells. Genetically engineered 
mice to overexpress miR-23a not only increase myelin related genes expression, but 
also myelin thickness in the corpus callosum 240. Interestingly, miR-23a has shown to 
up-regulate 2700046G09Rik, a lncRNA which increases the half-life of miR-23a. The 
presence of this lncRNA in oligodendroglia has been proposed to potentiate the 
activation of miR-23a/PTEN/Akt/mTOR and MAPK cascades regulating the expression 
of myelin related genes in Ols 241. 
 
MicroRNAs has also been proposed to be potential target of remyelinating drugs. miR-
221-3p was proven to inhibit Schwann cell myelination in vivo by targeting NAB1 242. 
Similar to this, miR-212 and miR-297c-5p were shown to inhibit the maturation of Ols 
243,244. In addition, the overexpression of miR-125a-3p has been described to impair 
rodent oligodendroglia maturation. More precisely, this microRNA reduces the number 
of MBP positive oligodendrocytes. Although MBP is not a predicted target of miR-
125a-3p, by in-silico analysis tools this microRNA has been reported to regulate 
myelination pathways up-stream. Interestingly, miR-125a-3p has been shown to be up-
regulated in MS patients´ CSF, which could indicate that this microRNA is inhibiting 
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remyelination245. Although the role of these microRNA in central nervous system 
remyelination should be studied deeply, its down-regulation may be a therapeutic 
approach to stimulate oligodendrocyte differentiation and remyelination. To conclude, 
miR-26a, a microRNA that is overexpressed on IFN-β treated patients, targets SLC1A1 
which is involved in glutamate receptor signalling pathway. Excessive glutamate is 
released in demyelinating lesions and this can be a cause of neuron toxicity 246. 
Targeting miR-26a can promote neuroprotection or at least inhibit neuron-toxicity in 
neurodegenerative diseases 247. 
 
6.3. ncRNA delivery to the CNS 
 
NcRNAs have shown to play a role as immunomodulators and myelin inductor making 
them therapeutic candidates for MS. The use of sncRNAs and more concretely 
microRNAs as therapeutic mediators may involve the manipulation of microRNAs 
levels by increasing or repressing their expression in the affected tissue. This could be 
done by miRNA mimic (agonist) or by anti-miR (antagonist) increasing or decreasing 
target genes expression respectively 248. In order to perform an effective and safety 
microRNA administration, two main considerations should be made: the route of 
administration and the delivery method.  
 
Regarding to the first question, microRNAs have been shown to be effective mediators 
in the CNS after direct administration in animal models 230. Nevertheless, direct 
administration by intrathecal injections should be avoided in human therapy, especially 
if repetitive administrations have to be made, therefore intravenous, intranasal or 
intraperitoneal administration have been studied as therapeutically approaches. 
However, the CNS in protected by the blood brain barrier (BBB) and delivery of 
microRNA or their repressors to the CNS is a challenging question. In addition, nucleic 
acids can be degraded by enzymes and they must be assisted to entrance into the target 
cells avoiding the risk of being taken by non-target tissues up.  To cover all these, 
microRNAs or their antagonists should be encapsulated to protect them and to cross the 
BBB and reach the CNS to produce the expected effect.  
 
In relation with this, several are the delivery methods that have been studied. These go 
from viral vector such as adenovirus, retrovirus or lentivirus to synthetic nanocarriers. 
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Viruses have demonstrated to be effective delivering microRNAs to the brain. However, 
safety questions should be taken into account such as a possible oncogenic 
transformation of the recipient cell. In addition, this delivery method can stimulate the 
innate and adaptive immune responses reducing its effectivity 249. On the other hand, 
synthetic nanocarriers have been appeared as promising microRNAs vehicles due to the 
known composition, easy to manage and analysed and lower immunogenicity 250. 
Several are the delivery systems to be used, standing out liposomes and nanoparticles. 
These have been shown to be able to cross the BBB and delivery a specific drug or 
molecule to the CNS 251. In addition, their surface can be bounded to a concrete ligand 
making them specific for a cell type or tissue. Interestingly, in the last years a new 
microRNA delivery method has been appeared which is a middle step between virus 
vectors and synthetic nanocarriers. This consists in the use of extracellular vesicles. 
 
As has been addressed before, EVs are 100 to 1000 nm size vesicles released 
constitutively by cells and that play an important role in intercellular communication by 
delivering proteins and genetic material, among others 252,253. They have been proven to 
cross the blood brain barrier 177, to take part in the transmission of information across 
the CNS 158 and to be a potential therapeutic methods for demyelinating. Interestingly, 
young rats derived EVs have shown to be able to induce myelin formation in aged rats. 
This effect was related with the microRNA cargo, and more concretely with the 
presence of miR-219 in the vesicles, reinforcing the role that EVs may play in 
microRNA delivery to the CNS for the treatment of MS.  
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The development of remyelination therapies is nowadays a priority in MS treatment. 
Due to the lack of this kind of therapeutic approaches, alternative strategies are being 
proposed. The work published by Pusic et al in 2014 182 was, in our opinion, a solid step 
in this direction. In brief, they demonstrate that young rat derived exosomes were able 
to induce remyelination in aged rats thanks to the presence of miR-219a-5p in the cargo 
of these exosomes. However, the analysis of the ability of these exosomes to induce 
remyelination in a pathological animal model was needed. “All this considered, this 
work began in 2013… 
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• Young rodent blood-derived exosomes were described to induce OPC 
differentiation and myelination in vitro and in aged rodents due to the presence 
of miR-219a-5p in their cargo. We hypothesised that these exosomes are able to 
induce OPC differentiation and remyelination in the Experimental Autoimmune 
Encephalomyelitis model.  
 
• The generation of a new scoring system for monitoring the Experimental 
Autoimmune Encephalomyelitis model will help and facilitate the acquisition of 
data and the reproducibility of the experiments.  
 
• If the pro-remyelinating effect shown in young rodent blood-derived exosomes 
was related with miR-219a-5p, we hypothesised that MS patients will increase 
miR-219a-5p levels after relapse.  
 
• The non-invasive delivery of miR-219a-5p to the CNS will decrease the clinical 
manifestation of the Experimental Autoimmune Encephalomyelitis model.  
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This work has moved forward during its development and new objectives have been 
appearing during this period, all of which have tried to understand previous steps. We 
have focused on the following:  
 
• To test the ability of young mice blood-derived exosomes to induce 
remyelination in a pathological animal model of demyelination (Chapter One). 
• To determine the ability of microRNA-219a-5p to induce OPC differentiation 
and remyelination (Chapter One). 
• To generate a new measurement method to analyse the clinical evolution of the 
EAE animal model (Chapter Two).  
• To characterise the level of miR-219a-5p in MS patients in relapse and 
remission (Chapter Three). 
• To find and elucidate a non-invasive and efficient microRNA-219a-5p delivery 
system to promote remyelination in the Central Nervous System (Chapter Four). 
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INTRODUCTION 
 
Multiple sclerosis (MS) is a central nervous system disease in which myelin is damaged 
by autoimmune attacks (known as relapses), producing demyelination plaques that are 
responsible for the clinical symptoms 19,254. During the first stages of the disease, the 
organism has the ability to repair these lesions by recruiting OPCs that migrate, 
differentiate to OLs and produce new myelin that wraps axons 41. This process, called 
remyelination, restores axons´ homeostasis and the transmission of action potentials 
179,255,256. However, with the progression of the disease, the remyelination ability 
declines and the disease enters to a chronic phase in which neurodegeneration is the 
main feature. 
 
Currently, there is a wide range of treatments for MS that immunomodulate or 
immunosuppress the immune system, decreasing, and in some cases even avoiding, the 
number of relapses. Unfortunately, there is no commercially available treatment to 
promote remyelination and/or neuroprotection. Neuroprotection and neurorepair are the 
next challenge in MS and the administration of an immunoregulatory treatment together 
with a remyelination therapy has been proposed to prevent relapses and 
neurodegeneration. Therefore, alternative strategies are being tested to promote 
remyelination. One of them consists in  the use of exosomes 183,257.  
 
Exosomes are 30-150 nm particles, formed inside multivesicular bodies and released to 
the extracellular environment upon fusion of these bodies with the plasma membrane 
143. Exosomes are cell-to-cell communication mediators; responsible for carrying 
information (in the form of proteins, lipids, genetic material and metabolites) that can 
modify the receptor cell 253. Exosomes are involved in the pathogenesis of multiple 
diseases 138, including neurodegenerative diseases. 162. In the case of MS, for example, 
exosomes have been related to the regulation of myelin membrane biogenesis 159,160 and 
the reparation of damaged neurons 161. Due to this, exosomes are being postulated as 
possible therapeutic agents. In this sense, Pusic and collaborators published in 2014 a 
work demonstrating that the administration of exosomes isolated from blood of young 
mice  to hippocampal slice cultures promoted the generation of new myelin. Moreover, 
they tested the effect of these young rodent blood-derived exosomes in vivo, by 
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intranasal administration of these exosomes in aged rats, showing positive results in 
myelin generation 182.  
 
Due to the lack of treatments to promote remyelination in MS and taking into 
consideration previous results, such as the mentioned above, we attempted to go a step 
further by studying the remyelination potential of young rodent blood-derived exosomes 
in a pathological animal model. Under the hypothesis that young rodent blood-derived 
exosomes might be able to promote OPCs differentiation and therefore remyelination, 
we generated a MS animal model in which the remyelination potential of young rodent 
blood-derived exosomes was tested. 
  
  
CHAPTER ONE 
 
	74 
RESULTS 
 
1. Exosomes characterization 
Nanoparticle Tracking Analysis (NTA) was used to characterize the size and 
distribution of isolated vesicles. We found two peaks of vesicles of 160 nm and 396 nm. 
The mode and the mean were 159.4 nm and 185.5 nm respectively. These results 
indicate a normal Extracellular Vesicles (EVs) distribution (Figure 13, A). Western Blot 
indicated higher concentrations of exosomes protein markers CD71 and CD107a and 
lower levels of the negative control protein (endoplasmic reticulum 78 glucose 
regulated protein; Grp78) in exosome sample compared to whole cellular extract 
(Figure 13, B). These results indicate the accuracy of EV isolation approach.  
 
Figure 13: Exosomes characterization:  A) Size profile characterization by NTA of a 
representative sample. Results showed a typical extracellular vesicles distribution with 
two peaks at 160 nm and 396 nm, a mode of 159.4 nm and a mean of 185.5 nm. B) WB 
of extracellular vesicles and whole cellular extract, which was used as a control of the 
purity of the vesicles sample. Results revealed higher concentrations of exosomes 
protein markers CD71 and CD107a in EVs sample when compared to the control, 
indicating that the sample was enriched in exosomes. In addition, lower levels of the 
negative control protein (endoplasmic reticulum 78 glucose regulated protein; Grp78) 
were shown in exosome sample compared to whole cellular extract indicating that 
exosome sample did not contain cells (images obtained from different gels and 
combined into a single image; full images in supplementary material section).  
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2. Young mice blood-derived exosomes do not ameliorate EAE clinical 
symptoms  
To test the ability of young- mice blood-derived exosomes to promote remyelination in 
the MS animal model, exosomes were administered intranasally at the disease onset. 
Three groups were analysed (n = 6 each), treated with young mice blood-derived 
exosomes at concentrations of 100 µg of protein, 200 µg of protein and a control group 
(PBS), following the previous protocol of Pusic et al. Clinical score and weight were 
measured daily showing no significant differences between groups (p = 0.5 for DPBS vs 
100 µg and p = 0.15 for DPBS vs 200 µg) (Figure 14, A and B). In order to analyse if 
exosomes were able to immunoregulate and prevent, or at least delay the appearance of 
the clinical symptoms, a second experiment was performed in which exosomes were 
administered 4 days after the disease induction at a concentration of 100 µg. However, 
no significant differences were observed (p = 0.42) (Figure 14, C and D). 
 
3. Young mice blood-derived exosomes do not promote remyelination in a 
cerebellar organotypic culture 
To study exosome-mediated remyelination independently of other processes that can be 
present in the EAE model and might affect the ability of young mice blood-derived 
exosomes to promote remyelination, we decided to test the remyelination potential of 
exosomes in a cerebellar organotypic culture, which is a less complex model. 
Organotypic culture were demyelinated with lysolecithin and treated with several 
concentrations of exosomes and the vehicle (DPBS) as a control. After three days in 
culture, confocal images for neurofilament (NFL) and myelin basic protein (MBP) 
revealed no significant differences in Manders´ colocalization coefficient values 
between groups and 20 µg of exosomes was stablished as the representative group for 
treated samples (Manders´ colocalization coefficient values: 0,72 +/- 0.9 for DPBS and 
0.78 +/-0.05 for 20 µg of exosomes) (Figure 15, A, B and C). To ensure that the model 
was working properly, the lysolecithin demyelinating effect was measured, showing 
lower Manders´ colocalization coefficient in lysolecithin treated slices when compared 
to non-demyelinated cultures concluding that lysolecithin induced demyelination 
(Figure 15, D). 
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Figure 14: Young mice-derived exosomes do not ameliorate EAE clinical symptoms; A) 
Clinical score averages of each group (n = 6) are shown. The treatments (100 and 200 
µg of exosomes and DPBS) were administered at the disease onset; score = 1 (arrow). 
B) Mean of area under the curve (AUC) for each group shown in A and their standard 
deviation. C) Clinical score averages of each group (n = 3 for DPBS and n = 4 for 100 
µg of exosomes) are shown. The treatments (100 µg of exosomes and DPBS) were 
administered 4 days after EAE induction (arrow). D) Mean of AUC for each group 
shown in C and their standard deviation. 
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Figure 15: Young mice-derived exosomes do not promote remyelination in a cerebellar 
organotypic culture: Organotypic culture remyelination analysis. Cultures were 
demyelinated with lysolecithin for 15 hours after which fresh media was added and 
treatment performed. Cultures were grown for 72 hours. A and B are representative 
areas of  treated (20 µg of exosomes) and non-treated (DPBS) organotypic culture 
slices, respectively. NFL is stained in green and MBP in red. Both images are maximum 
intensity projections  C) Manders´ colocalization coefficients of both treated and non-
treated samples ( 3 slices per group; three images per slice were acquired) 
demonstrating that young derived exosomes are not able to increase remyelination in 
the organotypic culture. D) Cultures were demyelinated with lysolecithin for 15 hours 
after which fresh media was added and the culture was allowed to grow for 36 hours. 
Manders´ colocalization coefficients for cultures treated with lysolecithin and untreated 
controls are shown, demonstrating that lysolecithin induced demyelination in the 
cerebellar organotypic culture.  
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4. Young mice blood-derived exosomes do not promote OPC differentiation 
Even though there was no decrease in the EAE score and no increase of remyelination 
in the cerebellar organotypic culture, we tested whether exosomes could promote OPC 
differentiation, a necessary step for remyelination. Three different concentrations of 
young mice blood-derived exosomes and the vehicle without exosomes were 
administered to the OPC media (0.5, 5 and 50 µg of protein) and RNA was extracted at 
2 time points (1 and 5 days after treatment). Gene expression analysis did not show any 
significant difference between the treated and untreated group at any time points and 
concentration (Figure 16, A and B). To confirm that OPCs were able to take exosomes 
up, exosomes were labelled with DiI Celltracker and administered to the cell culture. 
After 4 hours, 72% of the OPCs were stained, showing exosomes integration (Figure 
16, C). 
 
5. miR-219a-5p is not present in young- mice blood-derived exosomes 
To determine if the absence of the remyelination effect shown in our models was due to 
the lack of pro-remyelinating microRNAs in the young mice blood-derived exosomes, 
their cargo was analysed. To determine which microRNAs were present in the 
exosomes, a GeneChip miRNA 4.0 Array was carried out. 465 microRNAs were 
detected in our samples some of which have been proposed as endogenous references in 
plasma and serum samples (miR-146a, miR-16, miR-195, miR-30e and miR-744 miR-
109 and miR-191) 258,259. However, miR-219a-5p and none of the miRNAs proposed as 
remyelination promoters were detected (miR-138, miR-338, miR-9, miR-23, miR-19b 
and miR-146a). Furthermore, the absence of miR-219a-5p was confirmed by qPCR 
Figure 16, D). As previous experiments by other authors were performed in rats, we 
also isolated and analysed miR-219a-5p content in rat-derived exosomes by qPCR. In 
contrast to previous reports, our rat-derived exosomes did not have miR-219a-5p in 
their cargo. 
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Figure 16: Exosomes do not promote OPC differentiation. A and B) qPCR of OPC 
culture at day 1 and 5 after exosome treatment is shown and compared with a non-
treated culture, expressed as Log2 of the fold change. Genes of OPCs (NG2 and 
PDGFRα) of pre-oligodendrocyte (CNPase) and OLs (MOG, MBP and PLP1) do not 
show significant differences between groups (FC < 2). C) OPCs stained with Hoechst 
(blue) treated for 4 hours with Celltracker CM-DiI-labelled exosomes (red). Exosomes 
are taken up by OPCs with a 72 % efficiency. D) qPCR data of miR-219a-5p in young 
mice blood derived exosomes compared to the expression of miR-191 demonstrating 
that miR-219a-5p is not expressed in the exosomes, confirming data from arrays. 
 
6. miR-219a-5p does promote OPC differentiation  
To demonstrate that the lack of effect shown by our exosomes is due to the absence of 
miR-219a-5p in their cargo, miRIDIAN microRNA mmu-miR-219a-5p was 
administered to the OPC culture. Transfection efficiency was quantified using 
miRIDIAN microRNA Mimic Transfection Control with Dy547, which was 85% 
(Figure 17, A). Three days after the transfection with mmu-miR-219a-5p we found 
significant differences in gene expression pattern, showing an upregulation of myelin-
related genes (MBP, PLP1, MOG and CNPase) and a downregulation of OPC-related 
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genes (NG2 and PDGFRα) when compared to miRIDIAN microRNA Mimic Negative 
Control treated OPCs (Figure 17, B). These results demonstrate that miR-219a-5p is 
able to promote OPC differentiation. Furthermore, immunofluorescence images of MBP 
and OLIG2 labelled OPCs culture show the presence of positive cells for MBP 
confirming that OPCs are differentiating into oligodendrocytes (Figure 17, C).  
 
Next, to analyse if miR-219a-5p was able to promote or stimulate the remyelination 
process in a more complex model, miR-219a-5p was added to a lysolecithin 
demyelinated cerebellar organotypic culture. After 3 days in culture, qPCR was 
performed and an overexpression of OPCs related genes (NG2 and PDGFRα) and 
OLIG2 were detected. Myelin related genes were also up-regulated but not significantly 
(Figure 17, D). 
 
Figure 17: MiR-219 does promote OPC differentiation: A) Representative image of the 
transfection efficiency of mimic Dy547 in OPCs which is 85%. B) Gene expression 
patterns of OPC culture after treatment with miRIDIAN microRNA mmu-miR-219a-5p 
transfected with lipofectamine. MiRIDIAN microRNA Mimic Negative Control was used 
as a control. Results are shown as Log 2 of the fold change. C) Oligodendrocytes 
expressing MBP in an OPC culture demonstrating that miR-219 is able to promote the 
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expression of myelin related proteins D) Gene expression levels of the cerebellar 
organotypic culture treated with miRIDIAN microRNA mmu-miR-219a-5p after 3 days 
in culture.  
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DISCUSSION 
 
Pusic et al. proposed that exosomes isolated from blood of young rats promote 
myelination in healthy and demyelinated hippocampal slice cultures of rats. Moreover, 
the intranasal administration of those exosomes in aged rats was proposed to increase 
myelin levels 182. These interesting results opened a therapeutic way for MS patients for 
which no remyelination therapy is nowadays available. Nevertheless, the ability of pro-
myelinating exosomes should also be addressed in a pathological animal model of MS. 
In the present work we studied the remyelination potential of young mice blood-derived 
exosomes in the EAE animal model under the hypothesis that young rodent blood-
derived exosomes might improve clinical symptoms of the animals.  
 
In our experiments, different concentrations of exosomes isolated from blood of young 
mice were tested, but no effect in the clinical score of the EAE model after intranasal 
administration was observed. Then, a cerebellar organotypic model of demyelination 
was used, in order to understand the effect of the young mice blood-derived exosomes 
in a less complex model. However, even if different exosome concentrations were 
tested, we were not able to find a pro-remyelinating effect in the treated samples. Our 
next step was to check these young mice blood-derived exosomes in OPCs culture with 
the aim of studying their cell differentiation potential. Again, no significant differences 
were found in OPC differentiation after the treatment with exosomes.  
 
Pusic et al proposed that the pro-remyelination effect of the exosomes was related with 
their cargo, more specifically to pro-remyelinating microRNA in their cargos. 
MicroRNAs are single-stranded RNAs with around 22 base pairs that regulate gene 
expression. They have been shown to be involved in almost all biological processes 
(such as development, proliferation, differentiation and cell death) 260 and in several 
diseases like cancer or neurological diseases, and interestingly in MS 210,261–263. One of 
the microRNAs proposed by these authors, the miR-219a-5p, has been described to take 
part in OPC differentiation, and to promote myelination by regulating the expression of 
genes related to the differentiation and/or myelination pathways 78,227,228. 
 
With the aim of understanding the reason why young mice blood-derived exosomes 
were not promoting OPC differentiation, we decided to study the microRNA cargo with 
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a miRNA array. We detected more than 450 microRNAs in our exosomes, but 
surprisingly, miR-219a-5p was not present. This observation was confirmed by qPCR in 
two species (mice and rat exosomes). miR-138, miR-9, miR-23, miR-19b, miR-338  
and miR-146a – microRNAs which have also been described to promote OPC 
differentiation 231,237,264 – were neither present in the cargo of the exosomes. We were 
able to detect miRNAs that has been described in this kind of samples as endogenous 
controls; so, we discard technical reasons for explaining the lack of miR-219a-5p in our 
exosomes.  It has been widely described that the exosome concentration, cell of origin 
and cargo might be related to exogenous factors such as the recent ingestion of food, 
sport, diseases and environmental factors 265. In this sense, it has also been proposed 
that environmentally enriched conditions might affect exosomes’ content. Our data 
reinforce the hypothesis that the cargo of the exosomes is highly variable, which might 
be a limitation in their translations to clinical practice. 
 
To confirm if miR-219a-5p was a key factor in the cargo of pro-remyelinating 
exosomes, we tested the ability of synthetic miR-219a-5p to promote OPC 
differentiation. We wanted to administer the microRNA directly into the cells, to make 
sure that the miRNA by its own was able to induce OPC differentiation. To do that, 
miRIDIAN microRNA mouse mmu-miR-219a-5p was administered with lipofectamine 
to OPCs, seeing an increase in the differentiation of OPCs to OLs. As miR-219a-5p was 
able to induce OPC differentiation by its own, miR-219a-5p could be an essential 
component of young mice blood-derived exosomes for the induction OPC 
differentiation and myelination. Moreover, as we have shown, when miR-219a-5p is not 
present in the cargo of exosomes, those are not able to induce the expected effect. In 
addition, these results are in concordance with recent reports that have shown that OPCs 
overexpressing miR-219a-5p had the ability to promote remyelination and functional 
recovery after their transplantation in the cuprizone-induced MS animal model 233. MiR-
219a-5p has also been shown to attenuate demyelination in the cuprizone model 234. 
Moreover, Wang et al proved that miR-219a-5p was able to promote remyelination after 
lysolecithin induced demyelination 230. Furthermore, it has been reported that human 
endometrial-derived stromal cells were able to be programmed into pre-
oligodendrocytes by overexpressing miR-219a-5p 232. 
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Further, to confirm that miR-219a-5p was implicated in remyelination, we administered 
miRIDIAN microRNA mouse mmu-miR-219a-5p to a demyelinated cerebellar 
organotypic culture. For that we used again lipofectamine, a tested and proved method 
for the administration of microRNAs.  We found an overexpression of OPC-related 
genes, such as NG2 and PDGFRα. Although the most accepted hypothesis is that miR-
219a-5p promotes OPCs differentiation, there are new evidences suggesting that miR-
219a-5p can also promote the expression of “precursor cell” genes, such as NG2 233. 
Interestingly, OLIG2 is also overexpressed, indicating an enrichment of the mature 
oligodendrocyte subpopulation. Besides, myelin related genes are also overexpressed, 
indicating that a possible enrichment in myelin is starting. Hence, as the mentioned 
results showed, miR-219a-5p could play a dual role in the remyelination process, 
promoting both the generation of new OPCs and their differentiation. Again, miR-219a-
5p seems to be a key player in the promotion of remyelination and the lack of this 
microRNA in young mice blood-derived exosomes cargo can be a key factor in their 
remyelination failure. 
 
In short, with this work we have reinforced the idea that the cargo of the exosomes 
influences their remyelination potential. More concretely, we conclude that miR-219a-
5p is crucial for favoring remyelination and the enrichment of miR-219a-5p in the cargo 
of exosomes might be a therapeutic way to induce remyelination.  
CHAPTER ONE 
	 85 
MATHERIAL AND METHODS 
 
1. Exosome isolation and characterization 
5-7 week-old C57BL/6 mice were anaesthetised with inhaled isoflurane 2% and 
sacrificed by cardiac puncture to obtain blood. A pool of 2-4 animals was used to obtain 
sufficient blood to extract enough exosomes to carry out the experiments. For this 
purpose, ExoQuick-TC (ExoQuick-TCxxA-1; System Biosciences) was used as 
previously described 151. Briefly, blood samples were collected in citrate tubes, 
centrifuged at 1250 g for 15 minutes and the supernatant was recovered to obtain 
platelet-poor plasma (PPP). Then, 63 µl of ExoQuick-TC was added to 250 µl of PPP 
and incubated overnight at 4º C. Afterwards, to sediment the exosomes, two 
centrifugation steps were performed at 1500 g for 30 and 5 minutes, respectively. The 
pellet was resuspended in 200 µl of filtered DPBS.A Bradford assay was performed to 
quantify the protein levels of the samples, which were used to standardized exosome 
administration and for Western Blot (WB) analysis. Samples were frozen at -80º C until 
they were used.  
 
In order to characterize the population of exosomes Nanoparticle Tracking Analysis 
(NTA) and WB were performed. NTA was performed in a NanoSight LM10 device 
(Malvern) as previously described 266. Briefly, samples were diluted in filtered DPBS to 
get accurate acquisition (200-900 recorded tracks). Camera settings were fixed and 
maintained for all samples. For each sample, two videos of 1 minute were recorded and 
analysed with NanoSight NTA software 3.2 (Malvern) using the average count of the 
two duplicates for data representation 
 
The expression of CD107a, CD71, and Grp78  were determined in EVs by WB as 
previously described 267. Whole cellular extracts were used as controls in order to make 
sure that the exosome sample was pure and did not contain cellular debris. Briefly, 50µg 
of protein were denatured in sample buffer (50 mM Tris-Cl, 2% SDS, 10% glycerol and 
0.1% bromophenol blue) by heat denaturation in three steps of 5 min at 37º C, 65º C 
and 95º C. Protein extracts were loaded in 10% sodium dodecyl sulphate 
polyacrylamide gel to performed the electrophoresis and electro-transferred to a 
nitrocellulose membrane (GE healthcare, USA). Membrane blocking was carried out by 
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adding 5% skim milk powder/tris-buffered saline (TBS)-5% tween (TBS-Tween) 
(Milk) after what membranes were incubated overnight at 4º C with anti-CD107a, anti-
CD71, and anti-Grp78 (LS-C350569, Clone TiB-219  and G8918 Sigma, respectively)  
at 1:500 in blocking solution. After washing the membrane three times with TBS-0.1 % 
Tween-20 for 5 minutes, HRP-conjugated secondary antibody was used in blocking 
solution and incubated for 1 hour at room temperature (anti-rat IgG1 HRP 7077s 1:5000 
for CD107a and CD71; anti-rabbit IgG1 7074s 1:40.000 for Grp78, both from Cell 
Signaling). For protein band visualization LuminantaTM forte (Millipore) was used and 
images acquired using iBright FL1000 Imaging Systems (ThermoFisher). 
 
2. EAE induction 
All animal procedures were approved by the Biodonostia Health and Research Ethics 
Committee (CEEA17_002). In order to induce the model, 6-8 week-old female 
C57BL/6 mice (Charles River) were anaesthetised with isoflurane 2% and injected with 
150 µg of myelin oligodendrocyte glycoprotein (MOG35-55) (Ref: EPK1; Espikem), 1 
mg of Mycobacterium tuberculosis (Ref:3114; Difco) and 100 µl of Freund’s complete 
adjuvant (Ref:5881; Sigma) subcutaneously at two sites on the flanks at day 0. Mice 
were also intraperitoneally injected with 0.5 µg of Pertussis toxin (Ref: P2980; Sigma) 
at day 0 and 48 hours later. To measure the disease course, weight and clinical 
symptoms were observed and scored daily. To see the clinical scale, please refer to the 
supplementary information section, Supplementary Table 1 268.  
 
3. Organotypic culture 
Newborn P7 C57BL/6 mice were sacrificed by decapitation, cerebellums were extracted 
and placed in organotypic culture medium, with BME 24 ml (Ref:41010; Thermo 
Fisher); 24% HBSS (Ref:24020091; Thermo Fisher); 24% Horse Serum 
(Ref:26050088; Thermo Fisher); 0.125% Glutamine (Ref: 25030024; Invitrogen); 1% 
antimycotic and antibiotic (Ref:A5955; Sigma); 3.5% Glucose (Ref: A1422; Panreac) 
for every 50 ml. 300-µm sagittal sections were taken using a McIlwain tissue chopper 
(McIlwain). Sections were separated and plated on a Millicell Cell Culture Insert 
membrane (Ref: PCIM ORG 50; Millipore) on a P6 plate and incubated in organotypic 
culture media at 37º C and 5% CO2.  
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A demyelinating lesion was made as previously described 83. Briefly, after 7 days in 
culture, media was removed and new media containing lysolecithin (0.5 mg/ml, 
Ref:L4129; Sigma) was added and incubated for 15 hours at 37º C and 5% CO2. Then, 
lysolecithin media was removed and fresh media was added.  
 
4. Oligodendrocyte precursor cell culture 
The isolation of OPCs was done as previously described 59. Briefly, postnatal P1-P3 
C57BL/6 mice were sacrificed by decapitation. Once the brain was removed, meninges 
were extracted with the help of two forceps and a dissection microscope to obtain brain 
cortices. Then the tissue was digested mechanically and enzymatically with papain at 
37º C for 14 minutes. 25 ml of OPC medium (DMEM (Ref:041966; Thermo Fisher), 
supplemented with 10% Foetal Bovine Serum (Ref: 16000044; Thermo Fisher) and 1% 
Antibiotic-Antimycotic (Ref:A5955; Sigma)) and 300 µl of a DNAse solution (1%, 
Ref:DN-25; Sigma) was added to stop papain digestion. The sample was centrifuged at 
190 g for 10 min. The supernatant was removed and the pellet, after resuspension in 1 
ml of OPC media, was filtered through a 100-µm nylon mesh strainer (Falcon). Finally, 
up to 8 ml of OPC media were added to the cells which were seeded in a 75-cm2 Poly-
L-Ornithine coated flask. After one week of incubation at 5% CO2 and 37º C, renewing 
the media every 2-3 days, the culture was shaken for 15 hours at 200 rpm and one extra 
hour at 250 rpm. After that, the media was recollected and passed through a 40-µm 
nylon cell strainer (Falcon) and centrifuged at 190 g for 10 minutes. The pellet was 
resuspended in 10 ml of OPC media. The suspension was plated on an untreated plastic 
Petri dish at 37 ºC for one hour to allow the microglial cells to attach to the Petri dish. 
Then, the media was recollected, centrifuged at 190 g for 10 minutes, filtered again 
through a 40-µm strainer and incubated in a new uncoated Petri dish for 30 minutes. 
After the 30 minutes, the media was recollected, and centrifuged at 190 g for 10 minutes 
to finally obtain the purified OPCs. Cells were incubated in a laminin-treated plate to 
perform the experiments.  
 
 
5. Exosome administration 
In EAE: to allow a direct and feasible route of administration facilitating exosomes to 
reach the CNS, those were intranasally administered as previously described. Briefly 
CHAPTER ONE 
 
	88 
once the animals were anaesthetised with inhalatory anaesthesia with isoflurane 2%, 
four administrations of 5 µl each were given alternating nostrils. To find out if the 
exosomes had an immunomodulatory or remyelination potential, exosomes were 
administered at two time points in several experiments. Firstly, to test the remyelination 
capacity of the exosomes and assess whether they were able to reduce the clinical score 
once the symptoms appeared, exosomes were administered at the disease onset (score = 
1), at two different concentrations (DPBS as vehicle, 100 µg of quantified protein; 
replicating the data published by Pusic et al; and a higher concentration of 200 µg of 
quantified protein) (n = 6 per group). To analyse the immunomodulatory potential of 
exosomes and evaluate if they were able to cause a delay in the disease onset, they were 
administered 4 days after EAE induction (vehicle and 100 µg of quantified protein), (n 
= 3 and 4 respectively). 
 
In organotypic culture: 10µl of exosomes at different concentrations (10 µg, 20 µg, 40 
µg, 80 µg, 160 µg and 240 µg of quantified protein) diluted in DPBS were administered 
to each cerebellum slice (in triplicates) after replacing lysolecithin with fresh media and 
cultured for three days. Then confocal microscopy analysis was performed. 
 
In OPCs: 24 hours after cells were plated, exosomes were added at 0.5, 5, 50 and 100 
µg of quantified protein and maintained in culture for one and five days prior to RNA 
isolation. Triplicates were carried out. To confirm that exosomes were taken up by 
OPCs, exosomes were labelled with Dil (Celltracker CM-DiI, Thermo Fisher) as 
previously described 181. Briefly, exosomes were incubated with 1µg/ml of Celltracker 
CM DiI for 5 minutes at 37º C and 15 minutes at 4º C. Then the sample was centrifuged 
at 20.000 g for 20 minutes in order to pellet exosomes and remove excess of dye. Then, 
exosomes were resuspended in 10 µl of DPBS and added to the OPCs culture. After 
four hours, cells were fixed, labelled with Hoechts and images were taken with 20X 
magnification in a Nikon Eclipse 80i (Nikonn) using NIS elements AR 3.2 (Nikon). 
Fields were selected in an aleatory manner. Positive and negative cells for Celltracker 
CM DiI were count.  
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6. MiR-219a-5p transfection 
For miR-219a-5p transient overexpression, miRIDIAN microRNA mmu-miR-219a-5p 
and miRIDIAN microRNA Mimic Negative Control were used, both purchased from 
Dharmacon. miRIDIAN microRNA Mimic Transfection Control with Dy547 
(Dharmacon) was used as a control of the transfection efficiency. miRIDIAN 
microRNA transfection was carried out using Lipofectamine RNAiMAX (Ref: 
13778030; Thermo Fisher) following the manufacturer’s protocol.  
 
In OPCs: 24 hours after culturing the OPCs, 25 nM of miRIDIAN microRNA mimics 
were incubated in 50 µl of Opti-MEM medium (Ref:31985062; Thermo Fisher) 
containing 1,25 µl of Lipofectamin reagent for 5 minutes. After this period, the mix was 
added to each well containing 450 µl of OPC medium. After 24 hours, cells were fixed 
and labelled with Hoechts to quantify the percentage of transfected cells with 
miRIDIAN microRNA Mimic Transfection Control with Dy547. For functional 
analysis, three days after transfection, RNA was isolated. No media changes were done 
during this time. 
 
In cerebellar organotypic culture: after removing lysolecithin 25nM of miR-219a-5p 
mimic per slice were incubated in 50 µl of Opti-MEM medium containing 1,25 µl of 
Lipofectamine reagent for 5 minutes. Three days after transfection, RNA was isolated. 
No media changes were done during this periods. 
 
7. Immunofluorescence and confocal microscopy 
Three days after the administration of the exosomes, cerebellar slices were fixed with 
4% paraformaldehyde for 40 minutes at 25º C. Then, the slices were washed with DPBS 
and blocked in blocking solution (0.5% Triton (Ref: T8787; Sigma) and 10% goat 
serum (Ref: G9023; Sigma) in DPBS) for one hour. Primary antibodies against myelin 
basic protein (MBP) (Ref: Ab7349; Abcam) and neurofilament (NFL) (Ref: Ab8135; 
Abcam) (both 1:200 in block solution) were added and incubated overnight at 4º C. The 
next day, samples were washed with 0.1% Triton in DPBS and incubated with 
secondary antibodies for two hours in blocking solution. Secondary antibodies 
conjugated with Alexa Fluor 594 nm for MBP and Alexa Fluor 488 nm for NFL were 
used (Ref: A21209 and 21206; Thermo Fisher). Then three washes were done with 
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0.1% Triton in DPBS and stained with Hoechst (Ref: B2261; Sigma) 10% in DPBS for 
10 minutes. After two extra washes with DPBS samples were mounted in Fluoromount-
G (Ref: 0100-01; SouthernBiotech). Stacks of images were acquired by confocal 
microscopy using an LSM 510-Meta (Zeiss). Axonal tracks were sampled acquiring at 
least three images per slice and three slices per condition making a total of 9 images per 
condition. Images were obtained at 1µm intervals in white matter areas at x63 (1.4 NA) 
magnification for both channels sequentially, to avoid crosstalk. To conduct the analysis 
of the remyelination degree, maximum intensity projection of 10 intervals and 
Colocalization Threshold plugin from open source software ImageJ were used to 
calculate Manders Colocalization Coefficient, where 0 represents non-colocalization 
and 1 perfect spatial colocalization 269.  
 
To carry out the immunofluorescence to detect the expression of myelin related proteins 
in OPC culture, three days after miRIDIAN microRNAs were added, OPCs were fixed 
with 4% paraformaldehyde for 5 minutes at 25º C. Then, cells were washed with DPBS 
and blocked in blocking solution (0.5% Triton (Ref: T8787; Sigma) and 10% goat 
serum (Ref: G9023; Sigma) in DPBS) for one hour. Primary antibodies against myelin 
basic protein (MBP) (Ref: Ab7349; Abcam) and oligodendrocyte transcription factor 2 
(OLIG2) (Ref: Ab9610; Chemicon International) (both 1:200 in block solution) were 
added and incubated overnight at 4º C. The next day, samples were washed with 0.1% 
Triton in DPBS and incubated with secondary antibodies for two hours in block 
solution. Secondary antibodies conjugated with Alexa Fluor 594 nm for MBP and 
Alexa Fluor 488 nm for OLIG2 were used (Ref: A21209 and 21206; Thermo Fisher). 
Afterwards three washes were done with 0.1% Triton in DPBS and stained with 
Hoechst (Ref: B2261; Sigma) 0.1% in DPBS for 5 minutes. After two more washes 
with DPBS samples were mounted in Fluoromount-G (Ref: 0100-01; SouthernBiotech). 
Images were acquired in a Nikon Eclipse 80i (Nikonn) and analysed using NIS elements 
AR 3.2 (Nikon).  
 
8. RNA isolation 
From OPCs: One and five days after exosomes were administrated, total RNA was 
isolated from OPCs using the miRNeasy Mini Kit (Ref: 217004; Qiagen) following 
manufacturer’s instructions. Three days after OPCs were treated with miRIDIAN 
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microRNAs total RNA was isolated as previously described.  RNA concentration was 
measured using a NanoDrop ND-1000 spectrophotometer. 
 
From Cerebellar Organotypic Culture: Three days after transfection with miRIDIAN 
microRNAs the membrane where the slices were grown up was cut out, 700 µl of 
Qiazol were added and vortexed for one minute. Then total RNA was isolated form 
cerebellar organotypic culture using the miRNeasy Mini Kit (Ref: 217004; Qiagen) 
following manufacturer’s instructions. RNA concentration was measured using a 
NanoDrop ND-1000 spectrophotometer. 
 
From Exosomes: RNA isolation was done as previously described 151. miRNeasy Mini 
kit (Qiagen) was used to extract RNA from 500 µl of exosome samples. RNA 
concentration was measured using a NanoDrop ND-1000 spectrophotometer. 
 
9. Quantitative PCR 
For microRNA 219: RNA was reverse transcribed using TaqMan™ MicroRNA Reverse 
Transcription Kit (Ref: 4366596; Thermo Fisher) following manufacturer’s protocol in 
a Veriti Thermal Cycler (Applied Biosystems). miR-219a-5p expression analysis was 
performed using TaqMan™ Universal Master Mix II (Ref: 440043; Thermo Fisher) and 
miRNA TaqMan Assay (ID:522; Thermo Fisher). The qPCR was carried out in a 
CFX384 Thermal Cycler (Bio-Rad). Raw data was processed in Bio-Rad CFX Manager 
software. 
 
For genes: Total RNA was reverse transcribed using High-Capacity cDNA Reverse 
Transcription Kit (Ref: 4368814; Thermo Fisher) following manufacturer’s protocol in 
a Veriti Thermal Cycler (Applied Biosystems). Gene expression analysis for OPC 
differentiation was performed in order to establish the differentiation degree of the cells, 
both in the OPC culture and in the organotypic culture, using KiCqStart SYBR Green 
qPCR ReadyMix (Ref:KCQS02; Sigma) and KiCqStart SYBR Green Primers (Ref: 
KSPQ12012; Sigma). The expression levels of the following genes were analysed: 
platelet-derived growth factor α (PDGFRα) and neuron-glial antigen 2 (NG2) to 
determine OPCs; 2',3'-cyclic nucleotide 3' phosphodiesterase (CNPase) to determine 
pre-oligodendrocytes; myelin oligodendrocyte glycoprotein (MOG), myelin basic 
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protein (MBP), proteolipid protein (PLP1) to determine oligodendrocytes; ribosomal 
protein L13α (RPL13α) and phosphoglycerate kinase 1 (PGK1) were used as 
endogenous controls. The qPCR was carried out in a CFX384 Thermal Cycler (Bio-
Rad). Raw data was processed in Bio-Rad CFX Manager software and the subsequent 
analysis to calculate relative expression was carried out in Excel software using the 2-
DDCT method 270. 
 
10. MicroRNA microarray 
Total RNA (500 ng) was labelled using the FlashTag Biotin labelling kit (Ref: 
901911;Thermo Fisher) and hybridised to the GeneChip miRNA 4.0 Array (Ref: 
902412; thermo Fisher), which covers 1908 mouse miRNAs, following the 
manufacturer’s instructions. Briefly, RNA molecules were polyadenylated and a biotin-
labelled DNA molecule was attached in a subsequent ligation step. Finally, labelled 
RNA was hybridised to the array, washed and stained in a GeneChip Fluidics Station 
450 and scanned in a GeneChip Scanner 7G (Affymetrix). 
 
11. Statistical analysis 
For the EAE animal model, the area under the curve (AUC) of the overall disease 
severity was calculated for each mouse to analyse the disease severity for each group 
using non-parametric statistical tests (Wilcoxon rank-sum test) 271. Arrays were 
normalised by RMA using Expression Console software from Affymetrix.  
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INTRODUCTION 
 
Myelin is a lipid membrane that wraps axons, giving them trophic support and allowing 
the transmission of nerve impulses 10. However, in several diseases, such as multiple 
sclerosis (MS), this myelin is damaged by an autoimmune attack. In brief, activated T 
cells cross the blood brain barrier and damage oligodendrocytes; the cells responsible 
for generating myelin in the central nervous system (CNS). This leaves axons 
unprotected and blocks the saltatory nerve impulse transmission. Fortunately, after a 
demyelinating insult the body is able to regenerate the lost myelin in a process called 
remyelination. To do this, oligodendrocyte precursor cells need to proliferate, migrate, 
differentiate to oligodendrocytes and generate new myelin 21. After remyelination, 
saltatory nerve impulse transmission is recovered. This form of the disease, in which a 
period of neurological symptoms (relapse) is followed by a recovery stage (remission), 
is classified as relapsing-remitting MS (RRMS). This is the most common sort of MS, 
representing approximately 85% of patients 279. However, after several cycles of 
demyelination and remyelination this process tends to fail, leading the patient to a 
progressive form of the disease. Unfortunately, nowadays there is no treatment available 
to induce the regeneration of the myelin and the scientific community is elucidating new 
strategies to stimulate myelin regeneration and therefore neuroprotection. 
 
With regard to this, microRNAs have appeared as promising candidates to induce 
remyelination. They are small single-stranded RNAs (20-22bp) with regulatory 
functions by targeting sequence-specific messenger RNAs. One of these candidate 
microRNAs is miR-219a-5p, which has been shown to be a key factor in OPC 
differentiation and therefore in remyelination 230,231.  There are several works in mice 
models and transgenic animals that reinforce the role of miR-219a-5p in remyelination 
228,229,233. Interestingly, when a synthetic miR-219 was administered intrathecally to the 
experimental autoimmune encephalomyelitis animal model, a decrease in the clinical 
score was shown due to the generation of new myelin forming oligodendrocytes 230. In 
addition, as shown in Chapter One, miR-219a-5p might be a key factor in the cargo of 
exosomes to induce remyelination.  
 
CHAPTER THREE 
 
	110 
All this evidence suggests that miR-219a-5p could also be playing a role in human 
remyelination and therefore, we hypothesized that expression differences could be 
detectable between relapse and remission in MS patients.  
 
In this chapter, the expression of miR-219a-5p in blood patients in relapse and 
remission together with healthy controls will be analysed in order to understand better 
the role that this microRNA could be playing in remyelination. 
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MATERIAL AND METHODS 
Blood sample collection  
Whole blood (10 ml) was collected from 10 patients with RRMS and 10 healthy donors 
in the Department of Neurology at Donostia University Hospital. Two samples from 
each MS patient were collected: one during a relapse and another during remission. A 
relapse was defined as an episode of new neurological symptoms of at least 24-h 
duration, not associated with fever or infection 280. Relapse blood samples were 
collected before giving any corticosteroid treatment. Healthy controls (HC) were 
matched for age and sex. The same blood sample was used to isolate RNA from 
leucocytes, plasma and EVs. Samples from all donors were collected after receiving 
written informed consent. The study was approved by the hospital’s ethics committee 
and samples have been processed and stored at the Basque Biobank 
(www.biobancovasco.org).  
 
RNA isolation from leucocytes 
Total RNA was isolated from peripheral blood leucocytes with the LeukoLOCK kit 
(Ambion) using the alternative protocol to capture small RNAs. RNA concentration was 
measured using a NanoDrop ND-1000 spectrophotometer and RNA integrity was 
assessed using a bioanalyzer with the RNA 6000 Nano Assay Protocol (Agilent 
Technologies). Only samples with a RNA integrity number higher than 6 were included. 
This protocol was carried out in the context of a previous article by our group 261. 
 
MicroRNA microarray hybridization 
Total RNA (500 ng) was labeled using the FlashTag Biotin labelling kit (Genisphere) 
and hybridized to the GeneChip miRNA 1.0 Array (Affymetrix), which covers 847 and 
922 human miRNAs and snoRNAs, respectively, following the manufacturer’s 
instructions. Briefly, RNA molecules were polyadenylated and, in a subsequent ligation 
step, a biotin-labelled DNA mole- cule was attached. Finally, labelled RNA was 
hybridized to the array, washed and stained in a GeneChip Fluidics Station 450 and 
scanned in a GeneChip Scanner 7G (Affymetrix). This experiment was carried out in 
the context of a previous article by our group 261. 
 
 
 
CHAPTER THREE 
 
	112 
Microarray data analysis 
Raw data analysis was first performed, including a detection step (a probe set is 
detected above background with an associated p-value) resulting in a true/false call and 
a quantile normalization step using the miRNA QC Tool software (Affymetrix).  
 
RNA isolation from Plasma and Extracellular Vesicles. 
Plasma was obtained after centrifuging blood samples at 1500g for 15 minutes. Plasma 
samples were then used to obtain extracellular vesicles following a differential 
centrifugation step protocol as previously described 151. Trizol LS (#10296028, Thermo-
Fisher) was used to isolate RNA from both plasma and extracellular vesicle samples 
following manufacturers´ protocol. RNA was quantified by NanoDrop ND-1000 
spectrophotometer. 
 
miR-219a-5p quantification by ddPCR 
RNA was reverse transcribed using TaqMan™ MicroRNA Reverse Transcription Kit (# 
4366596; Thermo Fisher) following manufacturer’s protocol in a Veriti Thermal Cycler 
(Applied Biosystems). MiR-219a-5p expression analysis was performed using miRNA 
TaqMan assay (ID:522; Thermo Fisher) and QX200 droplet digital PCR system 
(BioRad). Analysis was carried out using QuantaSoft 1.6.6 software (BioRad) and data 
was expressed as the number of copies of miR-219a-5p per nanogram (ng) of total 
RNA. Non-parametric analysis was carried out by using Kruskal-Wallis test. 
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RESULTS AND DISCUSSION 
 
After a relapse, patients are able to regenerate the lost myelin. MiR-219a-5p has shown 
to positively mediate OPCs differentiation and remyelination. With the aim of 
understanding if the microRNA could be playing a role in patients remyelination after a 
relapse, we analysed miR-219a-5p levels in both relapse and remission, and also HC, 
expecting to find higher levels after relapse, as an indicator of remyelination. In the 
context of a previous work published by our group in which global microRNA 
expression pattern in leucocytes of relapse and remission patients were analysed by 
microarray 261, we checked this data to specifically determine miR-219a-5p levels in the 
same patients. As expected, microarray did not detect miR-219a-5p in relapse, 
remission nor HC samples. However, miR-219a-5p expression is expected to occur in 
the CNS and not in leucocytes, which are not involved in myelin regeneration. With the 
hypothesis that microRNAs that are generated in the CNS can be released into the 
blood, we decided to analyse plasma and extracellular vesicles (EVs) miR-219a-5p 
levels of the same patients and HC and compare them to leucocytes expression levels. 
In order to compare these samples, we decided to use droplet digital PCR to quantify 
with precision and high sensitivity the number of copies of miR-219a-5p per nanogram 
of total RNA.  
 
Interestingly, we were able to detect miR-219a-5p in the three types of samples. 
Although miR-219a-5p level in leucocytes was closed to cero, these results were of high 
interest as microarray was not able to detect miR-219a-5p expression in in the same 
sample, indicating that ddPCR is more sensitive than microarrays. Moreover, we 
compared miR-219a-5p expression levels in the three samples determining that EVs 
contained more copies of miR-219a-5p per nanogram of total RNA when compared to 
leucocytes or plasma (p<0,001 for both comparisons) (Figure 19, A). EVs are cell-
released vesicles that contain proteins and genetic material and that have been involved 
in cellular communication. In addition, EVs have been shown to contain a higher and 
different proportion of microRNAs than their parent cells 281, indicating that could be a 
method to concentrate microRNAs. Interestingly, CNS derived-EVs have been 
proposed to cross the blood brain barrier and to be found in blood 282. In addition, miR-
219a-5p has been described to be highly expressed in the CNS when compared to other 
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tissues (GTEx). These evidences made us think that a great proportion of EVs-derived 
miR-219a-5p could be derived from the CNS. 
 
Furthermore, we wanted to analyse if miR-219a-5p could be increased in relapse when 
compared to remission and healthy controls. When we made this comparison in 
leucocytes, no significant differences were found (Figure 19, B). Obviously, and as 
explained before, leucocytes are not involved in the myelin regeneration and no 
differences in the levels of miR-219a-5p expression were expected. Plasma samples 
showed an interesting pattern (with no significant differences), in which miR-219a-5p 
copies per nanogram of RNA were higher in relapse samples when compared to 
remission ones and the latter higher than in HC (Figure 19, C). However, due to the low 
miR-219a-5p levels in both leucocytes and plasma samples we consider that EVs could 
be the most representative sample to be analysed, as miR-219a-5p was found to be 
enriched in EVs. When we analysed the expression of miR-219a-5p in EVs, we detected 
higher levels in relapse versus remission, which could highlights the role that miR-
219a-5p is playing in active remyelination. Interestingly, relapse levels were similar to 
HC (Figure 19, D). These results could indicate that during remission, expression of 
miR-219a-5p is decreased as a consequence of a depletion in the remyelination 
machinery but after a relapse, this machinery makes an effort in order to compensate the 
lost myelin reaching HC miR-219a-5p levels. However, these results did not show 
significant differences between groups, probably because of the low number of samples 
and a poor statistical power, and we should be careful when interpreting these results.  
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Figure 19: miR-219a-5p copies per nanogram of RNA in Leucocytes, plasma and EVs 
(A). Relapse, remission and HC miR-219a-5p copies per nanogram of RNA in 
leucocytes (B), plasma (C) and EVs (D).  
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CONCLUSIONS 
 
We have shown that the isolation of EVs increases the microRNA concentration, 
making them a potential source for microRNA studies. In addition, EVs isolated from 
blood are an easy and feasible sample to work with in order to understand molecular 
pathways that are involved in CNS diseases. Finally, these results indicate that miR-
219a-5p might mediate in the remyelination process that takes place in MS patients. 
However, further experiments are needed in order to increase sample population and to 
obtain more robust results. 
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INTRODUCTION 
 
Myelin is a lipid membrane formed by oligodendrocytes in the central nervous system 
(CNS). Myelin wraps axons giving them trophic support and allowing a correct 
transmission of nerve impulses. However, in several diseases this myelin is damaged 
causing an incorrect nerve impulse transmission and an imbalance in the homeostasis of 
axons, which can lead to neurodegeneration. The most common demyelinating disease 
is multiple sclerosis (MS), a chronic CNS disease in which myelin is damaged by an 
autoimmune attack. In brief, activated T cells migrate across the blood brain barrier 
(BBB), and induce an autoimmune response against the myelin 273. Interestingly, in the 
first stages of the disease, myelin can be endogenously restored in a process called 
remyelination. To do this, oligodendrocyte precursor cells (OPC) proliferate, migrate to 
the lesions, differentiate to oligodendrocytes and finally extend myelin’s sheaths around 
axons 21. 
 
Nevertheless, when the disease progresses the remyelination potential decreases and 
tends to fail. The reasons why this occurs are still not clear but it is thought to be related 
with a lack of OPC, and insufficient migration or a poor differentiation 41,283.  
 
Nowadays there is a wide rage of treatments that are focused on the attenuation of the 
immune response but there is still no treatment that promotes the regeneration of the 
myelin and therefore alternative strategies are appearing. The detection of 
undifferentiated Ol in demyelinating lesions suggests that the stimulation of the 
differentiation process might be a feasible and potential way of inducing remyelination 
in MS patients 47.  
 
With regard to this, several microRNAs have appeared as OPC differentiation 
mediators. MicroRNAs are small non-coding RNA formed by about 22 base pairs with 
regulatory functions. More concretely, miR-219a-5p has been widely used in 
experimental analysis demonstrating that it is able to generate OPC differentiation and 
therefore remyelination 182,228,230,231,233,284, as we also showed in Chapter One. However, 
the administration of microRNAs to the CNS is a tricky question and only invasive 
administration methods have been tested in animal models 230,234. Although these 
experiments showed positive results, direct administration of microRNA to the CNS is 
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not feasible as a treatment for MS patients. In order to administer the treatment in a non-
invasive and efficient way, several delivery systems have been developed. The idea 
behind them is to dispense the microRNA to the CNS non-invasively and in a controlled 
manner, inducing OPC differentiation and remyelination.  
 
In this work we have quantified and compared the ability of two synthetic systems 
(nanoparticles and liposomes) and one biological (exosomes), as microRNA carriers 
and their ability to induce OPC differentiation in a primary oligodendrocyte precursor 
cell culture.  In addition, the Experimental Autoimmune Encephalomyelitis model has 
been used to study the remyelination potential of the most promising delivery system.   
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METHODS 
 
microRNA carriers generation and loading (Figure 21).  
Liposomes 
Mimic mmu-miR-219a-5p (mimic-219a-5p) and mimic Transfection Control with 
Dy547 (mimic-Red) (#C300576 and #CP004500 Dharmacon) enriched liposomes or 
empty liposomes were prepared by the lipid film rehydration method 285,286. Mixtures of 
lipids (typically 10 µmol) were prepared in a 6:1 v/v mixture of chloroform: methanol. 
The final mixtures contained 3ß-[N-(N',N'-dimethylaminoethane)-
carbamoyl]cholesterol (molar fraction: x=0.167), 1,2-dioctadecanoyl-sn-glycero- 3-
phosphocholine (DSPC: x=0.617) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N- [amino  (polyethyleneglyco l)-2000] (ammonium salt) (PEG-
DSPE: x=0.05) (Avanti Polar Lipids (AL, USA)). Some of the liposome formulations 
were fluorescently labelled by adding 13µL of 3,3′-Dioctadecyloxacarbocyanine 
perchlorate dissolved in chloroform (1mg/mL) (DOiC) to the lipid mixture before the 
lipid film formation. Lipid films were formed by evaporation of chloroform: methanol 
on a rotavapor operated under vacuum at 30°C and 2 hours drying under a nitrogen 
flow. Lipid films were hydrated with 2 mL of RNAse-free water at 65°C. MiRNAs 
were added in a ratio of miRNA:lipid of 0.9 nmol miRNA:µmol lipid. The lipid film 
with the miRNA was allowed to hydrate overnight at 4 ºC forming miRNA-PEgylated 
liposome complexes. After that, the liposome dispersions were diluted twice with water 
and extruded 16 times at 65 ºC through polycarbonate membrane filters (Whatman, 
Rentfort, UK) of decreasing pore diameter (400, 200 and 80 nm). After this process, 
miR-219a-5p-liposomes (219-Lp), mimic-Dye-547-liposomes (Red-Lp) and empty 
liposomes (E-Lp) were obtained. This protocol was carried out in CICbiomaGUNE.  
 
Nanoparticles 
Poly lactic-co-glycolic acid (PLGA) nanoparticles were synthesized using water in oil 
in water (w/o/w) double emulsion technique. In brief, miRIDIAN microRNA mmu-
miR-219a-5p or miRIDIAN microRNA Mimic Transfection Control with Dy547 were 
dissolved in 200 µl of surfactant (0.5% poly vinyl alcohol (PVA) as an excipient), and 
were homogenized with 10% w/v PLGA in dichloromethane with a Misonix sonicator 
probe (Misonix, Inc., NY, USA) at 10W for 3 min. This initial water in oil emulsion 
(w/o) was then added to 15 ml of 5% w/v solution of PVA for a second emulsion step 
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and was homogenized at 12W for 3 min. The resultant water in oil in water (w/o/w) 
double emulsion was then subjected to organic solvent evaporation under stirring at 600 
rpm overnight at room temperature. The sample was centrifuged in water, 4 times at 
14.000 rpm, to wash out any water-soluble surfactant and polymer residues. Finally, 
miR-219a-5p-nanoparticles (219-Np), mimic-Dye547-nanoparticles (Red-Np) and 
empty nanoparticles were obtained (E-Np). This protocol was carried out in 
TECNALIA. 
 
Exosomes 
pLKO.1 lentiviral particles containing miR-219a-5p sequence or empty particles were 
infected in HEK293T cells. Selection was made by culturing the cells with puromycin 
(Cayman Chemical) and cells were maintained with this antibiotic for the rest of the 
experiment to avoid the growth of non-infected cells. To isolate exosomes, cells were 
grown to a 80% confluence in media (DMEM Thermo Fisher, 10% FBS Thermo Fisher 
and 1% Puromycin) followed by a change in the media to OptiMEM (Thermo Fisher) 
containing puromicyn for 36 hours. Then, media was recollected and exosomes 
concentrated using Tangential Flow Filtration system with VivaFlow 50R  10.000MW 
membrane (Sartorious)  followed by the use of centrifugal filters of 10.000MW (Merck 
Millipore). Afterwards, exosomes were isolated by differential centrifugation steps. 
Briefly, the sample was centrifuged at 13.000g for two minutes, supernatant recollected 
and centrifuged again at 20.000g for 20 minutes. Then pellet was recollected and 
resuspended in dPBS. With this process miR-219a-5p enriched exosomes (219-Ex) and 
non-enriched exosomes (Ne-Ex) were obtained. A Bradford assay was performed to 
quantify the protein levels of the samples, which was used to standardise exosome 
administration. 
 
In order to obtain fluorescent exosomes for up-take experiments exosomes were 
labelled with CM-Dil (Celltracker CM-DiI, #C7001, Thermo Fisher) as previously 
described 287. In short, exosomes were incubated with 1 µg/ml of Celltracker CM DiI 
for 5 minutes at 37º C and 15 minutes at 4º C. Then the sample was centrifuged at 
20.000 g for 20 minutes in order to pellet exosomes and remove the excess of dye. 
Exosomes were resuspended in dPBS.  
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Figure 21: Schematic representation of liposomes, nanoparticles and exosomes with 
their main components and the type of miR219a-5p they were loaded with. Liposomes 
and nanoparticles were loaded with synthetic microRNA. In contrast, exosomes 
contained biologically produced microRNA. 
 
Characterization of microRNA carriers  
Nano Tracking Particle Analysis (NTA) 
NTA was performed in a NanoSight LM10 device (Malvern) as previously described 
266. In brief, samples were diluted in filtered dPBS to get accurate acquisition (200-900 
recorded tracks). Camera settings were fixed and maintained for all samples (gain: 6.9; 
camera level: 5). For each sample, two videos of 1 minute were recorded and analysed 
with NanoSight NTA software 3.2 (Malvern). Total particles counts were obtained and 
profile distribution graphs generated.  
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Droplet Digital PCR 
RNA encapsulated in liposomes, nanoparticles and exosomes was isolated using Trizol 
LS protocol following the manufacturer´s instructions (#10296028, ThermoFisher). 
Exosomes RNA was quantified by NanoDrop ND-1000 spectrophotometer. Levels of 
RNA in liposomes and nanoparticles were not quantified by NanoDrop ND-1000 due to 
the low yields of total RNA in the sample (only mimic-219a-5p was present). RNA was 
reverse transcribed using TaqMan™ MicroRNA Reverse Transcription Kit (# 4366596; 
Thermo Fisher) following the manufacturer’s protocol in a Veriti Thermal Cycler 
(Applied Biosystems). miR-219a-5p expression analysis was performed using miRNA 
TaqMan Assay (ID: 522, Thermo Fisher) and supermix for probes (#186-3023, BioRad) 
in a QX200 droplet digital PCR system (BioRad). Analysis was carried out using 
QuantaSoft 1.6.6 software (BioRad). In order to compare results between vehicles, the 
number of copies of miR-219a-5p were related to the number of particles quantified by 
NTA. 
 
CryoTEM 
Liposomal, nanoparticle and exososomal solutions were vitrified following standard 
protocols described elsewhere 288. Quantifoil holey carbon film grids (Orthogonal Array 
of 2µm Diameter Holes - 2µm Separation, mounted on a 300M Cu grid, #657-300-CU, 
Ted Pella) were vitrified in liquid ethane in Vitrobot (FEI) after a negative glow-
discharged treatment of the grids and deposition of 3 µL of each sample. Cryo-transfer 
sample holders of type GATAN Model 626 kept the sample vitrified during electron 
microscopy analysis. Every sample was observed on a JEM-2100F UHR (80-200kV, 
JEOL, Ltd.) field emission gun (FEG) transmission electron microscope at different 
magnifications (8000x and 30 000x).  Low-dose micrographs were recorded on a state 
of the art TVIPS F216 CMOS camera (2k x 2k). This protocol was carried out in 
CICbiomaGUNE.  
 
MicroRNA microarray 
Following manufacturer’s instructions, total RNA (500 ng) was labelled using the 
FlashTag Biotin labelling kit (Ref: 901911;Thermo Fisher) and hybridised to the 
GeneChip miRNA 4.0 Array (Ref: 902412; Thermo Fisher), which covers 1908 mouse 
miRNAs. Briefly, RNA molecules were polyadenylated and a biotin-labelled DNA 
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molecule was attached in a subsequent ligation step. Finally, labelled RNA was 
hybridised to the array, washed and stained in a GeneChip Fluidics Station 450 and 
scanned in a GeneChip Scanner 7G (Affymetrix). 
 
Oligodendrocyte precursor cell culture  
The isolation of OPCs was carried out as previously described 59. Briefly, postnatal P1-
P3 C57BL/6 mice were sacrificed by decapitation. Once the brain was removed, 
meninges were extracted and tissue digested mechanically and enzymatically with 
papain at 37ºC for 14 minutes. 25 ml of OPC medium (DMEM (#041966; Thermo 
Fisher), supplemented with 10% Foetal Bovine Serum (# 16000044; Thermo Fisher) 
and 1% Antibiotic-Antimycotic (#A5955; Sigma) was added to the sample. Then, 300 
µl of a DNAse solution (1%, #DN-25; Sigma) was added to stop papain digestion. After 
a centrifugation step at 190 g for 10 min, supernatant was removed and the pellet, after 
resuspension in 1 ml of OPC media, was filtered through a 100-µm nylon mesh strainer 
(Falcon). Finally, up to 8 ml of OPC media were added to the cells which were seeded 
in a 75-cm2 Poly-L-Ornithine coated flask. After one week of incubation at 5% CO2 and 
37ºC, renewing the media every 2-3 days, the culture was shaken for 15 hours at 200 
rpm and one extra hour at 250 rpm. This was followed by media collection, which was 
passed through a 40-µm nylon cell strainer (Falcon) and centrifuged at 190 g for 10 
minutes. The pellet was resuspended in 10 ml of OPC media. The suspension was 
plated on an untreated plastic Petri dish at 37 ºC for one hour to allow the microglial 
cells to attach to the Petri dish. Then, the media was collected, centrifuged at 190 g for 
10 minutes, filtered again through a 40-µm strainer and incubated in a new uncoated 
Petri dish for 30 minutes. After the 30 minutes, the media was collected, and 
centrifuged at 190 g for 10 minutes to finally obtain the purified OPCs. 20.000 cells 
were incubated on a laminin-treated plate to perform uptake and differentiation 
experiments. 
 
Up-take studies 
Note: The fact that each vehicle has to be generated under different protocols made it 
impossible for us to administer them in the same concentration. To solve that, we added 
each vehicle in order to dispense similar particles counts, independently of the volume 
that was added to the culture. Red-Lp, Red-Np labelled with DiOC18 and Coumarin 
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respectively and Ne-Ex labelled with CM-DiL Celltracker were added to the OPCs and 
incubated for 24 hours in order to determinate the percentage of cells that were up-
taking the particles. A total volume of 100 µl of Liposomes, 1 µl of Nanoparticles and 
10 µl of Exosomes (100 µg of quantified protein) were administered to the culture. 
These volumes made a final number of 2.7 x 10 5 or 6 particles for all vehicles.  
 
24 hours later, OPCs were fixed with 4% paraformaldehyde and labelled with Hoechst. 
Images were obtained with 20x magnification in a Nikon Eclipse80i (Nikon) and NIS 
elements AR 3.2 (Nikon) was used to capture the images. Fields were randomly 
selected. LSM 880 confocal microscopy (Zeiss) was used at a 60x magnification to 
obtain individual cell images. Positive and negative cells were counted and the average 
up-take levels quantified.  
 
Differentiation studies 
Similar to up-take studies, 219-Lp, E-Lp, 219-Np, E-Np, 219-Ex and Ne-Ex were 
administered to OPCs in the following concentrations: A total volume of 100 µl of 
liposomes, 1 µl of nanoparticles and 10 µl of exosomes (100 µg of quantified protein) 
were dispensed to the culture making a final concentration of 2.7 x 10 5 or 6  per well. 
Due to the low quantity of miR-219a-5p present in the cargo of exosomes, these 
vesicles were administered daily. A unique dose of liposomes and nanoparticles was 
administered at time zero. Three days after administration, RNA from OPC was isolated 
in order to perform gene expression studies and determine the degree of cell 
differentiation. RNA was isolated using Trizol LS protocol following the 
manufacturer´s instructions (#10296028 Thermo Fisher). Then, total RNA was reverse 
transcribed using High-Capacity cDNA Reverse Transcription Kit (#4368814, Thermo 
Fisher) following manufacturer’s protocol in a Veriti Thermal Cycler (Applied 
Biosystems). Gene expression analysis of 2',3'-cyclic nucleotide 3' phosphodiesterase 
(Cnpase) myelin oligodendrocyte glycoprotein (Mog), myelin basic protein (Mbp) and 
proteolipid protein (Plp1) were performed in order to establish the differentiation degree 
of the cells, using KiCqStart SYBR Green qPCR ReadyMix and KiCqStart SYBR 
Green Primers (KCQS02 and KSPQ12012, Sigma). Ribosomal protein L13α (Rpl13a) 
and phosphoglycerate kinase 1 (Pgk1) were used as endogenous controls. CFX384 
Thermal Cycler (Bio-Rad) was used to run the qPCR and raw data was processed in 
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Bio-Rad CFX Manager software. The calculation of relative expression was carried out 
with Excel software using the 2-DDCT method 270.  
 
Experimental Autoimmune Encephalomyelitis (EAE) 
All animal procedures were approved by the Biodonostia Health and Research Ethics 
Committee (CEEA17_002). 
 
Induction and clinical evaluation 
10 weeks old C57BL/6 female mice were immunized with Hooke KitTM MOG35-55/CFA 
Emulsion PTX kit (#EK2110, Hooke Laboratories) as described in the manufacturer´s 
protocol. Briefly, animals were anesthetized with isoflurane 2% and 100 µl of MOG35-55 
and Freund´s adjuvant emulsion were injected subcutaneously in two locations, 
administrating a total volume of 200 µl per animal. 2 and 24 hours after emulsion 
administration, 80 ng of Pertussis Toxin were administered to each animal. Animals 
were weighed and scored daily with the new clinical scale proposed by our group and 
defined in Chapter Two. The monitoring was performed in a blind manner in order to 
achieve objective scores.  
 
Exosomes administration 
100 µg of 219-Ex and Ne-Ex were administered 2 and 8 days after disease induction. To 
do this, mice were anesthetised with isoflurane 2% and 10 µl of exosomes (10 µg/µl) 
were administered to each animal in four doses, two per nostril, for 10 minutes.  
 
Sample extraction 
Animals were anesthetized with isoflurane 2% and cardiac puncture was carried out to 
obtain blood at final term. Additionally, spinal cords were extracted and fixed in PFA at 
4% for 72 hours. Then spinal cords were stored at 4ºC in PBS with 0.01% of azide until 
Magnetic Resonance Imaging was carried out.  
 
Plasma derived cytokine measurement 
Blood samples obtained from cardiac puncture were centrifuged at 300 g for 15 minutes 
and plasmas were isolated. Plasma concentration of IL-10 IL-17A and TNFα were 
measured by a mouse high sensitivity T cell magnetic bead panel as previously 
described and following the manufacture´s protocol (MHSTMAG-70K Millipore) 289. 
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Then Bio-Plex MagPix (MerckMillipore) was used to run the samples and perform the 
analysis.  
 
Magnetic Resonance Imaging 
Magnetic Resonance Images (MRI) of mice spinal cord (animals with lowest clinical 
score per group; n=1) were acquired using a Bruker Biospec USR 117/16 MRI system 
interfaced to 4 transmit and 8 receive RF channels with a XYZ set of actively shielded 
gradients 750 mT/m and a slew rate of 6660 T/m/s. RF transmission and reception was 
achieved by using a transmit volumetric coil of 72 mm of i.d. (T1148V3), and receive 
surface coil (mouse brain surface coil, T11657V3) of approx. 2 cm diameter, both from 
Bruker Biospin GmbH (Ettlingen, Germany).  
Tissue samples were immersed in PBS for imaging. After the acquisition of a series of 
scout images, Diffusion Weighted Images of the samples were acquired using a 
DtiStandard sequence for Buker software Paravision 6.0.1, with the following 
parameters: Spin-Echo DWI, 12 diffusion directions (d=4 ms, D=11 ms, b=1000 s mm-
2), 1 image with b=0 s mm-2, echo time TE= 21 ms, repetition time TR=3000 ms, N 
Averages= 2, Image Matrix of (256x256) points with a Field-of view FOV= (25.6 x 
25.6 mm), giving an in-plane resolution of (100 x 100 µm), and acquiring 60 
consecutive slices of 0.2 mm thickness. Spectrometer bandwidth was set to BW = 66 
kHz and the total scanning time resulted in 4h 9m 36s. The open source software DIPY 
(Diffusion Imaging in python), with local PCA denoising, was used for the processing 
of acquired DTI images, to obtain fractional anisotropy (FA) Further image analysis 
was performed with Image-J software, from NIH.  
 
Statistical analysis 
qPCR data relative expression was calculated by 2 -DDCT method. Mann Whitney test 
was used to analyse differences in the score of EAE animals and the significance of 
MRI fractional anisotropy of MRI images.  
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RESULTS AND DISCUSSION 
 
Vehicles characterization  
NTA was used to characterize the distribution in size and number of particles present in 
the samples. As shown in Figure 22 A, liposomes showed two main populations, the 
principal one at a size of 160 nm and a secondary one at 230 nm. Nanoparticles 
displayed a more homogeneous size distribution the main size being between 180 and 
220 nm. In contrast, exosomes were the most heterogeneous sample the distribution 
being between 150 and 400nm. These results are in concordance with the genesis 
procedure of each vehicle. On the one hand liposomes and nanoparticles are 
synthetically generated in the laboratory with standard protocols to produce a 
homogeneous sample. On the other hand, exosomes are membrane-bound particles 
secreted by cells. They have been described to be different in size depending on their 
biogenesis 290. Exosomes are described as the smallest vesicles; However, it must be 
noted that in many scenarios it can be difficult to separate those based exclusively on 
their size 152 indicating that our sample does not only contain exosomes, but also 
microparticles. These results were confirmed by electron microscopy (Figure 22, B) in 
which similar size vesicles can be found when compared to NTA.  
 
When we analysed the cargo of microRNA in each vehicle, we determined that 
liposomes were able to encapsulate miR-219a-5p more efficiently than nanoparticles 
and these more than exosomes. With the particle counts data obtained from the NTA, 
we quantified the copies of microRNA per particle, determining that liposomes were the 
most enriched particles followed by nanoparticles and finally exosomes (Figure 22, C). 
In our hands, exosomes were the most time-comsuming vehicle to be generated. 
HEK293T cells needed to be grown for approximately 2 weeks before isolating 
exosomes, which took two extra days. On the other hand, liposomes and nanoparticles 
took less time and the synthesis protocol was more reproducible. 
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Figure 22: A) Nanoparticle Tracking Analysis (NTA) of liposomes, nanoparticles and 
exosomes. B) Cryo-TEM images of the three vehicles showing correlation in size with 
NTA. C) Levels of miR-219a-5p in liposomes, nanoparticles and exosomes. Liposomes 
are the most enriched vehicles followed by nanoparticles and finally exosomes.  
 
Uptake and differentiation studies 
Later, we wanted to test the ability of these vehicles to be taken up by OPCs. To do this, 
we labelled liposomes, nanoparticles and exosomes with DiOC18, Cumarin and CM-
DiI respectively. 24 hours after administration, cells were fixed and microscopy images 
acquired determining that liposomes were taken up more efficiently by cells (95,83%, 
Stdv 5,9), followed by nanoparticles (83,98%, Stdv 5,1) and finally exosomes (61,48%, 
Stdv 2,8) (Figure 23, A and B). To study the potential of the three vehicles to induce 
OPC differentiation, a necessary step for remyelination, 219-Lp, 219-Np and 219-Ex 
were compared to their respective empty or non-enriched vehicles. Interestingly we saw 
that only exosomes were able to significantly increase the expression of myelin related 
genes (Cnpase, Mbp, Mog and Plp1) indicating a more differentiated state of the OPCs 
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(Figure 23C). However, our results indicate that exosomes, but neither liposomes nor 
nanoparticles, were able to induce OPC differentiation.  
 
Interestingly, exosomes showed the lowest miR-219a-5p and up-take levels when 
compared to liposomes and nanoparticles but was the only vehicle able to induce OPC 
differentiation. Our initial idea was that liposomes and nanoparticles could be more 
appropriate microRNA delivery systems due to their homogeneity in composition and 
cargo and that their generation can be controlled. On the other hand, exosomes are 
biologically formed vesicles, which play an essential role in indirect intercellular 
communication and can transfer cytosolic proteins, lipids, metabolites and genetic 
material from one cell to another 252,253 indicating that other factors can be acting as 
helpers of the effect produced by miR-219a-5p. In fact, our results show that the 
biological complexity of exosomes, seems to be beneficial for OPC differentiation. 
Moreover, exosomes can be integrated in two different ways; by direct fusion with the 
plasma membrane or by endocytosis 291,292 demonstrating the higher ability of exosomes 
to integrate to the receptor cell. In addition, their cargo contain some machinery that 
favours microRNA processing such as Dicer, Ago2 or TRBP 293 . In relation to this, 
exosomes have shown to be efficient microRNA delivery systems for several diseases 
294. In order to understand further which microRNAs could be favouring the 
demonstrated effect, a microRNA profiling of exosome cargo was carried out using 
microarray technology. Surprisingly, miR-219a-5p was not detected by this array. This 
unexpected result questions the sensitivity of microarray technology, given that we had 
already confirmed the overexpression of miR-219a-5p in these exosomes. Nonetheless, 
to be sure that miR-219a-5p was present in enriched exosomes, we performed a qPCR 
experiment, which confirmed our previous ddPCR data (Ct value in qPCR = 27). 
Additionally, both ddPCR and qPCR demonstrated that 219-Ex contained between 30 
and 100 times more miR-219a-5p when compared to Ne-Ex. 
 
miR-219a-5p enriched exosomes improve EAE clinical evolution. 
Once we had determined that exosomes were able to induce OPC differentiation, we 
wanted to go a step further and test their ability to improve EAE clinical score. 
Exosomes were intranasally administered as previously reported 177, to allow them to 
reach the CNS. Two doses were dispensed at days 2 and 8 after disease induction and 
the score was monitored daily. When analyzing the score, we could detect significant 
CHAPTER FOUR 
	 135 
differences at days 21, 22 and 25-29 when compared to the non-enriched Exosomes 
treated group. Interestingly, differences appeared after the disease peak, indicating that 
Exosomes could be promoting myelin regeneration (Figure 24, A). To confirm this, 
MRI images were obtained from spinal cords in mice (Figure 24, B). Fractional 
anisotropy is significantly increased in miR-219a-5p enriched exosomes treated animals 
when compared to non-enriched exosomes treated animals (p=0,001; Figure 24, C).  
 
 
Figure 23: A) Uptake studies of liposomes, nanoparticles and exosomes. Liposomes 
containing DioC18 (green) and mimic-Red (red), nanoparticles containing Coumarin 
(green) and mimic-Red (red) and exosomes labelled with CM-DiL are shown. 
Individual cells are confocal microscopy images of representative samples. B) 
Percentage of OPCs that are able to take up each vehicle. Liposomes are the most 
efficient vehicle followed by nanoparticles and finally exosomes. C) Expression levels of 
myelin related genes in  OPC cultures treated with each vehicle compared to the same 
empty vehicle. Exosomes are the only vehicle able to induce OPC differentiation.  
 
Additionally, we analyzed the inflammatory patterns in plasma of EAE mice, but no 
significant differences were found in plasma derived cytokine levels between both 
groups (Figure 24, D). This result indicated that miR-219a-5p enriched exosomes were 
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not regulating the immune system of the animal supporting the idea that significant 
differences shown in the clinical score evolution could be related to a regeneration of 
the myelin.  
 
 
Figure 24: A) Clinical evaluation of animals treated with non-enriched exosomas (Ne-
Ex) and with miR-219a-5p enriched exosomes (219-Ex). 219-Ex treated animals 
showed a significant decrease in the clinical evaluation after the disease peak (n=4).  
B) MRI of spinal cord of a Ne-Ex treated animal and a 219-Ex treated mouse showing 
the fractional anisotropy (FA). C) FA values of a section of the spinal cord of previous 
animals showing a decrease in FA values when treatment was Ne-Ex, indicating that 
remyelination is occurring. D) No significant differences between both groups in pro-
inflammatory cytokines were found, indicating that the effect induced by exosomes was 
not related to an anti-inflammatory process.  
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CONCLUSION 
 
Remyelination is a key aspect in MS pathology and a special effort is being made to 
promote this process. However, there is still no commercially available treatment to 
regenerate damaged myelin. Because of this, several strategies are being scrutinized. 
MicroRNAs have been postulated as a feasible and promising tool to induce OPC 
differentiation and therefore remyelination. However, microRNA delivery mechanisms 
to the CNS are still under study and the use of liposomes, nanoparticles and exosomes 
has been addressed in this work.  
 
Although liposomes and nanoparticles were more enriched in miR-219a-5p and showed 
higher uptake levels than exosomes, those exosomes were surprisingly, the only 
delivery system able to induce OPC differentiation. However, as mentioned before, 
exosomes are biological delivery systems which contain other proteins, lipids and 
genetic material that can be integrated into the cell in several ways and that contain 
microRNA processing molecules, indicating that the efficiency of exosomes as 
microRNA delivery systems could be influenced by their biological context, making 
them more efficient delivery systems than liposomes or nanoparticles. 
 
When exosomes were administered intranasally to the EAE models, they were able to 
decrease the clinical score, with no immuneregulation. In addition, significant 
differences were shown after the disease peak, indicating that they might be increasing 
the myelin production, which was also correlated with MRI results.  
 
To conclude, miR-219a-5p has been identified as a necessary but not sufficient 
condition to induce remyelination. Additionally, miR-219a-5p enriched exosomes 
stimulate OPC differentiation and improve EAE clinical evolution opening a therapeutic 
approach for MS patients. In addition, this work shows that the use of exosomes as a 
microRNA delivery system for CNS diseases can be a promising and feasible tool.  
 
 	
 	
 
 
 
 
 
 
 
 
 
 
 
 GLOBAL DISCUSSION  and 
personal opinion 
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…with the idea of confirming if young rodent derived exosomes were able to reduce the 
clinical score of the EAE model”.  
 
Unfortunately we were not able to see an improvement in the clinical score of the 
animals after intranasal administration of young blood-derived exosomes. Moreover, we 
could not see a positive effect either in the cerebellar organotypic culture or in the OPC 
culture. When we tried to investigate the reason for the lack of effect of our young 
blood-derived exosomes, we discovered that they did not contain miR-219a-5p or other 
pro-remyelinating microRNAs. 
 
At that point we decided to find out if miR-219a-5p was able, as previously described 
by several groups 228,231,233, to induce OPC differentiation. To do this, we chose a 
synthetic microRNA which was administered  to the OPC and cerebellar organotypic 
cultures with lipofectamine. We determined that this synthetic microRNA was able to 
induce OPC differentiation in the OPC culture and to increase the generation of OPC 
cells in the cerebellar organotypic culture. These data made us think about the 
possibility of administering the microRNA to the EAE model. 
 
However, and previous to continuing with this line of action, we wanted to understand 
the role that miR-219a-5p could be playing in patients’ remyelination. For that reason, 
we analysed the level of miR-219a-5p in patients’ blood. Although, we were not able to 
see significant differences between relapse and remission patients, we were able to 
detect a tendency in which miR-219a-5p is increased after a demyelinating insult. 
Further studies are needed to increase sample size, to study this process in more 
advanced stages of the disease and to isolate neuronal origin EVs by 
immunoprecipitation 295, but our results indicate that miR-219a-5p might be a key 
player in remyelination. Additionally, these preliminary results postulate miR-219 as a 
possible biomarker of the level of remyelination in MS patients.  
 
These results reinforced our idea of administrating miR-219a-5p to the animal model in 
order to promote remyelination. Nevertheless, we had to decide which could be the best 
and most effective method of delivery. Direct administration was previously 
demonstrated to be an effective way to induce myelin regeneration 230,234. However, we 
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considered that this was more a proof of concept rather than a real delivery system for 
MS patients. We thought that direct administration should be avoided in human therapy, 
especially if repetitive administrations have to be carried out (remembering that MS is 
distributed along space and time), therefore we selected a non-invasive delivery method. 
Several reports have been published indicating that intranasal administration of cells, 
molecules and exosomes could be an effective, non-invasive and secure method to reach 
the CNS 257,296–298 . 
 
With this objective, miR-219a-5p should be encapsulated for protection it and to allow 
it to cross the BBB and reach the CNS to produce the expected effect. Viral vectors 
were discarded due to safety questions, such as a possible oncogenic transformation of 
the recipient cell. In addition they can stimulate the innate and adaptive immune 
responses reducing its effectivity 249. Interestingly, liposomes and nanoparticles have 
been described as effective synthetic molecule delivery systems. In collaboration with 
CICbiomaGUNE and TECNALIA, liposomes and nanoparticles were respectively 
developed and loaded with the synthetic miR-219a-5p. In parallel, and thanks to 
collaboration with the University of Oxford, we generated exosomes enriched in miR-
219a-5p.   
 
Once the vehicles were characterized, we decided to test and compare the ability of 
liposomes, nanoparticles and exosomes to induce OPC differentiation. Interestingly, and 
although exosomes contained the lowest microRNA and uptake levels, it was the only 
vehicle able to induce OPC differentiation. In order to explain this, we should remember 
that exosomes are “biologically designed” to send information from one cell to another, 
making them, in our opinion, more efficient when compared to liposomes or 
nanoparticles. Additionally, they also contain other molecules such as proteins and 
genetic material that can interact with miR-219a-5p and increase its effect.  
 
With these results, we decided to address if miR-219-a-5p enriched exosomes could be 
able to induce an improvement in the clinical evolution of the EAE animal after 
intranasal administration. Interestingly, we saw an improvement in the clinical score 
when compared to non-enriched exosomes indicating that the use of miR-219a-5p 
enriched exosomes could be a therapeutic strategy for MS patients.  
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Personal opinion 
During the 5 years that I have worked in this project, several aspects have been 
discussed and studied. At this point I would like to give my personal opinion in relation 
to a) technical aspects and b) the use of microRNA delivery systems for demyelinating 
diseases and other neurodegenerative diseases.  
 
Technical aspects - remyelination models 
In a great number of works (including this one) the scientific community has shown it is 
able to promote myelin regeneration in several models. It is clear we are able to cure 
mice. However, nowadays there is still no remyelination strategy available for MS 
patients, indicating that the transfer of these results to the clinic is a difficult question. 
Animal models are just this, models that try to mimic the processes that take place in 
human pathologies. However, they have clear limitations regarding molecular 
differences or output deficiencies, among others.  
 
Multiple sclerosis is a disease which mainly affects young adults and has a clear chronic 
component. Moreover, age has been associated with the disease evolution, as 
remyelination potential decreases with age. Therefore, I consider that one factor that 
should be taken into account when using remyelinating models is age. However, the 
models that have been used in this thesis and that are commonly used, are all derived 
from young animals. For example, OPCs and cerebellar slices are obtained from 
newborn mice, while the EAE model is performed in young mice. If we are trying to 
understand the remyelination process and the ability of some drugs to promote it, I 
believe that older models should be used. I recognize that obtaining OPCs from adult 
animals is a tricky question, but some efforts have been made in this direction 59. 
Similar to this, cerebellar organotypic culture is more difficult to grow when derived 
from adult animals, but again, if we want to obtain more realistic data, this effort must 
be made. Finally, the EAE is a complex model, and the use of aged animals will help to 
mimick the process that takes place in MS patients, such as the decline of the 
remyelination ability.  
 
As mentioned above, another key aspect in the use of remyelination models is their 
output. The better output, the more realistic results will be obtained. Regarding 
cerebellar organotypic culture, confocal microscopy analysis is the gold standard tool 
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for analysing the remyelination level in the model. Briefly, antibodies against myelin 
and axons are used and confocal images are obtained to quantify the colocalization 
percentage. However, image reproducibility must be high in order to compare one slice 
to another. We experienced difficulties performing reproducible immunofluorescence 
for myelin and axons due to the high variability of the culture so we decided to use 
other techniques. In a similar approach we used Western Blot to quantify total myelin 
and axon protein levels. Additionally, qPCR for myelin related genes were carried out. 
Although these techniques showed promising results, they do not show if the myelin is 
wrapping axons and if real remyelination is occurring. In order to solve that, in an 
ambitious approach in collaboration with CICbiomaGUNE, we decided to quantify the 
remyelination level by MRI. We obtained excellent images when slices were not 
cultured (Figure 25). However, after one week in culture, slices lost their thickness and 
it was extremely difficult to obtain proper images to quantify remyelination. This work 
led us to present two posters in international congresses. At this point, I would like to 
mention that, in our hands, the organotypic culture model is a really complex model and 
that obtaining reproducible data is difficult. Although it is a widely used model and 
many articles have been published including this model, after this work I contemplate 
that it is not an appropriate model for studying remyelination. 
 
 
Figure 25: Cerebellar organotypic culture slice image obtained with MRI (Photo taken 
by Ander Egimendia) 
To continue with the output of remyelination experimental models, as widely explained 
in Chapter Two, we noticed that the EAE animal model clinical score could be 
improved. I wanted to highlight that the way data are obtained from this model is 
crucial to obtain objective, representative and realistic results of the experiments. To 
facilitate the data acquisition and analysis process, we tried to improve the clinical 
evaluation system and developed a mobile application (that is at the moment being 
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evaluated by a software company). Nevertheless, this is a secondary measurement of the 
degree of pathophysiological damage to the animals and therefore, histological analyses 
are commonly performed. In this case we decided to use MRI to characterize the 
remyelination degree at the end point. But I consider that producing and analysing MRI 
images throughout the evolution of the disease is the best way of characterizing the 
remyelination level of an animal, allowing the evaluation of this animal during the 
experiment and, in this way, reducing  the number of mice that are needed per group.  
 
To conclude this section, I would like to mention that during this work, I have changed 
my opinion regarding the models and their output methodologies. This evolution is 
reflected during this work, especially in Chapters One and Four. For example, 
organotypic cultures have not been used in Chapter Four, and the EAE induction 
methodology has been modified to obtain a more homogenous model. 
 
Therapeutic use of microRNA delivery systems 
It has been proposed that the use of an immunomodulatory or immunoregulatory drug 
in combination with a remyelination promoter could be an effective way of treating MS 
patients. In this work, we have proposed that miR-219a-5p is an efficient remyelination 
inductor and that the encapsulation of this microRNA in exosomes could be a feasible 
strategy to promote remyelination.  
 
On the other hand, liposomes and nanoparticles did not prove to be effective delivery 
systems in the OPC culture. However, this does not mean that they could not be 
effective in this process. Liposomes and nanoparticles could be synthetized in several 
ways and their components and their proportions can be modified in order to obtain 
more efficient vehicles. Additionally, the location of the microRNA were it is included 
in the vehicle could influence their effectiveness, as they have been shown to be around 
and inside liposomes and nanoparticles. In order to select the most efficient formulation 
of vesicles as microRNA delivery systems, we based on the expertise of our 
collaborators, their preliminary results and also on previous literature. However, and 
although these vehicles were not effective in our task, further studies should be made as 
they have clear advantages when compared to exosomes. For instance, their synthesis is 
well characterized and very reproducible and the components are perfectly known 
facilitating the approval of their use as therapeutic agents or mediators. 
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Regarding the use of microRNAs as remyelinating promoters, some authors have 
postulated that the combination of more than one microRNA could be a more effective 
way of inducing OPC differentiation and therefore remyelination. More concretely, 
miR-219a-5p in combination with miR-338 and miR-138 demonstrated they induce 
remyelination more efficiently than miR-219a-5p alone 230,231. However, in our 
experience miR-219a-5p on its one was more effective than the combination of these 
microRNAs (data not shown) and this is why we used only miR-219a-5p. But further 
studies could be made combining other microRNAs or other molecules with miR-219a-
5p in order to obtain more powerful results. 
 
As previously mentioned, we demonstrated that miR-219a-5p enriched exosomes were 
able to induce remyelination in the EAE animal model after intranasal administration. 
However, we did not prove if exosomes reached the CNS. Although some papers have 
been published indicating that intranasally administrated exosomes were able to reach 
the CNS 299 we would have liked to confirm it in our laboratory. In collaboration with 
CICbiomaGUNE, we are trying to label exosomes with a contrast agent that can be 
detected using MRI. This technique will aid the tracking exosomes in time to confirm if 
they are reaching the CNS and in what proportion. Another aspect that should also be 
kept in mind is if, once the vehicles reach the CNS, they have tropism to OPCs (which 
are the target cells of this therapy) or on the contrary, they become fused with other cell 
types. The exosomes that have been used in this work did not contain any factor that 
could aid them to target OPCs and therefore I consider that exosomes are targeting all 
cell types, This might produce side effects which should be addressed in further studies. 
Although we obtained positive results, I think that exosomes could be directed to OPCs 
by using antibodies, in this way improving the efficacy and reducing side effects, 
making this therapeutic strategy more effective and less risky. 
 
The EVs isolation method is also a relevant aspect to be mentioned, as several methods 
can lead to different EVs types. Although great effort has been made in order to 
standardize isolation techniques 300, there is still controversy in which is the most 
efficient method. For example, conditioned media has demonstrated to induce 
modification in cells after its administration in vitro 301, but the isolation of EVs by 
ultracentrifugation of the conditioned media was also effective 184, highlighting that 
very different techniques can lead to positive results. In Chapter One, we decided to 
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replicate some aspects of a previous work and therefore we used Exoquick TC. 
However, in Chapters Three and Four we decided to use the most efficient method to 
our hand 151, which consists in differential centrifugation steps.  
 
Another thing to consider when speaking about exosomes as remyelination mediators is 
the source of the therapeutic exosomes. EVs are, from a biological point of view, 
complex vehicles that contain a large number of components. In this work we have 
focused exclusively on microRNAs, but it has been suggested that they are only 1% of 
the cargo 302. Additionally, as we have shown in Chapter One, the environment can 
modify the cargo of vesicles, complicating the isolation of reproducible EVs batches.  
Therefore, the source of the EVs and the conditions under which they are obtained 
could influence their cargo and their ability to modify target cells. In this sense, 
established cell lines or cells isolated from the patient or a donor can be used to isolate 
EVs. Biofluids such as plasma or urine are also an alternative. It is not clear which 
source is the most efficient and each one has its detractors. I consider that the use of 
established cell lines facilitates the isolation of EVs under reproducible conditions. In 
Chapter Four we decided to use HEK cells as an easy to grow and manage cell line. 
However, I think that using neural derived cell types could be more effective as they 
may have tropism to the CNS. At the moment we are obtaining miR-219a-5p enriched 
exosomes from neural derived cell lines. 
 
Additionally, in our approximation we decided to modify HEK cells by bioengineering 
techniques to obtain exosomes enriched in miR-219a-5p. However, non-modified EVs 
have shown promising results 182,257. In fact, there are several clinical trials recruiting 
patients in which the ability of allogeneic mesenchymal stem cell derived exosomes in 
acute ischemic stroke or the effect of plasma derived exosomes on cutaneous wound 
healing will be addressed 303,304. Nevertheless, the modification of the cargo of EVs by 
bioengineering techniques is an interesting and promising field in EV-mediated 
therapies and I consider that it might be a more effective treatment method as our data 
demonstrate. In addition to microRNAs, vesicles can also be loaded with small 
compounds and drugs with anti-inflammatory effects. As an example, curcumin loaded 
exosomes demonstrated they induce neuroprotection 187. Finally, EVs can be modified 
to express membrane receptors of the target cell, in this way increasing the uptake by 
the target cell and decreasing off-target bindings 197, as previously mentioned.  
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To conclude, EVs have demonstrated they are key players in myelin regeneration and 
the applications that EVs could have in the stimulation of remyelination in pathological 
states are many 139. As we have mentioned, remyelination therapies are still not 
available and the use of EVs is becoming a promising and feasible method to induce 
myelin restoration, in this way decreasing neurodegeneration and therefore, increasing 
patients’ outcome. In Figure 26 we summarize some approaches that can be performed 
in order to obtain therapeutic EVs. Our knowledge about the therapeutic potential of 
EVs is just beginning and an exciting future awaits us… 
 
Figure 26: Summary of proposed therapeutic approaches for demyelinating diseases. 
Established cell lines, donor- or patient-derived cells are isolated and grown. EVs can 
be loaded with drugs/small compounds, miRNAs/siRNAs and/or surface antibodies, 
which provide new options in remyelination therapy. The loading can be performed 
during the cell culture (endogenous loading) or once EVs are isolated (exogenous 
loading)(reviewed in 305). This might depend on the strategy and purpose of the therapy 
306. Therapeutic EVs can be isolated by ultracentrifugation, differential centrifugation, 
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immunoaffinity or size-exclusion chromatography 307. Finally, EVs could be 
administered to the patient intranasally, intraperitoneally or intravenously and again, 
this is something that will vary according to the therapeutic strategy. 
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1. Environmental conditions affect the cargo of blood-derived exosomes, 
modifying therefore their functions.  
2. MiR-219a-5p induces OPC differentiation in primary cells and activates 
remyelination in the cerebellar organotypic culture. 
3. MiR-219a-5p is a key factor in the cargo of young blood rodent derived pro-
remyelinating exosomes to induce OPC differentiation and remyelination in the 
EAE animal model.  
4. The new EAE scale and the mobile application facilitate the acquisition of 
robust, reproducible and more objective data when monitoring EAE clinical 
evaluation. 
5. MiR-219a-5p is enriched in the EV fraction derived from plasma when 
compared to total plasma.  
6. MiR-219a-5p could play a role in the remyelination process after relapse in MS 
patients, being a possible biomarker of the remyelination stage. 
7. Liposomes and Nanoparticles are more efficient encapsulating miR-219a-5p and 
being up-taken by OPCs when compared to exosomes.  
8. MiR-219a-5p enriched exosomes is the only tested vehicle able to induce OPC 
differentiation.  
9. MiR-219a-5p enriched exosomes are able to induce EAE clinical improvement 
when intranasally administered to the mice.  
10. MiR-219a-5p enriched exosomes could be a promising and feasible therapeutic 
strategy to promote remyelination in MS patients.  
11. Exosomes could be a possible microRNA delivery system for other 
neurodegenerative diseases. 
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CHAPTER ONE: MiR-219a-5p is a key factor in the cargo of exosomes to induce 
remyelination.  
  
Supplementary Figure 1: Full-length gels of the Western Blot represented in Figure 13. 
Red squares represent the cropped areas shown in the Figure 13 for GRP78, CD107a 
and CD71. 
 
 
 
 
Supplementary Table 1: Experimental autoimmune encephalomyelitis clinical score. 
Modified from Hooke Laboratories. 
        
  EAE scoring (modified from Hooke´s laboratories)   
  Score Clinical observations   
  
0 
No obvious changes in motor function compared to non-immunized mice.   
  
When picked up by base of tail, the tail has tension and is erect. Hind legs 
are usually spread apart. When the mouse is walking, there is no gait or 
head tilting.   
  
0,5 
Tip of tail is limp.   
  
When picked up by base of tail, the tail has tension except for the tip. 
Muscle straining is felt in the tail, while the tail continues to move.   
  1 Limp tail.   
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When picked up by base of tail, instead of being erect, the whole tail drapes 
over finger. Hind legs are usually spread apart. No signs of tail movement 
are observed.   
  
1,5 
Limp tail and hind leg inhibition.   
  
When picked up by base of tail, the whole tail drapes over finger. When the 
mouse is dropped on a wire rack, at least one hind leg falls through 
consistently. Walking is very slightly wobbly.   
  
2 
Limp tail and weakness of hind legs.   
  
When picked up by base of tail, the legs are not spread apart, but held closer 
together. When the mouse is observed walking, it has a clearly apparent 
wobbly walk. One foot may have toes dragging, but the other leg has no 
apparent inhibitions of movement.   
  - OR -   
  
Mouse appears to be at score 0.0, but there are obvious signs of head tilting 
when the walk is observed. The balance is poor.   
  
2,5 
Limp tail and dragging of hind legs.   
  
Both hind legs have some movement, but both are dragging at the feet 
(mouse trips on hind feet).   
  - OR -   
  
No movement in one leg/completely dragging one leg, but movement in the 
other leg.   
  - OR -   
  
EAE severity appears mild when picked up (as score 0.0-1.5), but there is a 
strong head tilt that causes the mouse to occasionally fall over.   
  
3 
Limp tail and complete paralysis of hind legs (most common).   
  - OR -   
  
Limp tail and almost complete paralysis of hind legs. One or both hind legs 
are able to paddle, but neither hind leg is able to move forward of the hind 
hip.   
  - OR -   
  Limp tail with paralysis of one front and one hind leg.   
  - OR -   
  ALL of:   
  Severe head tilting,   
  Walking only along the edges of the cage,   
  Pushing against the cage wall,   
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  Spinning when picked up by base of tail.   
  
3,5 
Limp tail and complete paralysis of hind legs. In addition to:   
  
Mouse is moving around the cage, but when placed on its side, is unable to 
right itself. Hind legs are together on one side of body.   
  - OR -   
  
Mouse is moving around the cage, but the hind quarters are flat like a 
pancake, giving the appearance of a hump in the front quarters of the 
mouse.   
  
4 
Limp tail, complete hind leg and partial front leg paralysis.   
  Mouse is minimally moving around the cage but appears alert and feeding.   
  
Often euthanasia is recommended after the mouse scores 4.0 for 2 days. 
However, with daily s.c. fluids some mice can recover to 3.5 or 3.0. When 
the mouse is euthanized because of severe paralysis, a score of 5.0 is 
entered for that mouse for the rest of the experiment.   
  
4,5 
Complete hind and partial front leg paralysis, no movement around the 
cage. Mouse is not alert.   
  
Mouse has minimal movement in the front legs. The mouse barely responds 
to contact.   
  
Euthanasia is recommended. When the mouse is euthanized because of 
severe paralysis, a score of 5.0 is entered for that mouse for the rest of the 
experiment.   
  
5 
Mouse is spontaneously rolling in the cage (euthanasia is recommended). 
-OR- 
Mouse is found dead due to paralysis 
-OR- 
Mouse is euthanized due to severe paralysis 
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CHAPTER TWO: Development of a new EAE clinical score and a mobile application 
to monitor the model. 
 
Previous clinical scores used to evaluate EAE animals are shown. In Figure 27, the most 
basic scale to monitor EAE animals is shown. In supplementary material of Chapter 
One, Hookes laboratory clinical evolution can be found. This is an improvement of the 
score shown in Figure 27. In Figure 28 the scale proposed by Emerson et al can be 
found 278.  
 
 
Figure 27: The most basic scale used to evaluate clinical evolution of EAE animals.  
 
SUPPLEMENTARY MATERIAL 
	 167 
 
Figure 28: Emerson et al proposed this clinical evaluation system in 2009. Modified 
from 278  
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Extracellular vesicles (EVs) aremembrane-bound particles secreted by almost all cell types.
They are classified depending on their biogenesis and size into exosomes and microvesi-
cles or according to their cell origin. EVs play a role in cell-to-cell communication, including
contact-free cell synapsis, carrying active membrane proteins, lipids, and genetic material
both inside the particle and on their surface.They have been related to several physiological
and pathological conditions. In particular, increasing concentrations of EVs have been found
in many autoimmune diseases including multiple sclerosis (MS). MS is a central nervous
system (CNS) demyelinating disease characterized by relapsing of symptoms followed by
periods of remission. Close interaction between endothelial cells, leukocytes, monocytes,
and cells fromCNS is crucial for the development ofMS.This review summarizes the patho-
logical role of EVs in MS and the relationship of EVs with clinical characteristics, therapy,
and biomarkers of the disease.
Keywords: extracellular vesicle, exosomes, microvesicle, multiple sclerosis, biomarker, therapy
WHAT ARE EXTRACELLULAR VESICLES?
Extracellular vesicles (EVs) are membrane-bound particles com-
ing from inside a cell or formed directly from its membrane,
and excreted to the extracellular medium, that carry information
whose function is cell-to-cell communication without direct con-
tact. They play a role in physiological and pathological conditions,
being released during cell activation, stress, and apoptosis. Specifi-
cally, these vesicles carry proteins, lipids, and geneticmaterials such
as DNA, RNA, and miRNA, producing genotypic (Waldenström
et al., 2012) and phenotypic (van der Vos et al., 2011) modifica-
tions in the recipient cell. This is facilitated by the receptors on the
surface of the EV membrane that allow the target cell to identify
the vesicles and interact with them (Choudhuri et al., 2014).
EVs CLASSIFICATION
BIOGENESIS
Though there are several ways of classifying EVs, themain division
in nomenclature is based on biogenesis. Those formed insidemul-
tivesicular bodies and released extracellularly upon fusion of these
bodies with the plasma membrane are called exosomes (Théry
et al., 2009). Their main characteristic is to have a uniform size
of between 30 and 150 nm, making them the smallest EVs. On
the other hand, those known as microparticles (MP), microvesi-
cles (MV), or ectosomes come from the modification of the cell
membrane after external or internal stimuli, leading to a softening
of themembrane-adjacent structure and allowing evagination and
Abbreviations: BBB, blood–brain barrier; CNS, central nervous system;
CSF, cerebrospinal fluid; EAE, experimental autoimmune encephalitis; EEV,
endothelial-derived EV; EV, extracellular vesicle; LEV, leukocyte-derived EV; MEV,
monocyte/microglia-derived EV; MP, microparticle; MS, multiple sclerosis; MV,
microvesicle; PEV, platelet-derived EV.
vesicle formation followed by fission on the connectingmembrane
stalks until their full detachment. These MV/MPs vary greatly in
size, ranging from 0.3 to 1µm in diameter (Mause and Weber,
2010; Frey and Gaipl, 2011; Lai and Breakefield, 2012). However,
the current trend is to call the entire set EVs, the term used by
the newly formed International Society of Extracellular Vesicles
(Witwer et al., 2013).
In this review,we follow this trend,using the termEVs to refer to
all vesicles; we note, however, that specifically in multiple sclerosis
(MS) related-research most studies refer to them as MPs or MVs.
CELL ORIGIN
Extracellular vesicles have been also classified as a function of
their cell origin depending on the parental cell from which they
arose, so far the most studied being those obtained from cir-
culating cells in peripheral blood. Each cell has characteristic
markers on its membrane enabling subsequent identification of
the EV, e.g., as erythrocyte-, leukocyte-, platelet-, endothelial-,
or monocyte-derived. Further, studies focusing on central ner-
vous system (CNS)-derived EVs have described neural stem cell-,
neuron-, astrocyte-,microglia-, and oligodendrocyte-derived vesi-
cles (Lai and Breakefield, 2012) with the goal of finding markers
that may reflect CNS status, since they can be detected remote
from the site of release after cell activation.
TECHNIQUES FOR STUDYING EVs
The study of EVs is not straightforward, particularly with respect
to isolation and characterization due to their small size and the low
concentrations found in human fluids. Further, although efforts
have beenmade to unify criteria in EV research (Robert et al., 2008;
Dey-Hazra et al., 2010; Lacroix et al., 2012a; Witwer et al., 2013),
they are not yet clearly established, making it difficult to compare
Frontiers in Cellular Neuroscience www.frontiersin.org March 2014 | Volume 8 | Article 100 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sáenz-Cuesta et al. Extracellular vesicles in multiple sclerosis
studies. Differences derived from centrifugation protocols, fluo-
rochrome labeling, and gating strategies represent as yet unsolved
barriers to standardization. Nevertheless, the most widely used
techniques can be summarized as follows.
ISOLATION
The main approach that has been used for isolating EVs from
humanfluids or culturemedia supernatants is a series of sequential
centrifugation steps. Different purities are obtained depending on
the number of steps completed. Briefly, a first centrifugation step
at a low velocity (200–300 g) separates cells from EV-containing
fluid, which can be further purified or directly pelleted. For a fur-
ther purification, a second centrifugation must be carried out (at
2,000–10,000⇥ g, depending on the fluid or EV fraction required).
Otherwise, EVs can be directly pelleted from the first supernatant
(centrifuging at forces of 10,000 up to 100,000⇥ g ). Though
there are many variations among authors, the first approach to
EV analysis is usually based on the aforementioned steps. As
an alternative protocol to obtain a more pure EV fraction, a
sucrose gradient can be combined with one of the centrifugation
steps.
Another isolation technique is polymeric precipitation (e.g.,
Exoquick, System Biosciences, CA, USA). The main advantage of
this approach is rapid sample processing. However, the low purity
obtained and mixing of different EV subsets make results difficult
to interpret.
The extraction of EVs by passing a sample through filters is a
cheap and easy method that can be applied alone or combined
with centrifugation. There is, however, a risk of contamination
with particles other than EVs of the same size.
CHARACTERIZATION
Flow cytometry is the technique most widely employed for study-
ing EVs (including in MS research) to the possibility of using
multiple parameters to identify the same vesicle. It is a power-
ful characterization tool, the process is rapid and the results can
be quantified. Its main limitation is poor discrimination under
0.5µm. However, new high-resolution cytometers can detect
particles as small as 0.2–0.3µm.
Recently, two novel tools appeared on the market created to
characterize nanoparticles in size and concentration with a high
resolution. Theymeasure particles based on tunable resistive pulse
sensing (qNANO, IZON Science, New Zealand) and Brownian
motion of the particle with nanoparticle tracking analysis soft-
ware (NS500 and NS300, Nanosight, UK). The simple and user-
friendly operation and powerful measurements provided by these
instruments herald a new era in the analysis of EVs.
Electronmicroscopy is usually performed in combination with
flow cytometry to provide direct evidence of the presence of EVs,
and it provides what is arguably the highest quality morphologi-
cal information (Figure 1). On the other hand, the expensive and
complex processing of samples limits its use.
Fluorescence microscopy is normally used to analyze EV func-
tion in vitro, aswell as to localize EV in tissues andbuddingprocess.
In particular, confocal microscopy is widely used in EV research.
In addition, enzyme-linked immunosorbent and Western blot
assays have also been employed for analysis of EVs but are less
FIGURE 1 | Electron microscopy image of EVs. An electron microscopy
image of an EV cluster obtained from peripheral blood. Note the rounded
shape and cell membrane-like appearance of EV surfaces.
extensively used due to the poor characterization they provide
and that they are difficult to quantify, respectively.
Notably, next-generation sequencing techniques are currently
expanding to the field of EVs, specifically in the attempt to
characterize their genetic cargo.
EVs IN NEUROSCIENCE
Vesicle secretion and the transfer of material carried within them
in the CNS under physiological conditions were described many
decades ago (de Robertis and Bennett, 1954). The classic example
was the presence of vesicles in the neuronal synapses (de Rober-
tis and Bennett, 1955). However, the mechanisms involved and
modulation thereof by astrocytes, through the release of vesicles
into the synaptic space, have only been properly understood in
recent years (Antonucci et al., 2012). Vesicles have been impli-
cated not only in the propagation of signals, but also in control-
ling neurogenesis with exosomes being involved in the regulation
of myelin membrane biogenesis (Marzesco et al., 2005; Bakhti
et al., 2011) and repairing damaged neurons (Court et al., 2011).
Moreover, a recent study identified a new mechanism of regula-
tion of the axonal integrity mediated by oligodendrocyte-derived
EVs transferred to neurons (Frühbeis et al., 2013). It has been
observed that EVs are released by neural cells, oligodendrocytes,
neurons, microglia, astrocytes in the brain, and Schwann cells in
the peripheral nervous system (reviewed by Lai and Breakefield,
2012; Frühbeis et al., 2012). All this implies that EVs perform func-
tions necessary for growth and normal functioning of the nervous
system.
In addition, EVs are involved in processes of CNS diseases car-
rying specific pathological cargo or performing functions that
produce potential damage (Lai and Breakefield, 2012). Several
studies have found variations in the number and function of cir-
culating EVs in peripheral blood in diseases including Alzheimer’s
disease, dementia, epilepsy, stroke, traumatic brain injury,malaria,
and tumors (mainly glioblastoma), among others (reviewed by
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Lai and Breakefield, 2012; Doeuvre et al., 2009). To explore these
functions, most studies expose primary cell cultures to suspen-
sions of EVs analyzing the effects produced by EV in the cells such
as morphological changes, fusion processes, induction of prolifer-
ation, and apoptosis. Another approach is to analyze EVs derived
directly from human fluids. For this, peripheral blood and CSF are
the most frequently studied samples. On the other hand, few stud-
ies have explored whether variations in EVs in CSF directly reflect
the pathophysiology of the CNS (Morel et al., 2008; Huang et al.,
2009; Street et al., 2012;Verderio et al., 2012;Mobarrez et al., 2013;
Patz et al., 2013; Joshi et al., 2014) and only a couple of them have
examined EVs derived from brain cells obtained from the CSF as a
surrogatemarker for what occurs in the CNS (Verderio et al., 2012;
Joshi et al., 2014). Above all, it has not yet been elucidated whether
EVs are able tomigrate from the blood across the blood–brain bar-
rier (BBB) into the CNS (or not) and vice versa (Smalheiser, 2009).
More studies are required to provide evidence on whether there
is an EV-mediated communication channel between the nervous
and the cardiovascular systems.
MULTIPLE SCLEROSIS (MS) AS A NEUROIMMUNE DISEASE
Multiple sclerosis is a chronic autoimmune disease affecting the
CNS, the cause of which remains elusive. It is, however, established
that the pathogenesis of the disease involves genetic, environmen-
tal, and immune components (Bernard and Kerlero de Rosbo,
1992). There are different clinical forms, but the most prevalent
is relapsing–remitting MS, characterized by outbreaks of symp-
toms lasting 1–3weeks called relapses, followed by a recovery
phase. During relapses, multiple areas of demyelination emerge,
this being the main pathological feature of the disease. Immune
activation involved in the onset of the disease causes a release of
proinflammatory cytokines (TNF, IL1-beta, IFN-gamma) plus a
proliferation of leukocytes,monocytes, and platelets (Martino and
Hartung, 1999). At the same time, endothelial dysfunction of the
BBB affects its permeability, facilitating the activation, adhesion,
and transendothelial migration of monocytes and T-lymphocytes
into the CNS (Minagar et al., 2012). Cytokines and chemokines
released at the site of a lesion recruit glial cells, macrophages,
and lymphocytes perpetuating the immune activation leading to
a chronic inflammatory state (McFarland andMartin, 2007). Cur-
rently, the diagnosis of MS is based on the 2010 revisedMcDonald
criteria (Polman et al., 2011) including careful clinical evaluation
supported by MRI findings and oligoclonal banding in the CSF,
the main complementary tools. The treatment of MS has under-
gone a revolutionwith the advent of IFN-beta as a treatment in the
1980s and more recently with the new immunomodulator drugs,
such as natalizumab and fingolimod.
Several studies summarized in this review suggest EVs are active
players in the pathophysiological development of this disease.
More specifically, higher numbers of EVs have been observed in
MS patients than in healthy controls and a role for EVs has been
proposed in inflammatory progression and lesion repair. Because
of this, they could serve as new biomarkers of disease development
and targets for future treatments.
We will discuss these issues in the following sections. In Table 1
we summarize the origins and makers used for EVs reported.
IMMUNE ROLES OF EVs IN MS
One of the necessary processes for the establishment of MS is the
transendothelial migration of leukocytes into the CNS through
Table 1 | Cellular origins of extracellular vesicles (EVs) in multiple sclerosis research.
EV origin Marker Sample Technique Reference
Endothelial CD31+/CD42  PPP and MVEC FC Minagar et al. (2001)
WB and MVEC FC Jy et al. (2004), Jimenez et al. (2005)
CD51 PPP and MVEC FC Minagar et al. (2001)
CD54 WB and MVEC FC Jy et al. (2004), Jimenez et al. (2005)
CD106 WB and MVEC FC Jy et al. (2004)
CD62E WB and MVEC FC Jy et al. (2004), Jimenez et al. (2005)
CD146 PPP FC Lowery-Nordberg et al. (2011)
Platelet CD61 PFP FC Sáenz-Cuesta et al. (2014)
CD41 PPP FC Sheremata et al. (2008)
Leukocyte CD45 PFP FC Sáenz-Cuesta et al. (2014)
Monocyte CD14 PFP FC Sáenz-Cuesta et al. (2014)
Astrocyte GFAP CSF FM/WestB Verderio et al. (2012)
Neuronal SNAP-25 CSF FM/WestB Verderio et al. (2012)
Oligodendrocyte MBP CSF FM/WestB Verderio et al. (2012)
Microglia/macrophage IB4 CSF FM/FC/EM Verderio et al. (2012)
GENERAL MARKERS
Exosomes CD63 PFP WestB Williams et al. (2013), Gatson et al. (2011)
Microvesicles AnV CSF FC Verderio et al. (2012)
EM, electron microscopy (immunogold); PPP, platelet poor plasma; PFP, platelet free plasma; WB, whole blood; WestB, Western blot; CSF, cerebrospinal fluid; FC,
flow cytometry; FM, fluorescence microscopy; MVEC, microvascular endothelial cell culture.
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the BBB. This migration is favored by a weakening of the bar-
rier. The fact that this mechanism is crucial to the pathogenesis
of MS is demonstrated by the benefits observed with natalizumab,
which blocks the entry of leukocytes into the CNS (del Pilar Mar-
tin et al., 2008). Proinflammatory cytokines such as TNF-alpha,
IFN-gamma, and IL1-beta released by inflammatory cells mediate
the breaching of the BBB by the upregulation of the expression of
adhesion molecules (VCAM-1, E-selectin, and PECAM-1) (Dore-
Duffy et al., 1995), the loss of junctional integrity (Minagar et al.,
2003), and the release of endothelial-derived EVs (EEVs) (Mina-
gar et al., 2001). EEVs from the endothelial cells of BBB and
other EVs shed from surrounding cells [leukocytes (LEV),platelets
(PEV), microglia (MEV), and astrocytes] are vectors of numerous
agents carried inside these vesicles or bound to their plasmamem-
brane. The presence of metalloproteinases in EV cargo suggests
that they may participate in the degradation of the extracellular
matrix involved in BBB disruption (Sbai et al., 2010; Lacroix et al.,
2012b). Moreover, caspase 1 carried by EVs shed by monocytes
and microglia has been shown to regulate proteolytic activity of
metalloproteases on endothelial cells (Bianco et al., 2005; Sarkar
et al., 2009).
Minagar et al. (2001) hypothesized that plasma from MS
patients contains factors that can induce endothelial activation,
as suggested by the release into circulation of CD31+ EEVs from
microvascular endothelial cell culture (MVEC) – a BBB model –
treated with plasma from patients both in exacerbation and remis-
sion. After this pivotal study, Jy et al. (2004) demonstrated that
EEVs found in plasma are able to interact and form complex with
monocytes and induce their activation. These activatedmonocytes
express Mac-1 integrin, which is an ICAM-1 receptor. The union
of Mac-1 of monocytes with ICAM-1 of endothelial cells plays
an important role in the transendothelial migration of inflam-
matory cells. Moreover, activated T cells release EVs containing
the chemokine CCL5 and arachidonic acid responsible for pro-
moting recruitment of monocytes and upregulating ICAM-1 in
endothelial cells and LFA1 and Mac-1 in monocytes (Barry et al.,
1998). To sum up, these data suggest that EEVs shed from the
activated endothelial cells in MS patients promote the migra-
tion of monocytes and lymphocytes through the BBB and assist
with the formation of demyelinating lesions. A validation of this
hypothesis was performed in an elegant experiment carried by
Jimenez et al. (2005): they investigated the transendothelialmigra-
tion of monocytes using the MVEC model, adding plasma from
remitting or relapsing MS patients and controls, and found that
only the plasma from patients in relapse significantly promoted
transendothelial migration. See Figure 2 for a graphical summary
of this paragraph.
Shedding new light on the role of EVs, a few recent studies
have investigated EVs in the animal model of MS called exper-
imental autoimmune encephalitis (EAE). The first published by
Gatson et al. (2011) analyzed EVs (exosomes in this case) in late
pregnant compared to virgin EAE mice. Results showed that EVs
derived from serum of mice in late pregnancy were more numer-
ous than those isolated from virgin mice. The proliferation of
T-cells derived from splenocytes was also explored in the presence
of whole serum, purified EVs, and EV-depleted serum. The three
phases derived from pregnant animals were significantly more
suppressive of T-cell proliferation than EVs from virgin animals
or cells cultured without any EVs. On the basis of these findings,
authors concluded that EVs are responsible for immune modu-
lation during EAE pregnancy. A further study by the same group
analyzed this immune modulation showing a reduction in IFN-
gamma production and expression of Tbet (Th1 transcription
factor) in T cells exposed to pregnancy-derived EVs. In addition,
these researchers demonstrated the effect of pregnancy-derived
EVs on migration to lesion areas in EAE of oligodendrocyte pre-
cursor cells and their maturation (Williams et al., 2013). This
is the first publication that denoted a protective role of EVs in
MS/EAE.
Verderio et al. (2012) identified other EV origins analyzing in
depthCSF fromhumans andmice,both healthy andMS/EAE. Sev-
eral types of brain cell including neurons, astrocytes, and resident
microglial cells give rise to EVs. Peripheral macrophages are virtu-
ally absent in healthy brain parenchyma suggesting that myeloid
EVs obtained in CSF are derived from resident microglia in the
normal brain. This group also revealed that microglia store and
release IL1-beta and MHC-II suggesting that the EVs produced
fromreactivemyeloid cellsmaypropagate neuroinflammation and
provide an efficient route for rapid dissemination andpresentation
of antigens.
Regarding platelet-derived EVs (PEVs) in MS, P-selectin was
observed on PEVs capable of binding to PSGL-1 and PECAM-1
from lymphocytes by increasing the expression of integrins such
as a4b1 (VLA-4), promoting the binding of these cells to the
endothelium (Sheremata et al., 2008). Interestingly, this epitope
is the target of natalizumab, one of the recent therapies approved
for relapsing–remitting MS.
All this evidence supports the idea that EVs are involved in MS
playing a pathological role, acting as immunomodulator agents in
the disruption of the BBB and the propagation of inflammation
of the parenchyma but that, on the other hand, they contribute to
the repair of demyelinating lesions.
ARE EVs RELIABLE BIOMARKERS IN MS?
As stated above, the association between EV concentration and the
pathological condition of MS patients is clearly established. The
next challenge is to develop the application of EVs as useful bio-
markers: as well as providing relevant information, they are easy
to process at a low cost and hence their use could be extended
to large study populations. However, clearly, the adoption of EVs
as biomarkers needs to be based on an objective assessment of
their diagnostic and monitoring potential for the disease in ques-
tion. In the case of MS, EV measurements must be correlated
with the clinical judgment of the neurologist, established scores,
and the results of other complementary tests such as MRI. Sev-
eral studies discussed in the following paragraphs have addressed
these issues but it should be noted that the results are mixed,
sometimes inconsistent, depending on the type of EV (MV, MP,
or exosomes), their cell origin, methods employed, and analysis
performed.
EV CONCENTRATION AND CLINICAL STATUS
A relationship between EV counts in plasma and MS status was
first proposed by Minagar et al. (2001) more than a decade
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FIGURE 2 | Pathogenic roles of EV in MS. EVs are involved in the
transendothelial cell migration of lymphocytes and monocytes and the spread
of neuroinflammation. Metalloproteases carried by EEVs promote BBB
disruption. The release of proinflammatory cytokines from lymphocytes
augments adhesion molecules on endothelial cells facilitating cell adhesion.
In the CNS compartment, microglia play a key role in propagation of
neuroinflammation shedding MEVs containing IL1-b and MHC-II. BBB,
blood–brain barrier; CNS, central nervous system; AA, arachidonic acid; EEV,
endothelial-derived extracellular vesicle; LEV, leukocyte-derived extracellular
vesicle; MEV, microglia-derived extracellular vesicle.
ago. Their results revealed that CD51+ EEV concentrations were
higher in relapse and remission, while those of CD31+ EEVs were
only higher during relapse, compared to healthy controls. They
proposed that the increase in CD51+ EEVs was related to chronic
inflammation owing to endothelial erosion with subendothelial
matrix exposure, and that CD31+ EEVs reflect acute endothelial
damage. This was tested in vitro, and the results were only partially
reproduced. Together the findings pointed to the existence of fac-
tors present in the plasma of MS patients but not in the in vitro
model, such as activated leukocytes present during exacerbations,
which were able to regulate the release of EEVs. Authors also
described a concordance between CD31+ EEV counts and gad+
MRI findings. They claimed that these vesicles were as sensitive as
gad+ MRI for detecting disease activity, and also that a decrease
in vesicle count could precede a negativization of MRI findings.
However, this was criticized for being a premature speculation and
not supported by sufficient evidence (Larkin, 2001).
In the same line of research,3 years later Jy et al. (2004) explored
whetherCD54+ andCD62E+EEVs bound leukocytes in vitro and
inwhole blood fromMSpatients and controls. Theirmain conclu-
sion was that CD54+ EEVs form complexes with monocytes in a
TNF-alpha environment and also activated them. CD62E+ EEV–
monocyte complexes were more numerous during exacerbations
than in remission while the number of CD54+ EEV–monocyte
complexes remained unchanged, suggesting that the former would
be a better marker for monitoring MS. Authors reported that the
measurement of both EEV–monocyte complexes together as a sin-
gle EEV–monocyte complex fraction appeared to bemore sensitive
to MS exacerbation than gad+MRI and even more sensitive than
the CD31+ EEV analysis studied in their previous work. Finally,
free EEVs (unbound to cells) bearing CD62E allowed better dis-
crimination of disease activity (relapsing vs. remitting patients)
than CD54+ EEVs, but not compared to the previously reported
CD31+ EEVs.
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Conversely a year later, Jimenez et al. explored free CD54+ and
CD62E+ EEVs in vitro reporting an increase in bothmarkers dur-
ing relapse and normal values similar to control in remission. Ana-
lyzing EEVs from relapsing patients only, CD54+ and CD62E+
phenotypes were present in significantly higher numbers than
CD31+ EEVs, indicating that they were more sensitive (in vitro)
for identifyingMS status (Jimenez et al., 2005).As stated byWitwer
et al. (2013),EV studies are highly heterogeneous, this being attrib-
utable to the lack of standardizedmethods. Possibly, this underlies
the mixed results described here, particularly with respect to the
earlier work by Jy and colleagues.
Besides EEVs, other EVs have been explored including those
derived from platelets, leukocytes, and monocytes. Platelet acti-
vation in patients with MS may be secondary to endothelial
damage (Sheremata et al., 2008). CD62P (P-selectin) levels have
been shown to be higher in MS patients than controls. Twofold
higher CD41+ PEV counts were found in MS patients compared
to controls, these vesicles showing properties as anticoagulants
(Sheremata et al., 2008).Our group also demonstrated a significant
difference in CD61+ PEV, CD45+ LEV, and CD14+MEV counts
in samples from MS patients compared to those from healthy
controls (Sáenz-Cuesta et al., 2014). Moreover, the PEV count
was found to be higher in untreated MS patients than controls.
Relapsing–remitting patients had the highest counts for the three
subtypes of EVs while secondary progressive patients were found
to have similar numbers to those in healthy controls. We hypoth-
esized that EVs reflect disease status with more being shed during
inflammatory periods and numbers returning to baseline during
chronic progressive degeneration. Another approach to monitor-
ing the progression of the disease is to assess patient’s disability
using the Expanded Disability Status Scale. Our group found no
relationship, however, between EV counts and scores on this scale,
andnorwere the counts related to disease duration or patients’age.
In human CSF, the numbers of EVs have also been seen to be
higher in patients than controls (Verderio et al., 2012). Among
patients, the acute phase was associated with higher numbers of
MEVs than stable or chronic phases. In addition,MEVs counts cor-
related linearly with gad+MRI images. In line with this, the con-
centration of MEVs obtained from CSF of EAE mice reflects the
course and severity of EAE. The absolute numbers of MEVs were
closely associated with the course of the disease, peaking at onset
and during clinical relapses, and decreasing in the chronic phase
of the disease or stable phase. In this work, authors also explored
the potential of MEVs as a possible biomarker in MS plotting
ROC curves. Specifically, based on ROC analysis, they obtained
a sensitivity of 85% and specificity of 100% for distinguishing
clinically isolated syndrome patients from healthy controls, and a
sensitivity of 82% and specificity of 82% for differentiating stable
(relapse-free patients) from relapsing MS patients.
EVs AND MS THERAPY
Current MS therapy is based on the modulation of the immune
system with a wide range of drugs. In some cases, including
IFN-beta, natalizumab, and fingolimod, the effect of the drug
on EVs has been explored. However, there are several new drugs,
already approved (teriflunomide, alemtuzumab, BG-12) or in the
final phases of testing (laquinimod, alemtuzumab, ocrelizumab),
in which the potential modulation of EVs has not yet been
investigated.
IFN-beta has antiviral and immunoregulatory activity medi-
ated by its interaction with specific cell receptors on the surface
of human cells. The precise mechanism of action in MS is still
under investigation. So far, it is known that IFN-beta reduces the
permeability of the BBB inhibiting leukocyte migration to the
CNS (Calabresi et al., 1997) possibly interfering with endothe-
lial adhesion, shifting the cytokine balance from Th1 to Th2, and
increasing the expression of occludin at endothelial tight junctions
(Dhib-Jalbut et al., 1996).
The effect of IFN-beta 1b on EVs was first explored by Jimenez
et al. (2005) who observed an inhibitory effect on EEV pro-
duction in vitro from MVEC culture adding plasma from MS
patients, both in remission and relapse. Moreover, it was shown
that monocyte–EEV complex formation and transendothelial
migration are impaired after IFN-beta 1b exposure.
A first prospective study in a cohort with relapsing–remitting
MS revealed a reduction in the numbers of CD31+EEVs in plasma
from week 12 of treatment with IFN-beta 1a (Sheremata et al.,
2006). Conversely, no correlation was found with MRI, though
there was insufficient data to draw definitive conclusions. Find-
ings in a second cohort treated with high doses of INF-beta 1a
and followed-up for a year suggest that CD54+ EEV number rep-
resents a more sensitive marker of treatment effect than CD31+
or CD146+ EEV numbers, while results showed a correlation of
both CD31+ and CD54+ EEVs with T1-weighted MRI findings
(the relation with CD146+ EEV failing to reach statistical sig-
nificance) (Lowery-Nordberg et al., 2011). Authors speculate that
the decrease they observed in plasma vesicles with IFN-beta ther-
apy reflects a reduced interaction between CD4+ T-cells and the
endothelium and subsequently less migration of the cells through
a restored BBB.
Another immunomodulating drug approved (in 2006) for MS
treatment is natalizumab, a recombinant humanized monoclonal
antibody. A selective adhesion molecule inhibitor, binds to the
alpha-4 subunit of human integrins profusely expressed on the
surface of all leukocytes except neutrophils. In particular, it binds
to alpha-4-beta-1 integrin, blocking the interaction with its ana-
log receptor, the vascular cell adhesion molecule-1 (VCAM-1).
Disruption of these molecular interactions prevents mononuclear
leukocyte migration across the endothelium into the inflamed
parenchymal tissue (Selewski et al., 2010). In a recent study ana-
lyzing plasma PEVs, LEVs, and MEVs, our group found higher
counts of all three EV subtypes in IFN-beta and natalizumab-
treated than untreated patients (Sáenz-Cuesta et al., 2014). No
significant differences were found between the two therapies. A
plausible hypothesis specifically for the rise in LEV number in
natalizumab-treated patients is that blockage of leukocyte entry
into the CNS would result in increase in the number of leukocytes
in the blood compartment and, in turn, of LEVs in particular.
The rise observed in the other two EV subtypes is, however, less
well-understood.
Fingolimod is a new oral immunomodulator drug approved
for the relapsing–remitting form of MS. It binds and induces
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downregulation of the sphingosine 1 phosphate receptors present
in lymphocytes regulating their egress from lymphoid tissues into
the circulation. In that way, the drug reduces autoaggressive lym-
phocyte infiltration into the CNS (Chun andHartung, 2010). Acid
sphingomyelinase (aSMase) is inhibited by fingolimod (Dawson
and Qin, 2011) and this enzyme controls EV production. These
observations led Verderio et al. to theorize that using fingolimod
could inhibit MEV shedding from reactive microglia and also
macrophage infiltration into the CNS. Their experiments in an
EAE model confirmed that MEV numbers decreased to base-
line levels in the CSF with the administration of fingolimod. In
mice, symptom scores and MEV counts were correlated during
fingolimod treatment. Hence, a novel effect of fingolimod was
postulated, namely, that it limits the spreading of the inflamma-
tory signal by impairment of MEV production (Verderio et al.,
2012). Despite these conclusions, there have so far been no
reports evaluating the effect of fingolimod on EVs in humans,
probably because it has only relatively recently become available
commercially.
Apart from being biomarker for treatment response, it has been
proposed that engineered EVs be loaded and used to deliver exoge-
nous compounds for therapeutic purposes, raising the prospect of
a novel clinical application for EVs. Preliminary studies with exo-
somes have been carried out in some types of cancer (Kosaka et al.,
2013); however, more research is required before this approach
can be used in clinical practice as a complementary therapy. Par-
ticularly in MS, a recently published study explored the ability
of exosomes packed with microRNA to increase baseline myeli-
nation, reduce oxidative stress, and improve remyelination (Pusic
et al., 2014). The results showed a significant increase in myeli-
nation in hippocampal slice cultures. Nevertheless, the effects
of this therapeutic approach need to be investigated further,
first in an animal model such as EAE and later in a clinical
trial.
CONCLUDING REMARKS
Extracellular vesicles play important roles in the development
of MS, in particular activating cells during relapses, leading to
migration through the BBB, and spreading inflammation in CNS
tissue. On the other hand, a protective effect of EVs has been
described with the induction of maturation and migration of
oligodendrocyte precursor cells.
Regarding the application of EV research findings to daily clin-
ical practice, it is not yet possible to propose EVs as a specific
biomarker for MS due to no compounds having been sufficiently
closely linked to the disease. Nevertheless, there is evidence that
they reflect disease progression. Particularly, EEVs, PEVs, and
MEVs appear to be the most accurate markers. What is more,
the effects of treatments seem to be reflected in EV counts.
We consider it likely that new carefully designed studies with
longer follow-up periods will allow us to confirm the involve-
ment of EVs suggested by our current knowledge and open future
applications.
Finally, there is an urgent need for consensus guided by the
new scientific societies for EVs to standardize the methodolo-
gies and instruments used, in the analysis of EVs with potential
applications in clinical practice, and thereby make it possible to
obtain comparable results.
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The research in extracellular vesicles (EVs) has been rising during the last decade. However,
there is no clear consensus on the most accurate protocol to isolate and analyze them.
Besides, most of the current protocols are difficult to implement in a hospital setting due to
being very time-consuming or to requirements of specific infrastructure.Thus, our aim is to
compare five different protocols (comprising two different medium-speed differential cen-
trifugation protocols; commercially polymeric precipitation – exoquick – acid precipitation;
and ultracentrifugation) for blood and urine samples to determine the most suitable one
for the isolation of EVs. Nanoparticle tracking analysis, flow cytometry, western blot (WB),
electronic microscopy, and spectrophotometry were used to characterize basic aspects
of EVs such as concentration, size distribution, cell-origin and transmembrane markers,
and RNA concentration. The highest EV concentrations were obtained using the exoquick
protocol, followed by both differential centrifugation protocols, while the ultracentrifuga-
tion and acid-precipitation protocols yielded considerably lower EV concentrations.The five
protocols isolated EVs of similar characteristics regarding markers and RNA concentration;
however, standard protocol recovered only small EVs. EV isolated with exoquick presented
difficult to be analyzed withWB.The RNA concentrations obtained from urine-derived EVs
were similar to those obtained from blood-derived ones, despite the urine EV concentra-
tion being 10–20 times lower.We consider that a medium-speed differential centrifugation
could be suitable to be applied in a hospital setting as it requires the simplest infrastructure
and recovers higher concentration of EV than standard protocol. A workflow from sampling
to characterization of EVs is proposed.
Keywords: extracellular vesicles, protocol standardization, clinical application, nanoparticle tracking analysis,
flow cytometry, translational research, urine
INTRODUCTION
Extracellular vesicles (EVs) are membrane-bound particles shed
from almost all cell types, carrying components from the cell
donor such as lipids, proteins, RNA, glycolipids, and metabolites
(1). It has been suggested that they play several biological roles
like, for example, antigen presentation without cell contact (2),
microenvironment modification, and distant cell education (3),
roles that have been encompassed under the term “cell-to-cell
contact-free communication”. In turn, their biological functions
have been related to many pathophysiological processes, the most
studied being cancer (4), immune-mediated diseases (5), and
cardiovascular disorders (6).
Awidespread concern in the biomedical research community is
the gap between the basic research carried out in the laboratories
and the clinical setting where the new biological information
should have a direct impact. Many researchers have directed their
efforts toward bridging that gap and look for ways to trans-
late lab findings into clinical solutions, emerging therefore the
translational research. The translational research on EVs is not
foreign to this goal: the current knowledge about EVs, mostly
developed in vitro, has been proposed to be applied in a daily hos-
pital routine giving answers to specific health queries (7–13). This
possible application ranges from diagnostic to therapeutic objec-
tives, including disease monitoring and the search of prognostic
biomarkers, among others. But are the hospitals technologically
prepared to employ EVs studies routinely?
The main steps for studying EVs and applying the results
involve sampling (blood, urine, saliva, cerebrospinal fluid, joint
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fluid, breast milk, ascitic fluid, etc.) and isolation, to be afterward
characterized and analyzed their cargo and, finally, give a poten-
tial clinical interpretation and application. Concerning the first
steps, sampling and pre-analytical parameters have been widely
studied and are close to reach a consensus (14, 15). However,
isolation is still a critical step due to several reasons. First, the
methods to isolate EVs are currently highly diverse [reviewed by
Momen-Heravi et al. (16) and Witwer et al. (17)] and depending
on which one is employed, the results can be considerably differ-
ent, even having started from the same sample. At the moment,
most of them are based on EV density, including differential
centrifugation steps from low speeds (1,500⇥ g ) to ultracentrifu-
gation (>100,000⇥ g ), combined or not with density gradient
and/or filtration. Precipitation using polymers and immunoaffin-
ity agglutination are also widely used. Recently, the size-exclusion
chromatography (18) and chip devices (19) have been added to the
rest of methods. All of them, either by themselves or in combina-
tion, yield a solution enriched in EVs in different extents. Finally,
depending on several factors such as time consumption, cost,
friendly use, and reproducibility, these methods are or not able
to be applied in a daily clinical routine. Despite lots of important
works shedding light on this field, there is still a lack of consen-
sus (20) evidencing the urgent need of standardized protocols
appropriate for hospitals.
Considering the problems and needs regarding the use of EVs
in a clinical setting, we established the following objectives for the
present study: to compare several protocols for EVs isolation and
to analyze which of them could be themost suitable one to be used
in daily clinical setting.
MATERIAL AND METHODS
Blood and urine are the most widely used samples in a hospi-
tal setting, as they provide useful information and they are easy
to obtain with minimally invasive techniques. Thus, we decided
to isolate EVs from these biofluids as the starting point for EV
isolation.
Samples were collected from 10 healthy individuals (5 males
and5 females; average age= 37± 8 years old) and stored according
to the criteria of theDonostia node of the BasqueBiobank.All sub-
jects gave written informed consent and the study was approved
by the Hospital Ethics Committee.
Donors underwent a questionnaire about recent exercising
(within the last hour), drugs/medication intake, ovulatory cycle,
acute illness, and sleeping hours.
The workflow followed in the present work is summarized in
Figure 1.
BLOOD
Peripheral blood sampleswere collected at theDonostiaUniversity
Hospital at 8:30 a.m. on fasting and were processed separately
(without pooling them) within the first hour. After discarding the
first milliliter, blood collection was done by venipuncture with a
FIGURE 1 | Comparison of five protocols for EVs isolation. Blood and urine samples were isolated with five different protocols (seeTable 1 for more details)
and then characterized with five outputs methods.
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21-gageneedle in a 10-mlEDTA tube,a 3.8-ml citrate tube,and a 8-
ml serum tube [Vacutainer, Becton Dickinson (BD)], kept upright
and centrifuged at 2,500⇥ g during 15min. The supernatant was
recovered to obtain platelet-poor plasma (PPP) or platelet-poor
serum, being these samples the starting point for all the protocols.
Besides, additional blood samples were collected in EDTA and
serum tubes to perform a hemogram and obtain protein and lipid
profiles in the core laboratory of the Hospital. The parameters
tested are shown in Table 1.
Although we collected plasma and serum from peripheral
blood, the present work is focused on plasma. In this sense, we
are going to refer only to plasma in all the sections of “Materials
and Methods” for the sake of simplicity. The results and discus-
sion of blood-derived EVs will be also centered on plasma and
only relevant results will be presented in the case of serum.
URINE
Sixty milliliter-first void of the day was collected in aseptic condi-
tions by each individual at home, kept at 4°C until their processing
with an average time of 2.7 h between collection and processing.
Ten milliliters were sent to the core laboratory for the analysis
of the most common urine parameters (Table 1). The rest was
aliquoted in five tubes of 10ml and centrifuged at 2,500⇥ g for
15min in order to obtain cell-free urine (CFU).
EV isolation protocols
The protocols described below are summarized in Table 2.
Centri2500. This method is based on the protocol published by
Lacroix and colleagues (14). Briefly, 1.3ml of PPP or 9.5ml of
CFU obtained at the first centrifugation are centrifuged again at
2,500⇥ g during 15min to get 1ml of platelet-free plasma (PFP)
or 9ml of debris-free urine (DFU). Both PFP and DFU sam-
ples were stored at  80°C for later use. When needed, samples
Table 1 | Lab parameters analyzed in blood and urine samples.
Blood Creatinine (mg/dl) 0.9± 0.3
Total cholesterol (mg/dl) 184.9± 37.7
HDL (mg/dl) 69.9± 14.1
Triglycerides (mg/dl) 65.7± 20.1
LDL (mg/dl) 101.9± 37.5
Total proteins (g/dl) 7.2± 0.6
Albumin (g/dl) 4.3± 0.3
Hematocrit (%) 41.7± 3.4
Leukocyte (10e3/µl) 7.0± 2.5
Platelet count (10e3/µl) 238.7± 56.7
Lymphocyte count (10e3/µl) 1.9± 0.5
Urine Density (g/l) 1019.4± 7.7
pH 6.0± 0.9
Glomerular filtrate (mL/min/1.73m2) 84.3± 15.5
Erythrocyte count (ery./µl) Negative
Leukocyte count (leu./µl) Negative
Epithelial cell count (cells/µl) Negative
Values represent the mean±SD from the 10 healthy controls.
were thawed on ice and centrifuged once again at 20,000⇥ g dur-
ing 20min to pellet the EVs, discarding 900µl of supernatant,
following the protocols described by Ashcroft and colleagues (21)
and Jayachandran and colleagues (22). The pellet containing the
EVs was resuspended in 100µl of PBS (GIBCO,Life Technologies)
filtered twice through a 0.22µm-pore filter.
Centri13000. This method is based on the protocol published by
Dey-Hazra and colleagues (23) and Dignat-George and colleagues
(24). In brief, it is a modification of the previous method where
the second centrifugation performed on the 1.3ml of PPP was
done at 13,000 during 2min to obtain PFP or DFU. The rest of the
protocol was the same as the previous one. To note, this protocol
was not performed for urine samples.
Exoquick. The basis for this method lays on the precipitation of
EVs using a commercial agglutinating agent and was performed
following the manufacturer’s instructions. In summary, 63µl or
2ml of exoquick TC (System Biosciences) were added either to
250µl of PPP or to 9.5ml of CFU, respectively, and the mix
was incubated overnight at 4°C with no rotation. Then, two cen-
trifugation steps were performed at 1,500⇥ g for 30 and 5min,
respectively, to sediment the EVs and the pellet was resuspended
in 200µl of PBS. It needs to be noted that, although the first ver-
sions of the manufacturer’s instructions included a filtering step
using a 0.45µm-pore filter, it was removed in the latest version
and, thus, it has not been included in our protocol.
Salting out. This method has been adapted from the proto-
col recently published by Brownlee and colleagues (25) and it is
based on the precipitation of EVs through an aggregate of sodium
acetate 1M, ph 4.75. A centrifugation was performed on 1.3ml
of PPP or 9.5ml of DFU at 13,000⇥ g for 30min; we collected
the supernatant (1ml of PPP or 9ml of DFU), added sodium
acetate (dilution 1/10), and incubated on ice for 60min and, sub-
sequently at 37°C for 5min. The dilution was then centrifuged at
5,000⇥ g during 10min and the resulting pellet was washed with
Table 2 | EV isolation methods compared in this work.
Method Isolation principle Steps
Centri2500 Differential centrifugation 2500⇥ g 150 ⇥ 2+ 20,000⇥ g
200 to pellet the EVs
Centri13000 Differential centrifugation 2500⇥ g 150+ 13,000⇥ g
20+ 20,000⇥ g 200 to pellet
the EVs
Exoquick Agglutination–precipitation 2500⇥ g 150+ agglutination
with exoquick+ 1500⇥ g 300
and 50 to pellet the EVs
Salting out Precipitation 2500⇥ g 150+ 13000⇥ g
300+ acid precipitation+
5000⇥ g 100 to pellet the EVs
Standard Differential centrifugation –
size filtration –
ultracentrifugation
2500⇥ g 150+ 0.22-µm filter+
10,000⇥ g 300+ 1,00,000⇥ g
750 to pellet the EVs
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a buffer with sodium acetate at 0.1M to be finally resuspended in
200µl of PBS.
Standard. This is the method considered as the standard isola-
tion protocol nowadays (26). The starting point was 1.3ml of PPP
or 9.5ml of CFU that were filtered through a 0.22µm-pore filter
and centrifuged at 10,000⇥ g during 30min to obtain either PFP
or DFU. These were ultracentrifuged at 100,000⇥ g in an Optima
MAX tabletop centrifuge (Beckman Coulter) during 75min. The
resulting EV pellet was resuspended in 200µl of filtered PBS.
EV detection and characterization methods
Nanoparticle tracking analysis. The size distribution and con-
centration of EVs were measured using a NanoSight LM10
machine (NanoSight). All the parameters of the analysis were set
at the same values for all samples and 1min-long videos were
recorded in all cases. Background was measured by testing filtered
PBS, which revealed no signal. The EVs obtained from PFP (5µl)
were diluted with filtered PBS to 1:150 and the ones obtained from
DFU (5µl) to 1:50. For each sample, two measurements were per-
formed. It is necessary for a minimum of 200 tracks (movements
of single particles recorded by a camera) to obtain valid results.
The following parameters were measured: the mean and mode of
the size distribution and the concentration of EVs (27).
Flow cytometry. The labeling and gating of EVs were performed
as described by Sáenz-Cuesta and colleagues (28). Briefly, 4µl
of CD61-PE (Cytgonos) or CD45-PE (BD) monoclonal antibod-
ies were mixed with 40µl of resuspended EVs and incubated for
20min. Next, labeled EVs were washed once with 300µl of filtered
PBS, resuspended in further 200µl of filtered PBS and acquired
at low rate in a FACS Canto II flow cytometer (BD). Side and
forward scatter were measured on a logarithmic scale with the
threshold set at 300 for each parameter to avoid instrument noise
(background signal). Then, the lower limit was defined with the
exclusion of background noise given by the signal of PBS filtered
twice. To define the upper limit of the total MP gate, 1-µm non-
labeled polystyrene latex beads were used (Sigma-Aldrich). The
events that appeared in this region were included in the total
EV count and were further analyzed for specific labeling (posi-
tive for PE marker). We defined CD61+ EVs as platelet-derived
EVs (PEV) and CD45+ EVs as leukocyte-derived EVs (LEV). The
total and cellular origin-specific EV concentrations were obtained
using Trucount™ tubes [BD; Ref. (28)].
Western blot. Primary CD133 (Miltenyi Biotec S. L) and CD63
(Santa Cruz Biotechnology, Inc.) antibodies were used to study
specific EV transmembrane markers. Mouse and rabbit HRP-
conjugated antibodies (Cell Signaling) were employed as sec-
ondary antibodies. All protein procedures were done at non-
reducing conditions. Samples (10µl of PBS-resuspended EVs)
were incubated at 95°C for 5min, separated in SDS polyacrilamide
gels, and transferred to nitrocellulose membranes (GE Health-
care). Membranes were blocked for 1 h at room temperature with
5% milk (w/v) in TBS solution with 0.1% Tween-20 (T-TBS) and
incubated in the same solution with primary antibodies overnight
at 4°C. Primary antibodies were washed with the T-TBS solution
and incubation with secondary HRP-conjugated antibodies was
performed at room temperature for 1 h in the same solution used
for the primary antibodies. After washing with T-TBS solution,
the HRP signal was detected by a chemiluminiscent reaction with
the SuperSignalWest Dura ExtendedDuration Substrate (Thermo
Fisher Scientific, Inc.).
RNA isolation. A 185µl-aliquot of resuspended EVs was used
to extract total RNA with the miRNeasy serum/plasma kit (Qia-
gen). RNA concentration was measured with the nanodrop 1000
spectrophotometer (Thermo Scientific).
Cryo-electron microscopy. The cryo-electron microscopy (EM)
was performed following the protocol used byPerez and colleagues
(29). Briefly, 10µl of EV preparations were directly adsorbed
onto glow-discharged holey carbon grids (QUANTIFOIL Micro
Tools GmbH). Grids were blotted at 95% of humidity and rapidly
plunged into liquid ethane with the aid of VITROBOT (Maas-
tricht Instruments B). Vitrified samples were imaged at liquid
nitrogen temperature using a JEM-2200FS/CR transmission cryo-
electron microscope (JEOL) equipped with a field emission gun
and operated at an acceleration voltage of 200 kV.
Statistical analysis
The statistical analysis was performed with PASW Statistics v18.0
(SPSS Inc.). Kolmogorov–Smirnov and Shapiro–Wilk tests were
used to check normality of distributions. As all of the variables
were shown to follow a normal distribution, T -tests were applied
to assess differences between the groups. Pearson’s R correlations
were computed to explore the relations between lab parameters
and some EV parameters. Both differences between groups and
correlations between variables were considered significant when
p< 0.05.
RESULTS
BLOOD
EV concentration
Extracellular vesicles concentration was measured using two inde-
pendent methods: nanoparticle tracking analysis (NTA) and con-
ventional flow cytometry (FC). It is to be noted that the lower
detection limits are different, being 50 nm for NTA (27) and
around 400 nm for FC (30).
Nanoparticle tracking analysis
When using NTA, the software requires a minimum of 200 tracks
during the capture time of the video. In the case of the samples
processed with the salting out and standard methods, only few of
them reached that minimum. This was critical for NTA analysis
causing a high variability on these samples (Figures 2A,E). The
exoquick method yielded higher EV concentration values than
any other method used. We obtained four times higher EV con-
centration with exoquick than with centri2500 (p= 0.007) and
centri13000 (p= 0.05) and 23 times higher concentration values
comparing to salting out (p= 0.002) and standard (p= 0.002)
methods (Figure 2A). No significant differences have been found
either between theEVconcentrations obtainedwith the centri2500
and centri13000 methods, or between those yielded by the stan-
dard and the salting out methods. However, there are significant
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FIGURE 2 | Results of the comparison of five protocols for isolation of
EVs. Box plots show EV concentration measured by nanoparticle tracking
analysis [NTA; (A,E)] or conventional flow cytometry [FC; (B,F)], EV size
distribution measured by NTA (C,G), and concentration of RNA yielded from
EVs (D,H). In the left column, the results from plasma-derived EVs are shown
and in the right column those from urine. For statistical significance, see text.
All bars represent mean values with SD except for size plots (C,G) that bars
indicate mode with SD.
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differences between these two groups of methods (Figure 2A)
obtaining a p value of <0.001 for both centri2500 vs. salting out
and standard and 0.002 and <0.001 for centri13000 vs. salting
out and standard respectively. Regarding the EVs isolated from
serum, they were obtained using the exoquick, centri13000, and
standard protocols and we have observed that, as it happens with
plasma, the exoquick method yields significantly higher EV con-
centrations than the other two methods. When we compared
serum and plasma considering all isolation methods, 3.4 times
higher EV concentrations have been observed for serum using
exoquick and 1.3 times higher ones when using centri13000, but
these comparison did not reach statistical significance (see Table
S1 in Supplementary Material).
Flow cytometry. Although the EV concentrations obtained using
FC were lower than those obtained by NTA, there was good corre-
lation between the concentration profiles yielded by each approach
whenusing the averages for each isolationmethod for the compari-
son (R= 0.99; p< 0.001). Nevertheless, no significant correlations
were observed when performing the analysis for each isolation
method separately. Besides, significant differences were observed
between all isolationmethods except for centri2500 vs. centri13000
and salting out vs. standard (Figure 2B).
EV size
There is great similarity between the modes of EV size obtained
with the different isolation protocols ranging from 150 to 277 nm,
average of mode size: 228 nm (Figure 2C). In accordance to
these results, the EM images show EVs with a size between 100
and 200 nm (Figure 3A). Significant differences in size only exist
between the EVs isolated with the standard method when com-
pared to those obtained through the centri2500 and centri13000
methods, being the former the smallest of all at 158.7 nm. Besides,
the EM images of the EVs obtained with exoquick present sev-
eral filamentous aggregates and other globular structures not
considered EVs.
RNA concentration in EVs
Despite the salting out and the standard methods being the ones
that yield the lowest EV concentrations, the highest RNA concen-
trations have been obtained through these methods (19.5± 5.7
and 23.6± 8.2 ng/µl, respectively), higher thanwith the centri2500
and centri13000 methods (14.5± 3.3 and 12.5± 4.5 ng/µl, respec-
tively). It is remarkable that exoquick yields 18.1± 6.0 ng/µl of
RNA, despite having isolated around 23 times more EVs than the
salting out and standard methods (Figure 2D).
Western blot
The detection of EVmarkers through western blot (WB) was used
as a confirmation of the presence of EVs in the solutions obtained
at the end of the isolation protocols. The objective was not to per-
form a detailed characterization of the markers, but to look for
differences in their detection between the different methods.
Great inter-method variability has beenobserved. Briefly,CD63
detection is better in EVs isolated from plasma than in those
obtained from serum. Among the plasma-derived EVs, CD133
showed better signal for centri2500 and centri13000 than for the
FIGURE 3 | Characterization of EVs. (A)Two images of electronic
microscopy of EVs (pointed with red arrows) derived from plasma and
urine. Scale bar represents 100 nm.To note, in the image of urine-derived
EVs, it is observed contaminants not seen in the plasma-derived one.
(B)Western blot analysis using the specific EV markers CD133 and CD63.
In CD133 plasma samples, the specific bands are pointed with red arrows.
Positive control was performed with NHC-2 p10 cell line.
salting out and the standard protocols. The detection of CD133
was also worse in serum-derived sample than in plasma-derived
samples. Nonetheless, CD133 detection was better in urine-
derived EVs than in the samples obtained from blood (Figure 3B).
It is of note that the EVs isolated with exoquick could not be used
forWBmarker analysis using plasma samples due to be impossible
to dissolve its pellet.
URINE
EV concentration
In the NTA analysis of the EVs isolated from urine, we have
observed that the concentrations were as low as the great majority
of the samples have not reached the minimum track-count. Thus,
once again the interpretation of NTA data from urine-derived EVs
was carried out with caution. Exoquick was the method that yields
the highest EV concentrations from urine using either NTA or FC,
followed by the standard protocol. The centri2500 and salting out
protocols yielded very similar concentrations. Figures 2E,F sum-
marizes the EV concentration results from the application of the
different protocols to urine as measured by NTA and FC, respec-
tively (for p values, please see Table S1 in SupplementaryMaterial).
In summary, using both NTA and FC, we obtained a similar con-
centration profile to that of blood but with 10–20 times lower
concentrations.
EVs size
The modes of the size distributions obtained with the different
protocols were similar and, the average of these modes (207 nm)
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was similar to that achieved in blood samples (228 nm). As it hap-
pened with blood samples, the smaller EVs were isolated with the
standard method (162.5 nm) comparing to the other protocols
(Figure 2G). The results of the size assessed by NTA were, once
again, consistent with the observations done using EM. In most of
these urine samples, the number of contaminating particles that
could not be considered EVswas higher than in blood (Figure 3A).
RNA concentration in EVs
Higher RNA concentrations were obtained from EVs isolated with
the standard (33 ng/µl) and salting out (25.9 ng/µl) methods and
even higher than the concentrations obtained fromblood samples,
where the EV concentration was from 10 to 20 times higher than
in urine (Figure 2H).
Western blot
The EV samples isolated from urine using exoquick, in contrast
to the ones isolated from plasma, can be used for marker analysis
with WB (Figure 3B).
In brief, CD133 detection in urine-derived samples is better
with precipitant agents (exoquick and salting out methods) than
with centrifugation methods, although the standard shows bet-
ter results in urine and serum than in plasma. On the opposite,
CD63 signal is weak in urine-derived samples compared to that of
plasma- or serum-derived samples for all methods.
CORRELATION WITH LABORATORY PARAMETERS
We have also tested whether the EV concentration values obtained
with differentmethods and the different types of samples (plasma,
serum, or urine) could be reflected in some of the lab parameters
measured in blood and urine, especially the ones that are related
to the main components of EVs, i.e., lipids and proteins. Fur-
thermore, the analysis of these correlations would serve to test a
possible interference in EV quantification produced by these para-
meters, a phenomenon that has been previously described (31).
Interestingly, a significant correlation has been observed
between the concentration, as measured by NTA, of the EVs
isolated from plasma with the centri13000 method and the
total cholesterol (R= 0.953; p= 0.003) and LDL concentrations
(R= 0.935; p= 0.006) in blood. We have also detected a signifi-
cant correlation between the NTA-measured concentration of the
plasma-derived EVs isolated using the standard method and the
concentration of triglycerides in blood (R= 0.789; p= 0.007).
No significant correlation has been found between the concen-
trations of theEVsof specific cell-origins and the concentrations of
the respective source cells in blood. The concentrations of CD61+
(platelet origin) or CD45+ (leukocyte origin) EVs are plotted in
Figure S1 in Supplementary Material.
In regard to the EVs isolated from urine, the only significant
correlation we have observed is the one between the density of
urine and concentration of EVs, measured with both NTA and
FC, isolated with the salting out protocol (R= 0.841; p= 0.002 for
NTA and R= 1.000; p=> 0.001 for FC).
DISCUSSION
In the present work, we have studied and compared several widely
used methods for the isolation of EVs, including differential cen-
trifugation, agglutination, precipitation, and the one considered
the standard that includes ultracentrifugation (plus filter). All
methods under study can be applied using relatively simple tech-
nology, with the exception of ultracentrifugation, which must be
performed with an instrumentation that, even if it is easy to use,
is not usually found in most hospital laboratories. The election
of one or other method as the most suitable one to be used in a
hospital setting greatly depends on the goals to be reached with
the method, which could be, among others: to maximize the final
EV concentration, to obtain high levels of purity as measured by
markers and several classical characteristics of EVs, to select one of
the three fundamental types of EVs (exosomes, microvesicles, and
apoptotic bodies) or to get the less time and/or money consuming
protocol. We have set the first two as preferential aims, leaving the
rest out of the scope of this work.
ISOLATING EVs
Wehaveobserved that,besides being themethod that canbe imple-
mentedmost easily (it is quick and relies on very little technology),
exoquick is also the method that yields, in a statistically significant
manner, the highest concentration of EVs (as measured by NTA
and FC) compared to the other four isolation protocols. The EV
quantity is even higher when using serum as the starting sam-
ple. On top of that, to dissolve the pellet obtained using exoquick
from serum-derived samples is notably easier than plasma-derived
samples. Nonetheless, the considerably higher EV concentrations
obtained with exoquick (23 times higher than those obtained with
the standard protocol) could be linked to the aggregation and pre-
cipitation of other elements in suspension in the sample that are
not necessarily EVs; as it can be observed in the images obtained by
EM. Taylor and colleagues (32) demonstrated that using exoquick
more EVs are isolated than using ultracentrifugation (standard),
chromatography, and magnetic beads, and with a higher purity of
exosomal RNA and proteins. Our results only partially coincide
with the observations of Taylor and colleagues, as the RNA con-
centration we obtained with exoquick is lower than that yielded
by the standard method. In another study that compared the exo-
quick method with the standard method, the authors concluded
that a combination of these twomethods is the protocol that yields
the highest EV counts, although exosomes of higher quality were
obtained combining the standard methodwith the sucrose density
gradient (33). Yet, Exoquick is the most expensive of the methods
used in the present work.
The differences in EV concentration between the two centrifu-
gation methods (centri2500 and centri13000) are not statistically
significant. The sole differences are that the cluster of EVs observed
by FC in the FSC/SSC dotplot shows less debris around in the case
of centri13000 and that the EVs isolated with this method also
show a stronger labeling of CD63 inWB. The conclusions reached
at the workshop of the Scientific and Standardization Commit-
tee of the International Society of Thrombosis and Hemostasis to
promote the use of these protocols (15) and aimed to reducing
the variability due to a resuspension of the pellet (24). Nonethe-
less, in our opinion, the main drawback of this proposal is that, as
the EVs are not concentrated in a pellet–like, we performed with
the final centrifugation at 20,000⇥ g, a pellet-washing step cannot
be introduced and EVs are maintained in dissolution along with
many other contaminating particles such as protein aggregates.
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Regarding size, very similar EV sizes have been obtained with
these two methods, even when measuring size on EM imagery.
These suggest that the second centrifugation is probably not that
critical and could vary, at least between 2,500 and 13,000⇥ g, with
the objective of eliminating cell debris. Moreover, these meth-
ods collect six times higher EV concentrations than the standard
protocols, what can be explained by the fact that they are less
restrictive methods. Finally, the technical requirements for the use
of these methods are usually met in most basic research labo-
ratories and they are considerably less time-consuming than the
standard method.
Ultracentrifugation is nowadays the “gold standard” method
for the isolation of EVs, fundamentally exosomes. With the aim
of finding alternative methods to this protocol, Brownlee and col-
leagues (25) have recently described a new method called salting
out, based on the precipitation of EVs using the aggregate of
acetic acid. In the present study, the salting out method yielded
the lowest EV concentrations when compared to the other proto-
cols, although showing similar values to those obtained with the
standard method as the authors of the aforementioned article also
pointed. It has to be noted, though, that Brownlee and colleagues
isolated EVs from cell culture supernatants and, thus, comparisons
with the present work must be done with caution.
Although out of the main objectives of this work, we have also
compared the EVs isolated from three different types of samples:
plasma, serum, and urine. We have observed that higher concen-
trations of EVs are obtained from serum than from plasma for all
methods, and 10–20 times more, depending on the method, when
comparing plasma with urine. As comparisons between serum
and plasma have been performed by other authors (34, 35), we
just present our results.
The EV size distributions that we have obtained with the exo-
quick, salting out, centri2500, and centri13000 methods are very
similar, being the EVswith a size below200 nm themost abundant.
Nevertheless, a cluster of EVs can be observed with a size around
500–600 nm that could represent the population of microparti-
cles. On the contrary, the standard method isolates smaller EVs as
it uses a 0.22µm-pore filter leaving out the bigger EVs (micropar-
ticles and apoptotic bodies). We agree with Jy and colleagues (36)
that the capacity of the first four methods to isolate the bigger EVs
can be useful when applying these protocols in clinical practice.
In the case of urine, very low EV concentrations have been
obtained with the five methods and, thus, we recommend not to
dilute or to dilute very little urine-derived samples before ana-
lyzing them by NTA, FC, and WB. Once again, exoquick was
the method that yields the highest concentrations according to
other authors’ results (37). Certainly, when using urine samples,
it would be of great consequence to avoid contaminating proteins
such as Tamm–Horsfall, which traps EVs but it can be removed
with the simple addition of dithiothreitol and heat (38). Further-
more, Rood et al. (18) suggest that the most effective method in
terms of purity for urine-derived EVs to undergo downstream
proteomic analysis is the combination of ultracentrifugation fol-
lowed by size-exclusion chromatography. The major disadvantage
of this protocol would be that it is time-consuming and it requires
of specific infrastructure that make it difficult to be compatible
with clinical applications.
DETECTING AND CHARACTERIZING EVs
During the processing, after the centrifugation at 20,000⇥ g for
20min, a fine lipidic layer could be observed in some of the sam-
ples. This corresponded to a FC image with a higher EV density
(data not shown). Nevertheless, the presence of this layer did not
show correlationwithNTA results. It is well known that the density
and size of the EVs can overlap with these of lipoproteins and this
canproduce artifactual results in FCanalyses (31). Besides,wehave
found positive correlation between the LDL levels in blood and the
concentration of EVs obtained with several methods, which sug-
gests that, when isolating the EVs, some LDL particles are also
dragged and counted as EVs. One approach to measure the purity
of EVs is the EV/protein ratio (39), amethod that is easy to use and
yield reproducible results. However, it remains out of the scope of
the present work.
Themost widely usedmethods for the quantification of EVs are
NTA and FC. According to our data, the results yielded by these
two methods are not interchangeable, probably because the size
ranges that they can analyze are different. The correlation between
the two methods would be better studied using only the concen-
tration of EVs larger than 400 nm, as this is the minimum size
for the FC analysis. Nevertheless, we have looked for correlation
using concentration results for EVs larger than 400 nm in another
dataset (data not shown) and we have found none. Thus, we con-
sider that these two quantification methods do not exclude each
other but are complementary, as NTA gives more accurate counts
but FC allows the characterization of distinct cellular origins.
From the comparison of the methods that we have used to
study the size of EVs, we can conclude that, while the NTA, as it
allows to recover information from individual particles, allows to
obtain and compare size distributions, EM provides more robust
information on the characteristics of EVs but size distributions
cannot be obtained through EM imagery. Furthermore, NTA has
the advantage of performing a multiple analysis in few minutes.
Tetraspanins have been widely used as general markers of EVs;
however, during the last years, someworks have provided evidence
that not all vesicles express them at the same levels suggesting that
different EV subsets could coexist in the same pellet (40, 41). In the
case of urine-derived EVs, our results present low or undetectable
levels of CD63 except for those obtained with the standard pro-
tocol (Figure 3B). Both the previously described lack of CD63 in
urine-derived EVs larger than 100 nm (42) and its expression in
EVs obtained with the standard protocol (43, 44) are congruent
with our results. In the other hand,we found expression of CD133
with all the methods. In agreement with other authors, we con-
cluded that the presence of CD133+/CD63  EVs demonstrate the
recovery of the large ones that usually express this pattern of mark-
ers (45–47). Moreover, Bobrie and colleagues described the CD63
as a variable marker found only in a fraction of the sucrose gradi-
ent (40), which implies questioning the use of CD63 as a standard
EV marker (48). Finally, the expression of CD63 is susceptible to
SCORT regulation leading to the blockage of the budding of this
EV subset (49) and this mechanism could hypothetically be more
frequent in urine-derived EVs. Regarding to plasma-derived EVs,
the detection of the opposite pattern (CD133 /CD63+) in the
EVs obtained with standard protocol unravel the isolation of a
specific EV fraction, being probably only exosomes (46).
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FIGURE 4 | A proposed workflow for the study of extracellular vesicles (EVs) in a hospital setting.
(Continued )
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FIGURE 4 | Continued
Patients visited during the morning in the hospital, preferentially on fasting,
undergo sample collection of 30ml of blood (EDTA or citrate) and 50ml of the
first void urine. Immediately, 15ml of blood and 40ml of urine are destined to
the EV isolation protocol to obtain a pellet and the rest 15 and 10ml are sent
to the core laboratory to analyze biochemical parameters. The obtained EV
pellet resuspended in PBS could optionally be frozen at  80°C and continue
when required. Next, the detection/characterization of EV is divided in two
levels for quantification, size [nanoparticle tracking analysis (NTA)], and initial
characterization with flow cytometry (FC) followed by an extensive
description with western blot (WB) and electronic microscopy (EM).
Subsequently, the analysis of EV cargo with several omics platforms allows
the identification of specific compounds carried by EVs. EVs detection and
their cargo analysis could optionally be referenced, at least during the initial
setting of this workflow, to an expert EV laboratory in order to provide a
validation of the results and pass a quality control test. Finally, the detected
molecules are interpreted in the whole context of the patient with the aim of
identifying biomarkers or a target for a putative therapy. The results provided
by the study of EV are applied back to the patient improving the diagnosis or
course of the disease.
Regarding the RNA concentrations yielded by the different EV
isolation methods, we have observed great variability. Although
Taylor and colleagues conclude that exoquick isolates more than,
among othermethods, ultracentrifugation (32),we have observed,
unexpectedly, that the RNA concentrations obtained with the dif-
ferent methods are very similar, despite the notable differences in
EV concentrations. Surprisingly, high RNA concentrations were
obtained from urine (especially when using the salting out and
standard methods), concentrations similar to or even higher than
those obtained from plasma and serum, regardless of EV concen-
trations being between 10 and 20 times lower. These results lead
us to think that, as we have not used RNAses, we are measuring
the concentration not only of the RNA contained in the EVs but
of the free RNA. In a position paper of the International Society of
Extracellular Vesicles, the authors suggest that the use of RNAses
only removes the free RNA not specifically bound to EVs, while
their use in combination with proteases also removes the nucle-
oproteic complexes (50). In any case, if the final objective is to
use the RNA as a source of potential biomarker, we believe that it
would be useful to preserve not only the RNA inside the EVs but
the RNA stuck to their membrane.
EVs FROM BENCH TO BEDSIDE
The importance of the study of EVs in a hospital setting to com-
plement the diagnosis and prognosis of several diseases has been
well demonstrated (51–53). Moreover, their application in ther-
apeutic approaches has already been tested in clinical trials with
promising results (54). Nonetheless, we believe that the workflows
from the collection of the samples aimed at the isolation, process-
ing, and characterization of EVs to yield significant results to be
applied on patients need to be urgently standardized. Specifically,
the different isolationmethod can yield different types of EVs and,
thus, omics studies performed on them could give incomparable
results. Besides, not allmethods are applicable in a hospital setting.
With aim of contributing to this debate and in accordance to
the results of the present work, we consider that the centri13000
method is the most suitable one to be used in a hospital setting
as (a) it requires a simple infrastructure (and does not require
ultracentrifuge) that is available in any general laboratory, (b) iso-
lates EVs with similar characteristics to the ones isolated with the
standard method but in higher concentrations, (c) it recovers not
only small EVs as standard does but also the largest, and (d) in
analysis with FC and WB showed less contamination when com-
paring with centri2500. We concur with Deun and colleagues (55)
in that it is necessary for a validation of the isolation procedure
andwe propose that this validation could be carried out in referent
laboratories lead by group with great expertise in the study of EVs.
The results obtained in the hospital setting should be compared
to those obtained by the reference lab to assure a quality control.
On the other, for the posterior detection and characterization of
EVs, we recommend to analyze them with at least one quantifica-
tion method (NTA or FC) and one characterization method (WB,
EM, or FC) as they provide complementary information. Figure 4
summarizes a proposed workflow based on the discussion above.
To conclude, the isolation of EVs, at least for plasma-derived
ones, through differential centrifugation at medium speed (cen-
tri13000) and their posterior analysis with at least one quantifi-
cation method (NTA, for example) and another characterization
method (FC orWB, for example) could fit in a workflow that goes
from the patient to lab and all the way back to the patient and
would contribute to face several health problems.
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Abstract One of the most widely studied demyelinating
diseases is multiple sclerosis, which is characterised by the
appearance of demyelinating plaques, followed by myelin
regeneration. Nevertheless, with disease progression,
remyelination tends to fail, increasing the characteristic
neurodegeneration of the disease. It is essential to under-
stand the mechanisms that operate in the processes of
myelination, demyelination and remyelination to develop
treatments that promote the production of new myelin,
thereby protecting the central nervous system. A huge
variety of models have been developed to help improve our
understanding of these processes. Nevertheless, no single
model allows us to study all the processes involved in
remyelination and usually more than one is needed to
provide a full picture of related mechanisms. In this review,
we summarise the most commonly used models for
studying myelination, demyelination and remyelination
and we analyse them critically to outline the most suit-
able ways of using them.
Keywords Cell culture ! Multiple sclerosis ! Experimental
models ! Demyelination ! Remyelination !
Neurodegeneration
Introduction
Myelin is a lipoprotein structure produced by two types
of cells: oligodendrocytes (OLs) in the central nervous
system (CNS) and Schwann cells in the peripheral ner-
vous system. These cells are capable of generating
myelin sheaths that coat axons; this, on the one hand,
enables proper transmission of the nerve impulses, and
on the other, provides an appropriate environment for
the survival of axons, supplying the necessary nutrients
and maintaining axonal homoeostasis (Bando et al.
2008). Myelin sheaths are crucial for the development
and maintenance of our brain, and therefore, improving
our understanding of the processes involved in their
generation and repair are a clear goal in the neuro-
science field.
In certain diseases, myelin is damaged, impairing the
transmission of nerve impulses and compromising axon
survival, producing clear clinical symptoms. Myelin-re-
lated disorders can be divided into two large groups, dys-
myelinating and demyelinating diseases. The first group are
related to an inappropriate production of myelin, while in
the second, myelin is appropriately produced, but is dam-
aged by the disease, in a process called demyelination. The
most common disease in the second group is multiple
sclerosis (MS).
When a demyelinating lesion occurs, myelin repair
mechanisms are activated and the lesion is repaired with
the production of new myelin. Oligodendrocyte progenitor
cells (OPCs) are responsible for initiating this process. To
do this, OPCs migrate towards lesions, proliferate and
differentiate into OLs, which extend their membrane to
recoat the axons (Ffrench-Constant and Raff 1986; Gensert
and Goldman 1997; Rodriguez 2003; Watanabe et al.
2002).
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This process of remyelination enables, on the one hand,
the restoration of the saltatory conduction of nerve
impulses, and on the other, guarantees the maintenance of
the necessary conditions for axon survival. After repeated
cycles of demyelination/remyelination, however, the
remyelination efficiency decreases and fails to restore axon
function. Although the reasons for remyelination failure are
not well understood, patient age, a hostile environment in
lesions (e.g. cellular debris and inflammation), and pro-
gression of the disease itself may cause errors in the
migration, proliferation and differentiation of OPCs
(Franklin 2002), that result in a poor or ineffective
remyelination. As a consequence, axons remain unpro-
tected and they subsequently degenerate, promoting neu-
rodegeneration, as occurs in advanced stages of MS (Ben-
Hur 2011).
Increasing our knowledge of these processes is key to
improving our understanding of the disease mechanisms
and to developing therapies that increase remyelination
capacity. Two main strategies are currently used to
enhance remyelination: (1) the implantation of cells cap-
able of generating myelin (exogenous therapy), aiming to
repopulate the OPC-depleted tissue in the CNS, and (2) the
stimulation of endogenous cells, to improve their differ-
entiation and/or remyelination capacities (Miller and Fyffe-
Maricich 2010; Zhang et al. 2011).
In order to deepen our understanding of myelin forma-
tion, we need to use experimental models of the demyeli-
nation and remyelination processes. Such models would be
very useful to test the effect of potential therapies seeking
to promote remyelination and also prevent axonal degen-
eration, which is the final goal in the field of demyelinating
diseases. We should bear in mind that no model, no matter
how sophisticated, can mimic all physiopathological pro-
cesses that occur in humans. Nevertheless, there are models
that simulate several aspects of myelin-related diseases and
enable us to study myelination, demyelination and
remyelination.
The aim of this review is to present, in order of com-
plexity, the most commonly used models developed for
studying the different pieces of the myelin puzzle, and
describe their main characteristics and uses.
In Vitro Models
OPC Culture
During myelin production, OPCs differentiate to OLs,
which are the cells responsible for creating myelin sheaths.
The isolation and culture of OPCs can be a helpful tool for
understanding the mechanisms involved in the develop-
ment of myelin and for studying the effect of new therapies
on these types of cells in relation to migration, differenti-
ation, survival and proliferation (Chen et al. 2007; Dinc-
man et al. 2012).
Many types of tissue have been used as a source of
OPCs, including cryopreserved umbilical cord (Kurtzberg
2011), foetal brain (Monaco et al. 2012), brain biopsies and
embryonic stem cells (Bru¨stle et al. 1999). These sources
make it possible to work with human OPCs, but they have
the drawback that samples are difficult to obtain and their
use raises ethical concerns. Due to these factors, induced
pluripotent stem cells (iPSCs) have emerged as an alter-
native source for obtaining human OPCs (Ogawa et al.
2011). The generation of iPSCs not only allows us to work
with human-derived OPCs but also with large numbers of
cells. Moreover, iPSCs have a potential therapeutic role
since they can be obtained from patients themselves,
allowing allogeneic transplantation. For research purposes,
another option is to obtain OPCs from the optic nerve (Shi
et al. 1998) or brain cortex of young and adult rodents
(Wernig et al. 2008).
A variety of methods have been proposed for isolating
OPCs: using an oligodendrocyte selection kit (Pesheva
2006), magnetic-activated cell sorting (Dincman et al.
2012), manual sorting (Medina-Rodrı´guez et al. 2013),
immunopanning (Dugas and Emery 2013), fluorescence-
activated cell sorting (Chen et al. 2007) and generating an
immortalised cell line (Merrill 2009). All these methods
can achieve good cell quality and high OPC-content cul-
tures. Therefore, the method should be selected based on
the equipment and resources of each lab. Once the OPCs
have been isolated, differentiation, proliferation, survival
or migration assays can be performed.
For instance, to characterise the ability of a drug to
promote cell migration, we can measure the number of
cells that cross the membrane after culture in transwells. In
order to characterise each stage of OL differentiation after
the administration of a treatment, various types of markers
can be used for specific proteins, including platelet derived
growth factor (PDGFR) a, neuron–glial antigen 2 (NG2)
and A2B5 for OPCs, 20,30-cyclic nucleotide 30 phosphodi-
esterase (CNP), O1 and O4 for pre-OLs; myelin basic
protein (MBP), proteolipid protein (PLP), myelin oligo-
dendrocyte glycoprotein (MOG) and myelin-associated
glycoprotein (MAG) for OLs; and oligodendrocyte lineage
transcription factor 2 for all OL-lineage cells. For survival
or proliferation, specific markers of cell death (caspase-3)
or cell proliferation (5-bromodeoxyuridine) can be used
respectively. Then, results can be analysed by fluorescence
microscopy. Alternatively, flow cytometry can be used,
facilitating multiparametric analysis, though it does not
enable visualisation of cell morphology. Gene expression
analysis can also be used to characterise the culture (Dugas
et al. 2006; Robinson et al. 2014).
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This in vitro model based on OPC culture is simple, low
cost and high throughput. It represents a first step towards
ascertaining whether treatments or the manipulation of a
molecular pathway have positive effects on the cells
responsible for myelination and remyelination, as in the
work of Syed et al. (2013) who demonstrated that the
inhibition of phosphodiesterase 4 promotes OPC differen-
tiation. Moreover, since the cells are not influenced by
other types of cell or the environment, exposure of these
cells to a drug simplifies the interpretation and under-
standing of results (Merrill 2009). With this approach, we
can lay the foundations for further work with more com-
plex models.
‘‘Axon-Based Models’’: Co-cultures
These models of myelination involve obtaining axons,
either natural or artificial, on which to test the myelinating
ability of cells under study, as a potential therapy in
demyelinating diseases. It is possible to administer a drug
as a treatment together with the cells, and then study its
influence on myelin production by these cells. Below, we
describe two methods for obtaining axons: from explants
and by producing synthetic axons.
‘‘Natural’’ Axons
This model is based on culturing CNS explants (mainly
from rat or mouse embryos) in order to allow axons to
extend outwards. These axons serve as a substrate for
myelination by exogenous cells. Given differences between
types of explants, the best source depends on the type of
experiments to be conducted. One possibility is to obtain
dorsal root ganglion explants (Pa¨iva¨la¨inen et al. 2008).
Nevertheless, this type of explants has limitations: firstly,
dorsal root ganglia are not CNS neurons and, secondly,
their axons extend only a short distance (Chen et al. 2010;
Watkins et al. 2008). To improve our understanding the
CNS myelination, spinal cord explants is one of the most
widely used sources. A protocol improved by Thompson
et al. (2006) made it possible to obtain spinal cord in which
cell somas remained in the explant and axons extended
rapidly from the explant, this facilitating the observation
and measurement of myelination. Depending on the
method used to culture the spinal cord explant, axons can
also be obtained from motoneurons (Hedvika et al. 2012;
Hyung et al. 2015) or sensory neurons (Callizot et al.
2011). Another approach is the use of whole brain spheroid
aggregates. These are 3D explants that maintain the com-
plexity of in vivo biology and represent a halfway house
between in vitro and ex vivo models. They have multi-
layered myelin and can be used for de- and remyelination
studies (Vereyken et al. 2009).
Once the explants have been cultured, myelinating cells
are added. Using these models, it is possible to assess the
capacity of myelinating cells to form myelin around axons,
as well as the effect of drugs on these cells in the presence
of neuron–glia interaction. It is also possible to add to our
understanding of the mechanisms involved in the myeli-
nation process, as illustrated by the work of Chan et al.
(2004) that demonstrated the involvement of nerve growth
factor in the control of myelination. The effect of a cell
therapy can be analysed by measuring the quantity of
myelin produced by cells with immunofluorescence
microscopy of the axon (neurofilaments) or the myelin
(myelin basic protein, myelin oligodendrocyte glycoprotein
for more mature myelin and CASPR that can suggest more
compact myelin). To facilitate the monitoring of myelina-
tion, it is possible to add green fluorescent protein-labelled
OPCs (Chen et al. 2010). In parallel, electron microscopy
can be performed to determine the myelin g-ratio, which is
the ratio between the inner and the outer diameter of the
myelin sheath, and is used as an indicator of optimal
myelination (Chan et al. 2004; Chomiak and Hu 2009).
This is a myelination model that allows us to study
interactions between neurons and myelinating cells during
the myelination process. We need to bear in mind, how-
ever, that in these explants, besides neurons, there are other
types of cells that can also influence the myelination pro-
cess, producing uncontrolled effects (Pang et al. 2012). For
this reason, some authors classify these as ex vivo models.
Synthetic Axons
In order to avoid the uncontrolled interactions between
myelinating cells and other cells types present in the
explants, variants of the previous model have been devel-
oped that consists in the use of inert or synthetic axons (Lee
et al. 2012). In order to obtain inert axons, after purification
from a biopsy, the axons must be fixed with
paraformaldehyde (Rosenberg et al. 2008). Alternatively,
synthetic axons can be obtained by producing artificial
nanofibres. For this purpose, a wide range of materials have
been tested, from glass microfibres coated with a glial cell
matrix (Bullock and Rome 1990), passing through vicryl
microfibres, coated with extracellular matrices containing
molecules to promote cell attachment (Howe 2006), to
polystyrene (Lee et al. 2013; Seonok Lee et al. 2012) or
polycaprolactone (Diao et al. 2015) nanofibres designed
using electrospinning. A modification of this synthetic
axon model uses micropillar arrays, formed in a 96-well
plate, which consist of 50-lm-diameter conical structures
that cells are able to myelinate (Mei et al. 2014).
Artificial fibres can be coated with selected substances
(from proteins to microRNAs) (Diao et al. 2015), in order
to study in depth their effect on myelination (Lee et al.
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2013). This facilitates the subsequent design of remyeli-
nating therapies based on these substances.
Ex Vivo Models
Organotypic Cultures
These types of cultures involve the growing of tissue in
three dimensions, mimicking the structure and cell types of
living organs, making them an intermediate step between
cell cultures and animal models. These cultures enable the
development of models for certain neurological diseases
such as ischaemia, Parkinson’s disease and Huntington’s
disease, as well as MS (Daviaud et al. 2013).
Several CNS structures including the brain, cerebellum
and spinal cord can serve as the source for organotypic
cultures (Kipp et al. 2012), each with their own charac-
teristics. The cerebellum provides homogeneity in the type
of axons present, mostly Purkinje cell axons, while the
brain and the spinal cord have more axonal variety in terms
of type and diameter. On the other hand, the spinal cord
may be a good choice for OPC migration studies (Zhang
et al. 2011).
Briefly, with the help of a vibratome or tissue chopper
(McIlwain), approximately 300-lm slices of tissue are
obtained and then cultured on membranes (designed for
this type of culture) for subsequent demyelination. The first
report of induced demyelination dates from 1959, in which
Bornstein and Appel (1959) described successful
demyelination of a cerebellar organotypic culture by add-
ing serum from animals with experimental autoimmune
encephalomyelitis (EAE), an animal model of MS.
Nowadays lysophosphatidylcholine, a detergent that
mainly destroys myelin, is used as a demyelinating agent
(Birgbauer et al. 2004). After removing the detergent, the
OPCs in the culture proliferate in response to the
demyelination and differentiate to OLs that are capable of
regenerating the myelin, enabling remyelination studies
(Zhang et al. 2011).
This type of model allows us to assess the regenerative
capacity of endogenous cells and speed of regeneration
achieved under the influence of different drugs. It is also
possible to analyse remyelination by cell therapy. For this,
cytosine arabinose should be added to the culture to sup-
press the proliferation of endogenous cells (Nishimura
et al. 1985), in order to suppress the remyelinating potential
of the OPCs present in the tissue.
Several techniques can be used to measure remyelina-
tion. Confocal microscopy is useful to semi-quantitatively
assess the area occupied by myelin-coated axons (com-
pared to the total area of axons) (Pang et al. 2012). For this,
at the end of the culture period, the tissue is fixed and
immunofluorescence staining is performed to label axons
and myelin. The major inconvenience of this method is that
it is highly dependent on the analysis of images.
Attempting to address this problem, Zhang and collabora-
tors described an automatic quantification method using
Image-Pro Plus software (Zhang et al. 2011). In addition,
culture growth can be followed with time-lapse imaging
(Schna¨delbach et al. 2001; Zhang et al. 2011). As an
indicator of remyelination quality, we can measure the
distance between nodes of Ranvier, the so-called internodal
length: the shorter this distance, the poorer quality the
remyelination. Finally, g-ratios can also be calculated as a
measure of remyelination quality. Both of these indicators
can be calculated with data from electron microscopy
images.
To achieve a favourable culture growth, young animals
should be used. Nevertheless, it should be also taken into
account that demyelinating diseases do not tend to occur in
early stages of development, and this may have an impact
on the conclusions obtained. Finally, we have to take into
account that though the structure of the original tissue is
maintained, these models do not replace in vivo models,
rather they are useful for screening treatments in advance
of in vivo testing, thereby reducing the number of animals
used subsequently (Daviaud et al. 2013). In line with this,
Meffre et al. (2015) demonstrated the importance of these
kinds of models in drug discovery, having used them for
the development of therapies targeting liver X receptor
alpha.
In Vivo Models
Zebrafish
The zebrafish is a vertebrate animal that has been widely
used in developmental studies given that it has a short life-
cycle and is transparent, making it possible to visualise
internal structures noninvasively. Moreover, it has been
described that myelination in this fish species is similar to
that in mammals (Buckley et al. 2008). In fact, it has
homologous genes involved in the myelination process
(Dubois-Dalcq et al. 2008). For these reasons, embryos of
this species have been used in myelination studies (Kim
et al. 2011) and its larvae have been used in drug screening.
Further, transgenic zebrafish have been developed in
which OLs (Kirby et al. 2006), or both OLs and Schwann
cells (Jung et al. 2010), express membrane-targeted green
fluorescent protein, making these cells visible. Such mod-
els are useful for studying myelination in vivo (Jung et al.
2010), but do not allow analysis of remyelination due to the
lack of physiological demyelination. To perform remyeli-
nation studies in this type of model, demyelination has to
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be achieved, for example, by damaging myelin with laser
microsurgery (Kirby et al. 2006), or by producing trans-
genic individuals, such as the system reported in 2013 by
Park’s research group, in which OLs die after exposure to
metronidazole (Chung et al. 2013). In these models, the
remyelination process starts after the microsurgery or
stopping the drug treatment, respectively.
Both myelination and remyelination processes can be
monitored in vivo by time-lapse confocal microscopy
without the need to kill the animal, provided that OLs
express a fluorescent protein (Kirby et al. 2006). In addi-
tion, post-mortem immunofluorescence can be performed
to identify the proteins of interest.
This model provides a rapid method for assessing can-
didate agents for the treatment of demyelinating diseases,
given that it is possible to monitor OLs in vivo (Buckley
et al. 2010; Dubois-Dalcq et al. 2008). This was illustrated
by Franklin’s research group in 2010, with the develop-
ment of a screening platform based on this type of model
for identifying the most promising compounds to be tested
later in mammalian models (Buckley et al. 2010). These
models are not suitable, however, for testing cell therapy,
given the technical difficulties involved.
Mammalian Animal Models
A great variety of models allow us to study remyelination
in mammals. The main advantage of using mammal
models is that some biomolecular pathways are shared with
human forms of disease. In this review, we will focus only
on murine models, which are the most widely used for
studying myelin-related processes. Such models have been
developed for studying pathological processes associated
with demyelinating diseases and remyelination, and can be
classified into three types: models of toxicity, models of
viral infection and models based on immune response.
Given that there are several high-quality reviews of
mammalian models (Baker and Amor 2015; Kipp et al.
2012; Star 2012), we will only list them and briefly outline
some of their characteristics.
The ways of obtaining data are similar for all the murine
models listed, with some exceptions that will be specified
later and can be summarised as follows:
• During the development of the model, magnetic
resonance imaging and two-photon imaging can be
used for monitoring animals (Rassul et al. 2016).
• After killing animals, histopathological studies can be
performed to detect myelin or different types of CNS
cells in tissue with, for example, Luxol Fast Blue or
immunohistochemical and immunofluorescence analy-
ses. The remyelination quality can be assessed, by
determining the g-ratio of axons by electron
microscopy. Another possibility is to extract CNS
tissue, make an emulsion from this tissue and assess the
cell content in the emulsion by flow cytometry or gene
expression analysis (Robinson et al. 2014).
Models of Toxicity
Toxin-Induced Local Lesions These are models of localised
acute cytotoxicity, in which OLs are depleted (Magalon
et al. 2007) following an injection, by stereotaxy, of
ethidium bromide (EB) or lysophosphatidylcholine (LPC),
among other agents. EB is an intercalating dye that induces
the loss of OLs and astrocytes, but does not affect axons
(Kuypers et al. 2013). LPC alters membrane composition,
specifically of OLs, due to fusogenic properties of their
membrane; this triggers damage to the myelin (Allt et al.
1988; Vereyken et al. 2009). As a consequence of the
demyelinating lesion, microglia and macrophages move
towards the lesions generated, there is reactive astrogliosis,
axonal homoeostasis is disturbed, and OPCs proliferate and
migrate to the damaged tissue (Keough et al. 2015). There
is no consensus on whether or not this model shows con-
comitant demyelination and excessive inflammation
(Kuypers et al. 2013; Miron et al. 2011). Further, lesions
can be directed to different regions of the CNS and
peripheral nervous system, including the dentate gyrus
(Babri et al. 2015), sciatic nerve (Bondan et al. 2009),
spinal cord (Keough et al. 2015) and centrum semiovale
(Dousset et al. 1995). Such models have been used widely
in primates, as well as in rodents.
These toxin-induced models are highly reproducible
(Miron et al. 2011) and useful for studying the effect of
different drugs on remyelination alone, in the absence of
inflammation; this method was applied by Goudarzvand
and collaborators, for studying the involvement of vitamins
E and D3 in the enhancement of remyelination (Goudarz-
vand et al. 2010). It needs to be taken into account, how-
ever, that there is necrotic damage around the injection site
(Dousset et al. 1995; Miron et al. 2011).
Models of General Toxicity These models are based on the
production of demyelinating lesions by neurotoxic, chem-
ical, or biological agents administered through the diet. The
most widely used toxin is cuprizone, a copper-chelating
agent that induces OLs apoptosis, and as a consequence,
demyelination. Though the mechanism involved remains
unclear, it has been proposed that cuprizone produces
errors in the mitochondrial respiratory chain (Kipp et al.
2009). In contrast to EAE, that will be explained further
below, T cells do not play any role in the generation of this
model, and not all the regions of the brain are affected in
the same way (Torkildsen et al. 2008). By using different
lengths of cuprizone treatment, it is possible to produce an
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acute or a chronic model (6 or 12 weeks of treatment,
respectively). In both models, after stopping the cuprizone
treatment, there is spontaneous remyelination of the lesion,
this being slower and more limited in the chronic model
(Acs and Kalman 2012; Kipp et al. 2009). A variation of
these models has been developed, using cuprizone in
combination with rapamycin, achieving a complete
demyelination and slower remyelination than with cupri-
zone alone (Sachs et al. 2014).
This type of model is simple and reproducible, but we
must bear in mind the age, sex and the species of animals
used, since this can have an impact on the results (Kipp
et al. 2009). For instance, remyelination has been found to
be slower and more limited in old animals (Torkildsen
et al. 2008). These models make it possible to study
demyelination and remyelination processes that occur in
the CNS and the effect of drug and cell therapies (Acs and
Kalman 2012). Note that, to study cell therapies, it is
necessary to administer cells after withdrawing cuprizone
from the diet in order to avoid damaging the injected cells.
Further, we should emphasise that precursor cells are not
affected by cuprizone and hence they will compete with the
administered cells to repair the lesions (Kipp et al. 2009).
This model has helped to demonstrate the protective role of
rolipram in cuprizone-induced demyelinated animals (Sun
et al. 2012).
Models Based on Viral Infection
These models are based on the hypothesis that some viral
infections may cause demyelinating diseases such as MS.
The most commonly used viruses are the Semliki Forest
virus (Smithburn et al. 1946) and Theiler’s murine
encephalomyelitis virus (Theiler 1934). Semliki Forest
virus was first isolated in mosquitoes and rarely affects
humans. The virus can infect OLs and, due to its highly
virulent nature, the M9 mutant also usually causes the
death of the host. For this reason, the avirulent A7 strain is
more frequently used, showing its effect through the
immune response against infected cells and not through
virus replication with subsequent cell death. Theiler’s
murine encephalomyelitis virus leads to neuropathological
processes (such as paralysis and encephalomyelitis) in a
wide range of animal species. The most commonly used
strains include the virulent GDVII and the less virulent
Daniels and BeAn strains.
Models of viral infection allow us to explore the
potential effect of immunomodulatory and remyelination
therapies on CNS cells infected by a neurotropic virus
(Baker and Amor 2015). This feature is interesting since it
has been suggested that MS may be caused by a virus
(Oskari Virtanen and Jacobson 2012). On the other hand,
these models are not appropriate for testing cell therapies,
as the virus would have a tropism for injected cells, being
affected in the same way as endogenous cells. To date, they
have not been extensively used and this is attributable to a
range of factors: the long incubation periods between
infection and the onset of symptoms, the high mortality
rates among infected animals, in particular when we use
virulent strains, and the technical difficulties associated
with the manipulation of viruses. Nevertheless, their
application has contributed, for example, to the discovery
that a 40-nucleotide single-stranded DNA aptamer has the
ability to promote remyelination of CNS in mice after
Theiler’s virus infection (Nastasijevic et al. 2012).
Models Based on Immune Response: Experimental
Autoimmune Encephalomyelitis
The first reference to this experimental model dates from
1933, when Berry’s research group, after several consec-
utive intramuscular injections of brain emulsion, succeeded
in causing inflammation and demyelinating lesions in the
CNS of monkeys (Rivers et al. 1933). At that time, the
mechanism involved had not been identified, but now it is
known that this condition is mediated by specific T cells
against myelin antigens, and that it has clinical and
histopathological similarities to MS (Zamvil et al. 1986). In
fact, this is the experimental model that exhibits most
similarities to the human disease and the most commonly
used for studying remyelinating drugs in this disease.
The features it shares with MS include the destruction of
myelin, the development of lesions over time and across
the CNS, though mainly perivascular in scattered foci, and
the presence of immunoglobulins in both the cerebrospinal
fluid and the CNS. On the other hand, the processes of
demyelination and remyelination in this type of model are
less extensive and more acute than in humans (Miller and
Fyffe-Maricich 2010).
There are two subtypes of this model. The first is the
active one, in which animals are immunised against a
myelin peptide, together with Freund’s adjuvant and per-
tussis toxin. Depending on the peptide, animal host and
viral strain, numerous different models have been devel-
oped, and these are widely reviewed in the literature (Baker
and Amor 2015; Kipp et al. 2012; Star 2012). The second
subtype, the passive or the adoptive cell transfer model, is
produced by injecting specific active lymphocytes against
myelin, which are obtained from the lymph nodes of ani-
mals that have undergone active immunisation.
This is considered the gold standard model for the study
of MS. It is used for preclinical proof of concept for new
pathways and mechanisms of action in the pathogenesis of
autoimmune diseases. Many of the findings with this model
have been applied to treatments in patients. In fact, Susumu
Tonegawa and Peter Doherty were awarded a Nobel Prize
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for their work related to this model (Hohlfeld 2009;
Steinman 2003). Nevertheless, we must be cautious since
therapies proven to be effective in the animal model may
not produce the same positive effects in humans (Con-
stantinescu et al. 2011). Moreover, this type of model fails
to predict adverse effects of treatments, especially in cases
when treatments need to be long term, such as those for MS
(Daviaud et al. 2013; Steinman and Zamvil 2005). More-
over, it is an expensive animal model, in terms of time and
money, given the numbers of animals that are needed (due
to variability) and its low throughput (Zhang et al. 2011).
Its limitations are mainly related to a lack of understanding
of all the mechanisms involved in the pathogenesis of the
model, and the short time frame of the model for studying
chronic conditions. Finally, this is the most complex model
of all those mentioned in this review and its complexity
sometimes makes the interpretation of findings difficult
(Moreno et al. 2012).
As this review is focused on models for studying
myelination–remyelination, we want to emphasise the most
suitable type of model for this kind of research. Remyeli-
nation failure is characteristic of the chronic forms of MS.
For this reason, models of chronic EAE are particularly
suitable for studying remyelination due to the great simi-
larities with the secondary progressive MS (Constantinescu
et al. 2011). These are produced by myelin oligodendrocyte
glycoprotein (MOG35–55) peptide in Dark Agouti rats and
C57BL/6 mice (Lorentzen et al. 1995; Mendel et al. 1995).
The main information obtained from this type of model
is the animals’ clinical score. This information is subject to
observer bias; therefore, it is essential to carry out double-
blind experiments as well as robust statistical analyses
(Fleming et al. 2005). Furthermore, the findings obtained
with this model should be complemented with experiments
carried out using some of the other aforementioned models.
Other Models
In 2015, Gocke’s research group published a study that
combined an EAE model with a toxicity model, with the
goal of obtaining a model that overcomes the problems of
using these models on their own. In this new model,
demyelination occurs in the absence of neurodegeneration
which, according to the authors, makes it possible to assess
remyelinating therapies that have previously been difficult
to study given the neurodegeneration in EAE (Baxi et al.
2015).
Lastly, there are models that are based on the use of
genetically modified animals, in which T cells express
specific receptors of myelinating cells, in order to produce
demyelinating lesions. However, these models are not yet
commercially available, are rarely used, and require long
periods of development until the animals manifest clinical
signs.
Selecting the Appropriate Model In this review, we have
outlined models for studying the processes of myelination,
demyelination and/or remyelination. There is a wide range
of models and we believe that it is important to underline
certain characteristics of the models considered, to help us
to select the best models for our goals.
• Myelination, demyelination and remyelination
Although the final goal is to promote the production
of new myelin after the damage caused by some type of
disorders, not all the models assessed allow us to
analyse this directly. For example, the analysis of OPC
differentiation after a treatment can give us important
information about the process of differentiation in
particular, such as, whether a drug works in the
expected way, but does not help us determine whether
the compound improves axon survival. We should
remember that all the models provide complementary
information needed to improve our understanding of
the mechanisms related to remyelination processes and
to build a picture of the whole process.
• What question do we want to answer? As has been
emphasised, not all models can provide answers to all
questions. For this reason, it is important to clearly
define what types of data we require and seek to obtain
them with the most suitable model. For example, if we
want to analyse the molecules involved in the wrapping
of axons after a certain treatment, an animal model
would be too complex for this goal, and an axon co-
culture would be more suitable. Table 1 summarises the
main characteristics of all the models reviewed.
• Better to use more than one model It is advisable to use
more than one model, since different models can
provide complementary information that increases the
quality of the results. Each model has strengths and
weaknesses, and provides different types of data, which
well used, can be put together in order to obtain more
robust conclusions to guide the development of new
therapies.
• The most complex is not always the best The greater the
complexity of the model, the closer to the human
disease. Nevertheless, understanding the mechanisms
underlying remyelination with simpler models may
help us identify and improve our understanding of
certain processes that could lead to the development of
remyelinating therapies.
• From simple to complex models The simplest models
allow us to test more molecules/therapies, since it is
easier to obtain larger sample sizes with fewer ethical
constraints. Moreover, such models are easier to
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manage and less expensive. The compounds that have
yielded positive results can then be analysed in more
complex models, which better mimic the mechanisms
occurring in humans. In this way, as we move to more
complex models, we reduce the number of candidate
agents that are eventually going to be tested in clinical
trials (Fig. 1).
• We cure mice; what about humans? Treatments studied
in experimental models with positive results do not
always show the same effects in human patients, being
found to be ineffective or to produce serious side
effects. It is necessary to remember that we are working
with in vitro, ex vivo and in vivo experimental models
and extreme care must be taken in extrapolating the
Table 1 Summary of the main characteristics of the model types reviewed
In vitro models Ex vivo
model
In vivo models
OPCs Spinal cord
explants
(OPCs)
Synthetic
axons
Organotypic
cultures
Zebrafish Local
toxicity
General
toxicity
Viral
infection
EAE
EAE: experimental autoimmune
encephalomyelitis
??? ?? ?? ? ? ??? ? ? ? ?
Short periods of model
development
??? ??? ??? ??? ?? ?? ? ? ?
Presence of inflammation 0 0 0 0 ? ? ? ??? ???
Testing of drugs ??? ?? ?? ??? ??? ??? ??? ??? ???
Testing of cell therapies 0 ?? ??? ?? ? ?? ? ? ???
Ethical constraints ?? ?? ?? ?? ??? ??? ??? ??? ???
Demyelination studies 0 0 0 ?? ?? ? ? ? ???
Remyelination studies 0 0 0 ??? ?? ?? ??? ??? ???
Myelination studies ??? ??? ??? ? ??? 0 0 0 0
Level of complexity ? ?? ?? ?? ??? ??? ??? ??? ???
Closeness to humans
(inflammation, lesion type,
structure of processes)
0 0 0 0 ? ?? ?? ??? ???
‘‘???’’ indicates the highest value for that characteristic and ‘‘?’’ the lowest. ‘‘0’’ means that this characteristic is not present
EAE: experimental autoimmune encephalomyelitis
Fig. 1 Schematic representation of the complexity and number of
candidate treatments that can be tested in each model. From left to
right in vitro models, represented by an image of OPC culture stained
with DAPI (blue) and MBP (red); ex vivo models, represented by an
image of cerebellar organotypic culture stained with NFL (green) and
MBP (red); increasingly complex in vivo models, represented by
images of a Zebrafish and a mouse; and at the end of the process,
humans (Color figure online)
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results to humans, since no model is able to exactly
reproduce processes that take place in human diseases.
Concluding Remarks
In this review, we have outlined some of the most com-
monly used in vitro, ex vivo and in vivo models for the
study of myelination, demyelination and remyelination.
Once the aim of a research study has been defined, it is
essential to select the best model for building a picture of
the processes that we seek to study.
Clearly, simple models are the easiest experimentally,
less expensive and less time-consuming. Nevertheless, it is
impossible to draw far-reaching conclusions from a simple
model, such as OPC culture, in which demyelination and
remyelination cannot be studied. To address this, a model
in which more elements are involved, such as the EAE
animal model, should be used. On the other hand, its
complexity makes it difficult to obtain definitive conclu-
sions due to the limited understanding of the pathways
involved.
In the future, it would be helpful to have models that
were relatively simple to handle, but at the same time, able
to reflect the complexity of the process, including several
types of cells, inflammation, 3D structures, etc. Unfortu-
nately, such models have not yet been developed, but the
organotypic slice culture is a candidate, given that it is an
ex vivo model, that maintains the 3D structure of the tissue
from which it was derived, grows under controlled condi-
tions, and can be used to test many drug and cell therapies.
Nevertheless, we should not finish this review without
underlining that the use of more than one complementary
model is recommendable, in order to extract specific con-
clusions from each one and provide the most realistic
picture of the processes of myelination, demyelination and
remyelination.
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Multiple Sclerosis is a demyelinating disease of the central nervous system for which
no remyelination therapy is available and alternative strategies are being tested.
Extracellular vesicles (EVs) have emerged as players in physiological and pathological
processes and are being proposed as therapeutic targets and mediators. More
concretely, EVs have shown to be involved in myelination related processes such as
axon-oligodendrocyte communication or oligodendrocyte precursor cell migration. In
addition, EVs have been shown to carry genetic material and small compounds, and to
be able to cross the Blood Brain Barrier. This scenario led scientists to test the ability of
EVs as myelin regeneration promoters in demyelinating diseases. In this review we will
address the use of EVs as remyelination promoters and the challenges and opportunities
of this therapy will be discussed.
Keywords: remyelination, exosomes, myelin, multiple sclerosis, microRNAs, EAE, oligodendrocyte
INTRODUCTION
Myelin is a membranous sheath produced by oligodendrocytes (Ols) in the Q5
Q6
Q7
central nervous system
(CNS) that surrounds axons allowing the saltatory nerve impulse transmission. Moreover, myelin
protects axons and contributes to the maintenance of its homeostasis. Myelin can be damaged in a
physiological context, due to the normal aging process, but it can also be caused by pathological
mechanisms. The latter scenario occurs in a wide variety of pathological situations, such as
traumatic demyelination, leukodystrophies or multiple sclerosis (MS), being the last one the most
common demyelinating disease. Although no specific auto-antigen has been identified yet, MS
is considered a chronic autoimmune CNS disease that includes the breakdown of the Blood-
Brain Barrier, inflammation, demyelination, oligodendrocyte loss, gliosis and axonal degeneration
(Baecher-Allan et al., 2018). It is accepted that the activation of peripheral autoreactive e ector
CD4+ T cells that migrate into the CNS attacking the myelin sheath is the main cause of MS
appearance. Once in the CNS a second reactivation occurs in which other cells types such as B and
CD8+ T cells of the adaptive immune response, together with natural killers and microglia cells of
the innate immune system contribute to the disease causing oligodendrocyte destruction, myelin
loss, and an imbalance of the homeostasis of axons (reviewed in Baecher-Allan et al., 2018). This
imbalance causes axon damage and an ine cient nerve impulse transmission. In the first stages
of the disease, myelin can be restored, recovering normal electrical signal transmission. This is
a complex process named remyelination in which a dynamic combination of di erent signaling
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pathways and molecules such as growth factors, cytokines and
chemokines areQ8 tightly regulated (Kuhlmann et al., 2008). To
achieve remyelination, oligodendrocyte precursor cells (OPCs)
need to (1) proliferate, (2) migrate into the lesions, and (3)
di erentiate to myelinating Ols that will generate new myelin
(Miron et al., 2011). Nevertheless, with the progression of the
disease this process tends to fail. It is not completely understood
why remyelination capacity decreases with time, but a lack of
OPCs, a poor migration of these cells or their impossibility
to di erentiate to Ols have been proposed (Franklin, 2002). In
addition, it is increasingly recognized that age is not only a
risk factor for neurodegeneration but also adversely influences
regenerative processes and remyelination (Hampton et al., 2012).
Moreover, some factors such as genetic background and diet
are also involved in the reduction of the remyelination capacity
(revised in Adamo, 2014).
To avoid neurodegeneration and promote neuroprotection,
as well as the restoration of the fast saltatory conduction,
the generation of new myelin is of extreme importance. The
promotion of remyelination might protect axons avoiding
their degeneration and probably improving patients’ prognosis.
Therefore, pharmaceutical companies and researchers that work
in the field are trying their best to develop new remyelination
therapies.
To this end, the replacement of the endogenous OPC
population and the stimulation of endogenous OPCs to
regenerate myelin are being analyzed, being di erentiation a key
point in this process (Hartley et al., 2014). Finally, targeting
the immune system has been also pointed out as a therapeutic
strategy to induce remyelination (Dombrowski et al., 2017; El
Behi et al., 2017).
An ideal therapy should be able to cross the BBB and reach
the CNS, target OPCs and not other cell types and should
have minimal side e ects. Owing to their natural capacity to
a ect cell proliferation and di erentiation, and their potential
to cross BBB, extracellular vesicles (EVs) have emerged as
highly promising candidates for the treatment of demyelinating
diseases, as discussed in detail in the following sections.
WHY EXTRACELLULAR VESICLES?
Intercellular communication is a key factor for the functioning
and regulation of all biological processes. Apart from the two
classical mechanisms – direct cell-to-cell communication and
transfer of secreted soluble molecules –, in the last years
extracellular vesicles (EVs) have been found to play a central role
in intercellular communication.
Extracellular vesicles are membrane-bound particles secreted
by cells. There are di erent types of EVs and the most common
classification is based on their size and biogenesis (Raposo
and Stoorvogel, 2013). EVs formed inside multivesicular bodies
and released upon fusion of these bodies with the plasma
membrane are called exosomes. Their main characteristic is to
have a uniform size of between 30 and 150 nm, thus being the
smallest EVs. On the other hand, those known as microvesicles,
come from the evagination and direct budding from the plasma
membrane. Microvesicles vary greatly in size, ranging generally
from 0.3 to 1 µm in diameter; however, it must be noted that
in many scenarios it can be di cult to separate exosomes from
microvesicles purely based on their size (Willms et al., 2018).
Another type of membrane vesicles are apoptotic bodies, which
are 1–5 µm in size and were described many years ago and
have di erent features to those derived from living cells (György
et al., 2011). Currently, the generic term EV is used to refer to
the complete set of secreted vesicles (Gould and Raposo, 2013).
EVs play an essential role in indirect intercellular communication
as their membrane, cytosolic proteins, lipids, metabolites and
genetic material can be transferred between cells (Théry et al.,
2001; Valadi et al., 2007). They can follow two di erent ways of
integration: by direct fusion with the plasma membrane or by
endocytosis (Morelli et al., 2004; Montecalvo et al., 2012).
Most cell types release EVs being secreted both in physiologic
and pathogenic conditions. They can be isolated frommany body
fluids, including plasma and cerebrospinal fluid (CSF). EVs are
involved in many biological processes, their capacity to regulate
immune response and cell di erentiation being the two most
important processes in the context of this review (Robbins and
Morelli, 2014). Moreover, EVs take part in the transmission of
information across the CNS (Frühbeis et al., 2013b) and have
been found to play a role in the regulation of synaptic activity
(Fauré et al., 2006) and myelin sheath biogenesis (Marzesco et al.,
2005; Bakhti et al., 2011), as well as in the repair of damaged
neurons (Court et al., 2011).
The pathogenesis of several diseases has been shown to be
linked to EVs, including cancer (Robbins and Morelli, 2014),
neurodegenerative diseases (Basso and Bonetto, 2016; Thompson
et al., 2016) and, of particular interest to this work, MS (Verderio
et al., 2012; Sáenz-Cuesta et al., 2014a,b; Selmaj et al., 2017). The
implication of EVs and their ability to carry messages from one
cell to another suggests that the use of EVs as a drug delivery
system or as a treatment, might be an interesting way of targeting
and modulating the course of the disease. Moreover, the fact that
EVs are able to cross the BBB makes them strong candidates for
CNS disease therapy (Jan et al., 2017).
THERAPEUTIC POTENTIAL OF EVS FOR
DEMYELINATING DISEASES
Several works have been published demonstrating the therapeutic
potential of EVs. These works will be discussed in the following
paragraphs and have been summarized in Table 1.
In some demyelinating pathologies, such as MS, the immune
system is responsible for the damage caused to myelin. In fact,
all the available treatments for MS are immunomodulatory or
immunoregulatory drugs that prevent autoimmune attacks on
the myelin sheath. In this way, the ability of exosomes isolated
from pregnant mice serum or human periodontal ligament
stem cells-derived exosomes to reduce the clinical score of
the Experimental Autoimmune Encephalomyelitis (EAE), an
animal model of MS, has been addressed by inhibiting the
immune response, and more concretely by dampening Th1
response (Williams et al., 2013; Rajan et al., 2016). In addition,
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TABLE 1 | Summary of therapeutic potential of EVs for demyelinating diseases.
Reference EVs type EVs Source Isolation method Principal
experiment
Route of
administration
Result
Williams et al.,
2013
Exosomes Virgin and pregnant
mice serum
Ultracentrifugation EAE Intravenous Stablished EAE
supression.
Rajan et al., 2016 Exosomes HPLSC culture
supernatant
ExoQuick TC EAE Intravenous Inmmunomodulation of
EAE.
Zhuang et al., 2011 Exosomes Glioblastoma culture
supernatant
Sequential
centrifugation steps
EAE Intranasal EAE inhibition.
Frühbeis et al.,
2013a
Exosomes Oli-Neu cultures
supernatant
Sequential
centrifugation steps
Oligodendrocyte-
neuron
co-culture
N/A Exosomes mediated
communication.
Krämer-Albers
et al., 2007
Exosomes Primary
oligodendrocytes
culture supernatant
Ultracentrifugation Oligodendrocyte
culture
N/A Exosomes contain PLP,
MBP, MOG and CNP.
Bakhti et al., 2011 Exosomes Primary
oligodendrocytes
culture supernatant
Sequential
centrifugation steps
Oligodendrocyte
culture
N/A Oligodendrocytes
derived exosomes
inhibit OPC
differentiation.
Kurachi et al., 2016 Extracellular
vesicles
MVECs culture
supernatant
ExoQuick TC Oligodendrocyte
Precursor cell
culture
N/A OPCs survival,
proliferation and
motility.
Otero-Ortega et al.,
2017
Exosomes MSC culture
supernatant
miRCURY
Exosomes Isolation
Kit
Subcortical
ischemic stroke
Intravenous Promotion of
olifodendrocyte
formation and
remyelination.
Pusic and Kraig,
2014
Exosomes Youth and
Environmental Enriched
rat serum
ExoQuick TC Old rats Intranasal Enhanced myelin
content.
Pusic et al., 2016 Exosomes Environmental Enriched
rat serum
ExoQuick TC Demyeliantion
hipocampal slice
culture
N/A Myelination increased
and oxidative stress
reduced.
Doeppner et al.,
2015
Extracellular
vesicles
MSC culture
supernatant
PEG precipitation
method
Ischemic stroke Intravenous Neuroprotection and
neuroregeneration.
Drommelschmidt
et al., 2017
Extracellular
vesicles
MSC culture
supernatant
PEG precipitation
method
Perinatal brain
induced
inflammation
Intraperitoneal Immunomodulation and
reduction of micro- and
astrogliosis.
the intranasal administration of curcumin-loaded glioblastoma-
derived exosomes to EAE animals ameliorated the clinical
symptoms of the model. Although the mechanism of action is
not clear, the induction of immune tolerance and the apoptosis
of activated immune cells are postulated to be behind this
process. This data demonstrate that exosomes could work as
anti-inflammatory drug delivery vehicles (Zhuang et al., 2011).
As was mentioned in the introduction, Ols are responsible
for generating myelin that enwraps axons. The communication
between Ols and axons is essential for the survival and functional
maintenance of both. Interestingly, this communication between
Ols and axons has been shown to be mediated by exosomes and,
in addition, the interactions between Ols and axons might a ect
the cargo of exosomes (Frühbeis et al., 2013a). Moreover, when
the cargo of exosomes released by Ols was analyzed, researchers
found that those vesicles contained high levels of myelin related
proteins; more concretely PLP, MBP, MOG, and CNP (Krämer-
Albers et al., 2007). This data was the first evidence of the possible
role that exosomes could be playing in myelination. In a more
recent work, it was suggested that Ol-derived exosomes were
able to inhibit the di erentiation of OPCs (Bakhti et al., 2011).
Even though the authors did not demonstrate the mechanism
by which Ols regulate OPCs in an inhibitory way, these results
reinforce the implication of exosomes in OPC di erentiation, an
essential step for myelination and remyelination. In a di erent
work, the ability of pregnant mice serum-derived exosomes to
promote the tra cking of OPCs into lesions from EAEmice after
intravenous administration was shown (Williams et al., 2013)
emphasizing the implication of exosomes in myelination related
processes.
To analyze the role that EVs play in pathological systems,
several models have been used. In a model of white matter
infarction in rats, researchers demonstrated that EVs derived
from microvascular endothelial cells (MVECs) were taken up by
OPCs, inhibiting the apoptosis of OPCs and promoting survival,
proliferation and motility of the cells. The authors demonstrate
that those EVs contained microRNAs and adhesion molecules
which were responsible for the shown e ects (Kurachi et al.,
2016). Moreover, Mesenchymal Stem Cell-derived exosomes
(MSC-Exs) have been shown to promote oligodendrocyte
formation and remyelination in a model of subcortical ischemic
stroke. After intravenous administration of MSC-Exs, authors
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were able to detect higher levels of MOG protein and more
myelinated axons. Interestingly, the 2416 proteins detected in the
exosomes and described to be involved in brain repair functions
were suggested by the authors as mediators of the e ect (Otero-
Ortega et al., 2017).
Furthermore, a work published in 2014 demonstrated that
exosomes from young and environmentally enriched rats
significantly increased the myelin content, oligodendrocyte
precursor and neuronal stem cell levels and reduced oxidative
stress and astrogliosis in demyelinated hippocampal slice cultures
(Pusic and Kraig, 2014; Pusic et al., 2016). They also tested the
e ect of these exosomes in vivo by intranasal administration in
aged rats, showing positive results in myelin generation. The
authors related the exosome-derived pro-remyelination e ect
to their cargo, suggesting that the presence of miR-219 was
responsible for promoting remyelination (Pusic and Kraig, 2014).
Another aspect of demyelinating diseases is that the lack
of myelin wrapping axons might, if remyelination does not
take place, induce the disruption of the axons and, therefore,
neurodegeneration. Neuroprotection is a key factor which
might improve patients’ outcome and increase their life quality.
Regarding to this, mesenchymal stem cells derived EVs were
shown to be e ective peripheral immunomodulators inmodels of
traumatic brain injury after both intravenous or intraperitoneal
administration, decreasing inflammation and increasing
neuroprotection, angiogenesis and neurological function,
opening therapeutic possibilities in which neuroprotection can
be reinforced (Doeppner et al., 2015; Drommelschmidt et al.,
2017).
DELIVERY INTO THE CENTRAL
NERVOUS SYSTEM
To be able to use EVs as therapeutic biopharmaceuticals for
treating MS, it is imperative to ensure that EVs will reach their
target cells in the CNS. That can be achieved, for example, by
delivering EVs directly to the brain, by using systemic injections,
or by administering vesicles via intranasal route. The intranasal
route can be e cient for di erent cell type derived EVs, including
T-cell, fibroblast and tumor derived exosomes (Zhuang et al.,
2011). This delivery route not only leads to increased brain
accumulation of exosomes, but more importantly, it also results
in reduced inflammation in EAE animals if exosomes are loaded
with therapeutic anti-inflammatory molecules, as was previously
mentioned (Zhuang et al., 2011). The latter clearly underlines
the potential of EVs for treating MS via the intranasal route,
which is further supported by successful experiments conducted
in the context of other CNS diseases such as Parkinson’s disease
(PD). In a mouse model of PD, catalase-loaded macrophage
exosomes reached the brain and provided antioxidant-mediated
neuroprotection (Haney et al., 2015). Neuroprotection was also
induced by curcumin loaded embryonic stem cell exosomes in an
ischemia-reperfusion injury model (Kalani et al., 2016). Repeated
treatments with curcumin loaded exosomes led to a reduction of
inflammation and improved neurological score and restored the
expression of several BBB proteins.
However, it appears that EV loading with exogenous cargoes
prior to intranasal administration is not always essential for
therapeutic e ects in the CNS, as recently demonstrated in
a status epilepticus mouse model. Unmodified human bone
marrow derivedMSC-Exs reduced neuron loss and inflammation
in the hippocampus of treated mice, which more importantly led
to preservation of memory function (Long et al., 2017). These
properties of unmodified MSC-Exs for treating CNS disease
are particularly interesting and promising for MS. Given the
trend toward replacing certain MSC cell therapies with EV based
therapies, and the fact that a number of MSC cell therapies have
been tested in Phase I/II clinical trials for treating MS as well
(Heldring et al., 2015), it is likely that MSC EVs will gain further
focus in the short term for targeting MS pathology as well.
In addition to the intranasal administration route, as described
above, other local delivery options have shown e cacy for EV
based CNS therapies as well. Unilateral direct brain infusion
of glioblastoma derived exosomes, pre-loaded with hydrophobic
siRNA, led to exosome-dependent bilateral Huntington mRNA
silencing in the brain of treated mice (Didiot et al., 2016).
Other therapeutic strategies not directly relying on drug delivery
can be e cient as well. Intracerebral neuroblastoma exosome
administration to an Alzheimer disease mouse model reduced
amyloid-b levels in the brain and lowered the associated
synaptotoxicity, tapping thus into natural EV-mediated Ab
clearance pathways (Yuyama et al., 2014). Similar e ects were
observed also when using primary neuron exosomes, the e ect
being cell type specific as glial exosomes were less e cient in
the capture of amyloid-b (Yuyama et al., 2015). This is not
surprising as the transport of exosomes to brain parenchyma can
be specifically related to the presence of specific surface molecules
such as folate receptor a (Grapp et al., 2013) as well as other EV
related signatures that can, for example, mediate periphery-brain
signaling in inflammation (Balusu et al., 2016).
In many cases, however, systemic rather than local therapeutic
EV administration would be preferred for various reasons,
including the safety of the treatment administration. Despite
the fact that BBB is virtually impermeable to most molecules
there is some evidence that unmodified exosomes can enter the
brain to some extent (Yang et al., 2015), but brain exposure is
significantly increased when using certain brain targeting ligands
such as the rabies glycoprotein derived RVG peptide (Wiklander
et al., 2015). The brain targeting RVG peptide, even though the
precise targeting mechanism has not been fully elucidated, led to
increased brain delivery of siRNA when decorated on dendritic
cell exosomes (Alvarez-Erviti et al., 2011). Using that strategy,
it was possible to lower the levels of Bace1 on both mRNA and
protein levels in the brains of wild type mice (Alvarez-Erviti et al.,
2011), and in reduced level of a-synucleinmRNA in S129D a-Syn
transgenic mice (Cooper et al., 2014).
CHALLENGES AND OPPORTUNITIES
Two characteristic aspects of MS are inflammation and
neurodegeneration. The inhibition of inflammation and the
promotion of remyelination are postulated as two therapeutic
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FIGURE 1 | SummaryQ3 of
Q4
proposed therapeutic approaches for demyelinating diseases. Established cell lines, donor- or patient-derived cells are isolated and grown.
EVs can be loaded with drugs/small compounds, miRNAs/siRNAs and/or surface antibodies, which provide new options in remyelination therapy. The loading can
be performed during the cell culture (endogenous loading) or once EVs are isolated (exogenous loading\reviewed in Vader et al., 2016). This might depend on the
strategy and purpose of the therapy (Sutaria et al., 2017). Therapeutic EVs can be isolated by ultracentrifugation, differential centrifugation, immunoaffinity or
size-exclusion chromatography (Lener et al., 2015). Finally, EVs could be administered to the patient intranasally, intraperitoneally or intravenously and again, this is
something that will vary according to the therapeutic strategy.
ways to improve patients’ outcome. As it has been widely
shown, EVs can play a role in both immunomodulation and
remyelination. But, what is the future going to be like with EVs
mediated MS therapy? (Figure 1).
The First Thing to Consider
The first thing to consider is the source where EVs are isolated
from. In this sense established cells lines or cell isolated from
the patient or a compatible donor can be used to isolate EVs.
Biofluids such as plasma or urine are also an alternative. It is
not clear which source is the most e cient and each one has
got detractors. In this sense and as explained above, several are
the sources that have been used with promising results, opening
a wide range of EVs origins to be used. However, we consider
that EVs isolated from cell culture might be more reproducible
and “easy to manage.” In this way, cell therapies derived EVs
are suggested as strong candidates as disease treatment. The
use of cell-free stem cell-based therapy decreases the risk of
cell therapy maintaining the beneficial e ect of those cells. As
an example, Mesenchymal Stem Cell derived vesicles have been
widely studied as therapeutic mediators for several diseases
(Review in Börger et al., 2017; Phinney and Pittenger, 2017).
We consider that it might be a feasible treatment for MS acting
as immunomodulatory agents and tissue repair mediator. In
addition to the source, the isolation method is also a relevant
aspect to be mentioned, as several methods can lead to di erent
EVs types. Although several e ectors has been made in order
to standardize isolation techniques, there is still controversy
(Gardiner et al., 2016).
A Second Consideration
A second consideration can be the use of non-modified or
bioengineered vesicles. The use of non-modified EVs has shown
promising results (Pusic and Kraig, 2014; Pusic et al., 2014).
In fact, there are several clinical trials recruiting patients in
which the ability of allogenic mesenchymal stem cell derived
exosomes in acute ischemic stroke or the e ect of plasma
derived exosomes on cutaneous wound healing will be addressed
(NCT02565264, 2015; NCT03384433, 2017). Nevertheless, the
modification of the cargo of EVs by bioengineering techniques is
an interesting and promising field in EV-mediated therapies and
we consider that it might be a more e ective treatment method.
It has been proved that cells which are genetically modified to
overexpress a concrete microRNA, release EVs enriched in that
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microRNA (Squadrito et al., 2014). In this sense, microRNAs
have shown to be involved in the di erentiation of OPCs; more
concretely miR-138, miR-219 and miR-338 (Dugas et al., 2010;
de Faria et al., 2012; Wang et al., 2017). The enrichment of those
microRNAs in the cargo of EVsmight induce OPC di erentiation
and therefore remyelination after demyelination. Vesicles can
also be loaded with small compounds and drugs with anti-
inflammatory e ects. In this sense, curcumin loaded exosomes
demonstrated to induce neuroprotection (Kalani et al., 2016).
We also propose that nowadays immunomodulatory drugs could
also be loaded in exosomes in order to obtain a controlled and
direct administration into the CNS. This therapeutic approach is
of interest due to the immunological component of MS. Finally,
EVs can be modified to express membrane receptors of the target
cell, in this way increasing the uptake by the cell and decreasing
non-specific bindings (Alvarez-Erviti et al., 2011).
Extracellular vesicles have demonstrated that they are key
players in myelin regeneration and the applications that EVs
could have in the stimulation of remyelination in pathological
states are many. As we have mentioned previously, treatment
to induce remyelination is still not available and the use
of EVs is becoming a promising and feasible method to
immunomodulate, induce myelin restoration, and in this
way decreasing neurodegeneration and therefore, increasing
patients’ outcome. However, even if the implication of EVs in
remyelination related processes has been addressed in several
works, our knowledge about the therapeutic potential of EVs is
just beginning and an exciting future is awaiting us.
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